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Abstract
An increased risk or a history of cardiovascular disease (CVD) is associated with worse
survival prospects. Clinical guidelines recommend several treatments for primary
and secondary prevention. These guidelines are mainly based on clinical trials and
hospital data. Data from routine clinical practice could provide insights in longevity
and longevity improvement in the general population as opposed to selected patients.
The primary objectives of this research were to investigate how a history of CVD
affects longevity in residents of the United Kingdom at retirement age, and to inves-
tigate which treatments improve longevity.
Medical records from 1987 to 2011 from general practices contributing to The
Health Improvement Network (THIN) database were used to develop two specific
survival models: to estimate the hazards of all-cause mortality associated with a his-
tory of acute myocardial infarction (AMI) and related treatments, and to estimate
the hazard of all-cause mortality associated with statins prescribed as primary pre-
vention of CVD. The models were multilevel Cox’s proportional hazards regressions
that included comorbidities, treatments, lifestyle choices, and socio-demographic fac-
tors. The models were specified for ages 60, 65, 70, and 75. More accurate estimates
of longevity at these key ages could inform future medical management by clinicians
and financial planning for retirement by individuals, actuaries, and the government.
This research found that survival prospects after AMI were reduced by less than
previous studies have reported. Furthermore, currently recommended treatments for
CVD were associated with mixed survival prospects, in which coronary revasculari-
sation and prescription of beta blockers and statins were associated with improved
prospects and prescription of ACE inhibitors and aspirin were associated with wors-
ened prospects.
i
Table of Contents
Abstract i
List of Tables v
List of Figures vii
List of Publications ix
Dedication x
Acknowledgements xi
1 Introduction 1
1.1 Rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Relevance of survival models in medicine . . . . . . . . . . . . 2
1.1.2 Relevance of survival models in retirement planning . . . . . . 3
1.1.3 Existing cardiovascular disease survival models . . . . . . . . . 9
1.2 Research objectives and aims . . . . . . . . . . . . . . . . . . . . . . 12
1.3 Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.4 Thesis outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2 Review of cardiovascular disease 19
2.1 Cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.1.1 Primary risk assessment . . . . . . . . . . . . . . . . . . . . . 20
2.1.2 Primary risk management . . . . . . . . . . . . . . . . . . . . 23
2.2 Acute myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . 25
2.2.1 Secondary risk management . . . . . . . . . . . . . . . . . . . 27
2.2.2 Existing survival models . . . . . . . . . . . . . . . . . . . . . 31
3 Review of primary care data 42
3.1 Medical data sources . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Primary care databases in the United Kingdom . . . . . . . . . . . . 46
ii
iii
3.3 The Health Improvement Network database . . . . . . . . . . . . . . 51
3.4 Selected age cohorts . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.5 Selected medical history . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.6 Coding of covariates . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4 Review of statistical methods 63
4.1 Survival analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.1.1 Survival time . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.1.2 Descriptive analysis . . . . . . . . . . . . . . . . . . . . . . . . 65
4.1.3 Regression analysis . . . . . . . . . . . . . . . . . . . . . . . . 68
4.2 Missing data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.2.1 Missing data in primary care records . . . . . . . . . . . . . . 83
4.2.2 Methods to deal with missing data . . . . . . . . . . . . . . . 85
4.2.3 Multiple imputation . . . . . . . . . . . . . . . . . . . . . . . 87
4.3 Model building . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.3.1 Study design . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.3.2 Selection of covariates . . . . . . . . . . . . . . . . . . . . . . 94
4.4 Model assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
5 Survival models for acute myocardial infarction 103
5.1 Analysis procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.1.1 Study design . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.1.2 Selected medical history . . . . . . . . . . . . . . . . . . . . . 106
5.1.3 Model development . . . . . . . . . . . . . . . . . . . . . . . . 108
5.2 Description of cohorts . . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.3 Survival models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
5.4 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.4.1 Performance statistics . . . . . . . . . . . . . . . . . . . . . . 125
5.4.2 Internal validation . . . . . . . . . . . . . . . . . . . . . . . . 126
5.4.3 External validation . . . . . . . . . . . . . . . . . . . . . . . . 127
5.4.4 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . 132
5.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
6 Survival models for statin prescription 136
6.1 Analysis procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
6.1.1 Study design . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
6.1.2 Selected medical history . . . . . . . . . . . . . . . . . . . . . 138
6.1.3 Model development . . . . . . . . . . . . . . . . . . . . . . . . 142
6.2 Description of cohorts . . . . . . . . . . . . . . . . . . . . . . . . . . 145
6.3 Survival models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
6.4 Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
6.4.1 Performance statistics . . . . . . . . . . . . . . . . . . . . . . 153
iv
6.4.2 Internal validation . . . . . . . . . . . . . . . . . . . . . . . . 154
6.4.3 External validation . . . . . . . . . . . . . . . . . . . . . . . . 154
6.4.4 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . 156
6.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
7 Discussion 159
7.1 Main findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
7.1.1 Survival models for acute myocardial infarction . . . . . . . . 160
7.1.2 Survival models for statin prescription . . . . . . . . . . . . . 162
7.2 Strengths . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
7.3 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
7.4 Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
7.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
Bibliography 174
A Appendix statistical methods 194
B Appendix survival models for acute myocardial infarction 200
C Appendix survival models for statin prescription 219
List of Tables
2.1 Existing survival models of all-cause mortality after acute myocardial
infarction (AMI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.1 Primary care databases and national surveys in the United Kingdom 47
3.2 Information selected from medical records contributing to The Health
Improvement Network (THIN) primary care database . . . . . . . . 56
3.3 Mosaic classification . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.1 Characteristics of cases and controls in matched age cohorts . . . . . 112
5.2 Baseline treatments by ischaemic heart disease . . . . . . . . . . . . . 117
6.1 Characteristics of men and women in age cohorts without cardiovas-
cular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6.2 Prevalence of statin prescription by cohort’s age, cardiovascular risk
group, and sex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
7.1 Average period expectation of life for various scenarios based on the
survival models for acute myocardial infarction (AMI) . . . . . . . . . 171
A.1 Prevalence missing observations in 60-year old cohort . . . . . . . . . 194
A.2 Prevalence missing observations in 65-year old cohort . . . . . . . . . 195
A.3 Prevalence missing observations in 70-year old cohort . . . . . . . . . 197
A.4 Prevalence missing observations in 75-year old cohort . . . . . . . . . 198
B.1 Description and coding of variables in matched age cohorts . . . . . 200
B.2 Prevalence antiplatelet therapy in matched age cohorts . . . . . . . . 202
v
vi
B.3 Characteristics of patients with complete and incomplete medical records
in matched age cohorts . . . . . . . . . . . . . . . . . . . . . . . . . . 203
B.4 Distribution of recorded and imputed values of variables with missing
data in matched age cohorts . . . . . . . . . . . . . . . . . . . . . . . 204
B.5 Characteristics of patients lost to follow-up in matched age cohorts . 204
B.6 Prevalence coronary revascularisation given ischaemic heart disease
(IHD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207
B.7 Prevalence of diabetes in men and women with ischaemic heart disease
(IHD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207
B.8 Correlations of district’s characteristics and the adjusted hazards of
all-cause mortality associated with general practices . . . . . . . . . . 217
B.9 Performance statistics of survival models based on complete medical
records and irrespective of completeness in matched age cohorts . . . 218
C.1 Characteristics of patients with and without Townsend deprivation
score in age cohorts without cardiovascular disease . . . . . . . . . . . 220
C.2 Original and modified QRISK2 algorithm . . . . . . . . . . . . . . . . 221
C.3 Description and coding of variables in age cohorts without cardiovas-
cular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222
C.4 Characteristics of patients with complete and incomplete medical records
in age cohorts without cardiovascular disease . . . . . . . . . . . . . . 223
C.5 Distribution of recorded and imputed values of variables with missing
data in age cohorts without cardiovascular disease . . . . . . . . . . . 224
C.6 Characteristics of patients lost to follow-up in age cohorts without
cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
C.7 Cases and controls staying in initial treatment arm of statin prescrip-
tion during follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
C.8 Performance statistics of survival models based on complete medical
records and irrespective of completeness in age cohorts without cardio-
vascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
List of Figures
1.1 Former British pension system (2011-2015) . . . . . . . . . . . . . . . 4
1.2 Current British pension system (since April 2015) . . . . . . . . . . . 5
2.1 QRISK R©2 cardiovascular disease calculator . . . . . . . . . . . . . . 22
3.1 Selected age cohorts . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5.1 Selected age cohorts for acute myocardial infarction matched by sex,
year of birth, and general practice . . . . . . . . . . . . . . . . . . . . 105
5.2 Prevalence of treatments by cohort’s age in patients with acute my-
ocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
5.3 Prevalence of ischaemic heart disease (IHD) and coronary revasculari-
sation given IHD, by deprivation . . . . . . . . . . . . . . . . . . . . 118
5.4 Unadjusted and adjusted hazards of all-cause mortality associated with
ischaemic heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . 120
5.5 Adjusted hazards of all-cause mortality associated with treatments for
ischaemic heart disease . . . . . . . . . . . . . . . . . . . . . . . . . . 124
6.1 Selected age cohorts without cardiovascular disease . . . . . . . . . . 139
6.2 Prevalence of statin prescription by cohort’s age in patients without
cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
6.3 Unadjusted and adjusted hazards of all-cause mortality associated with
statin prescription . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
B.1 Prevalence of comorbidites by cohort’s age in patients with acute my-
ocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
vii
viii
B.2 Prevalence of lifestyle factors by cohort’s age in patients with acute
myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
B.3 Survival model for 60-year old matched cohort . . . . . . . . . . . . . 209
B.4 Survival model for 65-year old matched cohort . . . . . . . . . . . . . 211
B.5 Survival model for 70-year old matched cohort . . . . . . . . . . . . . 213
B.6 Survival model for 75-year old matched cohort . . . . . . . . . . . . . 215
B.7 Adjusted survival curves associated with ischaemic heart disease (IHD) 216
C.1 Prevalence of comorbidites and lifestyle factors by cohort’s age in pa-
tients without cardiovascular disease . . . . . . . . . . . . . . . . . . 225
C.2 Prevalence start of statin therapy given prescription prior to cohort’s
age by QRISK2 group . . . . . . . . . . . . . . . . . . . . . . . . . . 226
C.3 Unadjusted and adjusted hazards of all-cause mortality associated with
lipid-lowering therapy prescription . . . . . . . . . . . . . . . . . . . . 228
C.4 Unadjusted and adjusted hazards of all-cause mortality associated with
statin prescription in complete case analysis . . . . . . . . . . . . . . 229
List of Publications
• Gitsels, L. A., Kulinskaya, E., and Steel, N. (2016). Survival benets of statins
for primary prevention: a cohort study. PloS One, 11(11):e0166847.
• Gitsels, L. A., Kulinskaya, E., and Steel, N. (2017). Survival prospects after
acute myocardial infarction in the UK: a matched cohort study 1987-2011. BMJ
Open, 6:e013570.
• Kulinskaya, E. and Gitsels, L. A. (2016). Use of big health and actuarial data
for understanding longevity and morbidity risk. Longevity Bulletin, (9):1518.
ix
xSurvival
Acknowledgements
I would like to thank my supervisors Prof Elena Kulinskaya, Prof Nicholas Steel, and
Mr Nigel Wright for their time and support. In particular, I would like to thank
Elena for guiding me to become an independent academic researcher. I appreciate
her vast knowledge in a wide range of fields and her assistance in all forms of writing,
from conference abstracts to academic papers to this thesis. I would like to thank
Nicholas for sharing his medical expertise and for his guidance in presenting and
communicating my work to a medical public in a clear, concise, and effective way. I
would like to thank Nigel for sharing his actuarial expertise.
I would also like to thank my former epidemiology classmates Maria Tran and
Nisha Rajendran for discussing and proofreading parts of my work throughout my
PhD project. Their feedback helped me improve explaining my work.
Finally, I would like to thank my mother Dr Janneke Gitsels-van der Wal for
introducing me to the academic life. Her prediction that I would become a statis-
tician has hereby come true. It was a great, unique experience to work together on
conference posters and an academic paper in midwifery science, which were my first
peer-reviewed publications.
xi
Chapter 1
Introduction
This Chapter starts by explaining the rationale for developing survival models to
estimate longevity given a history of cardiovascular disease and related treatments in
people at retirement age. Next, the research objectives and aims are listed. Then,
the contributions of the research are presented. Finally, the thesis outline is provided.
1.1 Rationale
Cardiovascular disease (CVD), which is an umbrella term for diseases of the heart and
circulation (Townsend et al., 2015), is one of the main causes of death in the world
(Naghavi et al., 2015; Newton et al., 2015; WHO, 2015a). In the United Kingdom
(UK), CVD is the number two cause of death for men and women, accounting for 28%
and 26% of deaths, respectively (Townsend et al., 2015). Longevity prospects of a
person can inter alia be explained by comorbidities, treatments, lifestyle choices, and
socio-demographic factors (WHO, 2015a). Longevity can be estimated by a survival
model, which ideally consists of all risk factors that can explain the variations in the
outcome. Precise estimates of longevity prospects and understanding variations in
longevity prospects are important to many parties.
1
21.1.1 Relevance of survival models in medicine
For instance, survival models are of interest to clinicians, because they can identify
specific patient characteristics associated with different survival rates. These findings
can be used to counteract the harmful effects and enhance the protective effects of
modifiable risk factors. For example, cholesterol level and blood pressure can be
targeted to improve survival prospects (NICE, 2011, 2015). This could be in the form
of routine screening, early intervention, or patient education programmes that could
help patients better understand the risks associated with certain lifestyles and how
these risks can be lowered by changing their lifestyle.
With an ageing population and medical advances improving survival prospects,
chronic medical conditions like CVD become increasingly prevalent (Naghavi et al.,
2015; WHO, 2015c). With a higher prevalence of these medical conditions, survival
variations can be analysed in greater detail. In other words, a higher degree of
differentiation between patients is possible, in which interactions between medical
conditions, treatments, lifestyle choices, and socio-demographic factors can also be
studied. A survival model that is estimated on a heterogeneous sample of patients,
could lead to pharmacosurveillance in which the safety and effectiveness of treatments
in groups of patients can be assessed (Platt et al., 2008). The effect of treatments
might differ by sex, age, or other clinically defined subpopulations (Hippisley-Cox
and Coupland, 2010a,c). By detecting the differences in effectiveness, clinicians can
provide custom tailored care for the patient that helps improve the respective survival
prospects. Subsequently, survival models can provide risk thresholds for action and
updates for clinical guidelines of prevention and risk management (Wright and Dent,
2014).
Survival models can not only be used for individual risk assessment but also
to assess the well-being of an entire population. This in turn can inform resource
3allocation decisions for optimal positive net benefits (Hingorani et al., 2013). The
increase in prevalence of chronic medical conditions can put pressure on resources such
as general practitioners, specialised doctors, surgeons, caretakers, medical centres,
medical equipment, drugs, money, and time. The higher prevalence of chronic medical
conditions can also increase the experience of doctors and surgeons, and lead to a
greater variation in performance of health care and greater difference in survival
prospects by medical centre. With more precise estimates of survival prospects and
a greater understanding of survival variations among patients and medical centres,
resources can be allocated in a strategic way.
Thus, medical professionals and local health authorities can benefit from survival
models because the results can inform the shape of future medical management and
strategic resource allocation.
1.1.2 Relevance of survival models in retirement planning
Survival models are of interest in retirement planning, because they can inform in-
dividuals about how to spend their pension pot during retirement, inform actuaries
about pricing of annuities and life insurance, and inform governments about taxation,
national insurance rates, and pensions.
Individuals
It is recommended to plan one’s finances for retirement to ensure there is enough
income to live off during retirement. The key information in financial planning for
retirement is one’s life expectancy, because this will inform the individual how much
income can be spent per year. In the UK, sources of income could be the state
pension, occupational pension, personal pension, defined benefit (DB) pension, or
defined contribution (DC) pension (Office for National Statistics, 2013). Access to
the pension pot is granted when a person reaches the minimum pension age of 55,
4Figure 1.1: Former British pension system (2011-2015)
People who reached the minimum pension age of 55 could take out a 25% tax-free
lump sum from their pension pot, after which they had the following options for
spending their pension pot: withdrawal of first 30,000£ at marginal tax rate, with-
drawal after first 30,000£ at 55% tax rate, purchase of annuity, capped drawdown,
and flexible drawdown after first 310,000£ (Baxter, 2015a). This system pushed
people in purchasing an annuity unless they had a very small or large pension pot.
which will rise to age 57 in 2018 (Baxter, 2015a). In April 2015, the laws regarding
how and when the pension pot can be spent were reformed (Baxter, 2015b). Under
the former pension system of the UK, which was active from April 2011 to April
2015, people were effectively encouraged to buy an annuity if their pension pot was
worth between 30,000 and 310,000£, see Figure 1.1. As the majority of people had
a pension pot of this size, 75% of people ended up with an annuity (HM Treasury,
2014).
In April 2015, the British government modified the rules on pensions to offer
greater freedom to individuals in choosing how and when to access their pension pots
during retirement. The reasoning behind this change was that annuities no longer
suited everyone due to increasing life expectancy and diverse wishes for retirement
(HM Treasury, 2014). Fifty years ago a 65-year old had a life expectancy of 12
5Figure 1.2: Current British pension system (since April 2015)
People who reached the minimum pension age of 55 can take out a 25% tax-free lump
sum from their pension pot, after which they had the following options for spending
their pension pot: withdrawal at marginal tax rate, purchase of annuity, drawdown,
and purchase of other products created by providers (Baxter, 2015a,b).
years, whereas it is 21 years today. Furthermore, while previously retired people were
relatively inactive, nowadays they are more active, often having part-time jobs at the
start of their retirement. With increasing life expectancy and a varied lifestyle during
retirement, purchasing a range of products instead of one product might be more
suitable (Baxter, 2015a). With the current pension system, everyone has the option
of a 25% tax-free lump-sum, withdrawal of money, drawdowns of money, purchase of
an annuity, and the purchase of other products created by providers, see Figure 1.2.
Under the former and current pension system, buying an annuity was and is a
fixed and one-time purchase. In April 2017, the pension system will be reformed to
permit second-hand annuities (Baxter, 2015a). It is expected that only a minority of
people would like to sell their annuity. An example of when it would be attractive
to sell an annuity and receive a lump sum is when life expectancy has declined due
to an unexpected unfavourable event that happened after the annuity was bought.
Second-hand annuities will be subject to adverse selection in which sellers have the
advantage over buyers. This is because sellers would have better knowledge about
their own life expectancy due to complete information on known medical history,
6lifestyle choices, and socio-demographic factors (Baxter, 2015a).
Thus, the change in pension system and the future reforms of second-hand an-
nuities requires more active decision-making by individuals regarding how to spend
their pension pot (Baxter, 2016). Survival models can inform individuals how certain
medical conditions, treatments, lifestyle choices, and socio-demographic factors affect
their survival prospects at different retirement ages.
Actuaries
Survival models are of interest to actuaries because they can provide insights on
survival variations and are thereby informative for the pricing of annuities and life
insurance. In estimating life expectancy, actuaries deal with basis and longevity risk
(Barrieu et al., 2012). The basis risk is here defined as life expectancy being incorrectly
estimated, i.e. that there is a residual between estimation and observation. When life
expectancy is over-predicted, the insurance company gains profit. This is because the
annuity was specified to provide an income for more years than expected and when
the client has passed away, the insurance company can keep the money that was
left over. However, when life expectancy is under-predicted, the insurance company
loses money. This is because the annuity was specified to provide an income for
fewer years than expected and since an annuity is a guaranteed income for life, the
insurance company has to continue providing an income until death. It is therefore
of great importance to estimate life expectancy as accurately as possible to minimise
the basis risk.
Longevity risk is defined as the risk of an unexpected increase in life expectancy,
due perhaps to changing lifestyles in the population and to medical advances (Barrieu
et al., 2012). Prior to modelling survival data, the baseline characteristics of the
sample are examined. During this stage, time trends in incidence and prevalence of
risk factors can be identified. Examples include an obesity epidemic and a rise in drug
7prescriptions (Hardoon et al., 2011; WHO, 2015b). Survival models in turn can test
whether the hazardous or protective survival effects of lifestyle choices, treatments,
or other factors change over time. The results can inform the insurance company
which risk factors might be a longevity risk and should be taken into account when
predicting life expectancy.
There are different types of annuities that focus on various details of the client.
For example, enhanced annuities specialise in poor health status or lifestyle choices
(Thurley, 2015). Survival models can provide estimates of the hazards associated
with certain medical conditions, treatments, and lifestyle choices. By having more
information about the health status and lifestyle of the client, life expectancy can
be more accurately estimated. This is beneficial for the client because the client
would receive a higher retirement income per year than when the information is not
available and the life expectancy of the average, healthier person is used in calculating
the income. Greater accuracy in estimating life expectancy is also beneficial for the
insurance company because it minimises the basis risk.
With increasing life expectancy and increasing years of retirement, annuities need
to cover more years (HM Treasury, 2014). This means that there is more uncertainty
to take into account, and therefore the estimated life expectancy is less precise and
the basis risk is greater. Survival models developed on long follow-up data of a
heterogeneous sample can identify new risk factors or combinations of risk factors
that explain survival variations to a higher degree and lead to better differentiation
between groups of people and their respective survival prospects at the baseline.
Thus, actuaries can benefit from survival models because the results can provide
insights into the basis and longevity risks of estimating life expectancy, and in turn
can lead to better pricing of annuities and other insurance products.
8Government
Survival models are also of interest to the government as the estimates can inform
decisions related to the tax schemes, national insurance rates, and pension system.
The UK has an ageing population, which means that there is an increase in the
dependency of retired people on the workforce (UK Parliament, 2015). This puts
pressure on welfare spending while less revenue is collected. It is therefore of im-
portance to identify and forecast demographic and health trends in the population
and to understand survival variations within the population in order to sustain the
economy.
Survival models can identify age-specific risk factors of ill-health and mortality.
The results can be informative for predicting healthy life expectancy and total life
expectancy. Differentiating between the two can be indicative of when people are
likely to retire and the length of their retirement. This in turn can inform the expected
participation in the workforce at each age, what a reasonable minimum retirement
age is for the population, and the expected dependency by retired people on the state.
There are great variations in healthy and total life expectancy. For example,
between the least and most deprived areas in the UK, there is almost 17 years dif-
ference in healthy life expectancy for both men and women, and there is 8 and 6
years difference in total life expectancy for men and women, respectively (White and
Butt, 2015). Survival models can identify specific profiles associated with different
life expectancies. Furthermore, these profiles would help elucidate which modifiable
risk factors to target in order to improve the well-being of the population. The re-
sults could give rise to or enhance the promotion of a healthy lifestyle, provision of
preventative healthcare, provision of services to overcome addictions, taxation of un-
healthy goods, and allocation of medical resources to the ones most in need or who
would benefit the most. A healthier population means that more people can be part
9of the workforce and be part of it for a longer time period. Better distribution of
governmental funds, guided by the estimates of quantitative methods such as sur-
vival models, would release pressure on welfare spending, increase tax revenues, and
increase pension savings (UK Parliament, 2015).
Thus, the government can benefit from survival models, because the results can
assess the well-being of the population and thereby inform the shape of future health
policies, tax schemes, national insurance rates, and the pension system.
1.1.3 Existing cardiovascular disease survival models
Numerous survival models for CVD have been developed (NICE, 2013a). In the past,
health scientists typically performed patient-level, incidence-based data analysis. In
contrast, actuaries typically performed clustered, prevalence-based data analysis and
used the results from clinical studies. As the insurance industry does not publish their
survival models, this thesis reports survival models developed in clinical studies. The
current subsection provides an overview of the different study designs, data sources,
and data modelling techniques used in developing the survival models. These models
are described in detail in Chapter 2.
CVD survival models were developed by either randomised control trials or cohort
studies (CTTC, 2012; Hardoon et al., 2011; Luepker, 2011; Nakamura et al., 2006;
NICE, 2013a; Ridker et al., 2008; Smolina et al., 2012a). The study populations
consisted either of cases and controls or cases only. The studies that only included
cases, could investigate survival variations after the diagnosis of the medical condition
in great detail. However, these studies could not estimate the effect of the medical
condition itself on survival time due to the lack of a control group. In contrast, studies
that included both cases and controls, could not investigate survival variations given
the medical condition in great detail due to limited medical information available
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for the entire sample, but could estimate the effect of the medical condition itself on
survival time. The effect of the medical condition on survival time, however, was most
likely overestimated as the estimate could not be adjusted for important risk factors.
The cases may be more likely to have comorbidities and an unhealthy lifestyle, which
are independent predictors of survival, and so adjustment for these risk factors is
important.
Multiple data sources were used to develop CVD survival models, ranging from
prospectively collected trial-cohort data to routine data from hospitals, primary care,
or disease and mortality registers (Briffa et al., 2009; Capewell et al., 2000; Chang
et al., 2003; CTTC, 2012; Gerber et al., 2010, 2009; Herzog et al., 1998; Kirchberger
et al., 2014; Koek et al., 2007; NICE, 2013a; Nigam et al., 2006; Quint et al., 2013;
Smolina et al., 2012b). The data source(s) used define the constraints of the study
design, the inclusion and exclusion criteria of the sample, the sample size, the length
of follow-up period, and the range of risk factors that can be adjusted for in the
analysis. Thus, the data source determines what health outcomes can be studied and
the generalisability of the results.
Of the different data sources, primary care data have rarely been used to develop
CVD survival models. Primary care data could be an important new source of infor-
mation on survival prospects associated with medical conditions treated in routine
clinical practice. Approximately three decades ago, the migration from paper to elec-
tronic medical records began to take place, giving rise to electronic medical records
databases (Shephard et al., 2011). This provides relatively easy access to data on
the target population due to the number of medical records included in the database.
Such a database is populated with medical records from multiple medical centres
and is updated on a routine basis. The long follow-up of a large sample of patients
from multiple medical centres can lead to greater confidence in the results due to
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more precise estimates and better coverage of the underlying population. Also, the
high volume of person-years of data on a wide range of available risk factors, permits
the development of more complex statistical models. Complex modelling can enable
better understanding of the variations in the outcome of interest.
Various techniques of data modelling can be considered in developing survival
models. This involves making assumptions about censoring, covariate selection in-
cluding interaction effects, time dependency of survival prospects, survival variations
by medical centres when applicable, and types of missing data when present (Allison,
2001; Therneau and Grambsch, 2000). Most of these assumptions were not explored
by previous CVD survival models (Briffa et al., 2009; Capewell et al., 2000; Chang
et al., 2003; Gerber et al., 2010, 2009; Herzog et al., 1998; Kirchberger et al., 2014;
Koek et al., 2007; Nigam et al., 2006; Quint et al., 2013; Smolina et al., 2012b). In
case of violated assumptions, the results might be biased or less precise.
Thus, previous CVD survival models have been developed using various study
designs, data sources, and data modelling techniques. Studies including only cases
were used to estimate survival variations given CVD while studies including both
cases and controls were used to estimate the survival prospects of CVD. Combining
these two study designs to create a new survival model of CVD should yield more
accurate estimates of survival prospects of CVD where the risk factors explaining
survival variations given CVD can be adjusted for. This new survival model can be
achieved by making use of primary care data, which has information on general and
CVD specific risk factors for both cases and controls. Due to the extensive content in
primary care data, there is an opportunity to test new combinations of risk factors,
including interaction effects and the time-dependency of effects, in explaining survival
variations. Furthermore, there is an opportunity to take general practices into account
in the survival model such that survival variations between practices can be explored.
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Pursuing these options can provide insights on current treatments in routine clinical
practice.
1.2 Research objectives and aims
The primary objectives of this research are to investigate how a history of a CVD, in
particular acute myocardial infarction (AMI), affects longevity in residents of the UK
at retirement age, and also to investigate which treatments improve longevity. Specif-
ically, data from The Health Improvement Network (THIN) primary care database
are used to develop survival models for longevity in the presence or absence of AMI
and survival models for longevity in the presence or absence of statins prescribed as
primary prevention of CVD. Snapshots of medical history are obtained at four differ-
ent target ages, namely 60, 65, 70, and 75. The research focuses on survival prospects
and variations given this medical history. These results can inform both the style of
financial spending by an individual during retirement and the management of their
basis and longevity risks by insurance companies. The results can also inform health
care requirements and resource allocation in the population.
The main objectives are to develop population-based survival models addressing
the following goals:
1. Determine the effects of AMI, statins prescribed as primary prevention of CVD,
and other AMI related treatments on longevity at the four target ages.
2. Establish a list of additional risk factors affecting longevity by themselves or in
interaction with the medical condition, treatments, and other risk factors.
3. Quantify the protective or harmful effects of these risk factors.
4. Establish the clinical and actuarial implications of found variations in longevity.
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The aims of the research are:
1. Investigate how the presence and duration of comorbidities and treatments af-
fect the hazard of mortality at each age and whether they can be related to
age-specific medical management.
2. Investigate the survival benefits of statins prescribed as primary prevention of
CVD for various CVD risk groups at each age and whether this can inform risk
thresholds for action.
3. Investigate how modifiable risk factors such as cholesterol level, blood pres-
sure, body mass index, alcohol consumption, and smoking affect the hazard of
mortality at each age and whether they can inform public health measures.
4. Investigate the effect of general practice on the hazard of mortality at each age
and whether this is a factor additional to the socio-demographic factors of a
district to consider in resource allocation.
5. Estimate the years lost or gained in effective age for each of the medical condi-
tions, treatments, lifestyle choices, and socio-demographic factors at each age,
and investigate how this could inform individuals about financial planning for
retirement.
6. Investigate which medical conditions, treatments, lifestyle factors, socio-
demographic factors, and interactions of risk factors at each age do and do
not contribute in explaining survival variations and therefore to minimise the
basis risk of estimating life expectancy for the pricing of annuities.
7. Investigate whether the effects of treatments, lifestyle choices, or other risk
factors on longevity change over time and might form longevity risks that should
be taken into account with pricing of annuities.
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1.3 Contributions
This research contributes to existing CVD research by developing survival models that
estimate both the effect of AMI on survival time and the survival variations given
a possible history of AMI at different retirement ages, and by developing survival
models that estimate the effect of statins prescribed as primary prevention of CVD
at different retirement ages.
The newly developed AMI survival models address the issue of lack of estimation
of the hazardous effects of AMI by incidence study designs due to the exclusion of
controls, as well as address the issue of overestimation of the hazardous effects of
AMI by prevalence study designs due to the limited number of risk factors adjusted
for. This is achieved by making use of primary care data, which have information
on a wide range of risk factors for both cases and controls. Hence, many of the
different groups of risk factors, which are classified in this research as comorbidities,
treatments, lifestyle choices, and socio-demographic factors, can be represented and
adjusted for in the analysis. In general, an epidemiological study would only test for
interaction effects with age, sex, and the main exposure of interest. However, the
newly developed AMI survival models test for interaction effects within and between
all groups of risk factors. In turn, survival variations are examined in greater detail.
The results could inform pharmacosurveillance, lead to improved resource allocation,
be of guidance in strategic financial planning for retirement, and contribute to better
pricing of annuities by minimising the basis risk and managing the longevity risk of
life expectancy estimations.
The newly developed statins survival models address the issue of strict inclusion
and exclusion criteria of clinical trials. Clinical trials typically perform analyses on
ideal patients, making it difficult to generalise the results to the wider population
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(Godlee, 2014). The newly developed statins survival models more accurately as-
sess the potential survival benefits of statins prescribed in the general population by
performing the analysis on an intention-to-treat basis on primary care data.
Under the National Health Service (NHS), 99% of British citizens are registered at
a general practice (NHS, 2013). Survival models produced from a sample of primary
care data can thus be representative of the whole of the UK. Furthermore, primary
care has a better coverage of AMI cases compared to hospitals and disease registers,
because it includes patients who were diagnosed immediately and patients who were
not sent to the hospital but were diagnosed in routine practice later by blood test
results (Herrett et al., 2013b). This means that the results of these newly developed
survival models are representative of a wider range of AMI cases in the UK than
previously. The survival models are in turn more applicable in the clinical and actu-
arial fields because the sample is more similar to the target population. Furthermore,
risk management of patients will be relatively straightforward for clinicians, because
the risk predictions are based on routinely measured factors. In addition, potential
longevity risks are easier to identify for actuaries due to longer follow-up in primary
care data compared to hospital data and disease registers, which do not routinely
record death dates.
The newly developed survival models address the issue of interdependence of pa-
tients from the same general practice and the issue of missing data. Most previous
models failed to address both issues appropriately when present and the interaction
of these issues. General practices vary in health outcomes and survival rates due to
differences in their patient populations and provision of patient care (Rasbash et al.,
2012). As it is impossible to adjust for all important risk factors on the individual
level in the analysis, taking clustering by practice into account could lead to increased
explanation of survival variations and more accurate estimates of survival prospects.
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Missing data is also a common issue with observational data. There are several meth-
ods available to deal with missing data in order to obtain unbiased estimates. The
developed survival models provide more accurate and unbiased estimates by address-
ing clustering by general practice and dealing with missing data appropriately.
The newly developed survival models are estimated at four different target ages,
namely 60, 65, 70, and 75. These are ages when people would typically retire from
work, and therefore it would inform financial planning of retirement for individuals
and pricing of annuities for actuaries. Furthermore, CVD becomes more prevalent
from age 60 onwards (Townsend et al., 2015), making primary prevention of CVD
by administration of statins more relevant to individuals aged 60 and older. The
results can facilitate individuals and general practitioners to make a decision about
statins use at key ages. With CVD being more common from age 60 onwards, these
age-specific results can also inform clinicians about ongoing medical management of
AMI and can inform local authorities about resource allocation.
Thus, this research contributes to existing CVD survival research by assessing
and quantifying effects of various risk factors by making use of primary care data,
addressing assumptions of homogeneous population and complete survival data, and
analysing age-specific data of people at retirement age. As noted above, these results
are relevant to several interested parties in the medicine and retirement planning
fields.
The findings of the survival models were published in the peer-reviewed journals
PLoS One (Gitsels et al., 2016) and BMJ Open (Gitsels et al., 2017), and in the
Longevity Bulletin of the Institute and Faculty of Actuaries (Kulinskaya and Gitsels,
2016).
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1.4 Thesis outline
This Section provides the outline of the following chapters of the thesis.
Chapter 2 is a literature review of CVD. First, the risk assessment of a first cardio-
vascular event and risk management by statin prescription in the UK are discussed.
Second, the CVD subtype AMI is defined and the risk management for secondary
prevention of AMI in the UK is described. Third, existing AMI survival models are
discussed in detail.
Chapter 3 is a review of primary care data and its use. First, routine data are
compared and contrasted with prospectively collected trial-cohort data. Second, the
availability and validity of primary care data in the UK are discussed, in particular
The Health Improvement Network (THIN) database that is used for this research.
Third, the inclusion and exclusion criteria of the studied age cohorts and the recorded
characteristics on these cohorts are described.
Chapter 4 is a review of statistical methods. First, the choice and assumptions of
the specified survival model are explained. Second, the process of model development
with regard to the study design and the selection of covariates is described. Third,
the way missing data were dealt with is discussed. Fourth, the assessment of the final
models is explained.
Chapter 5 presents the survival models that estimated the hazard of all-cause
mortality associated with a history of AMI and estimated the survival variations given
a possible history of AMI. The analysis procedure is explained and the studied cohorts
are described. The effects of a history of AMI, treatments, and general practice on
survival time at different retirement ages are presented. The survival models and the
estimated effects are assessed and compared with the results of previous studies.
Chapter 6 presents the survival models that estimate the hazard of all-cause mor-
tality associated with statins prescribed as primary prevention of CVD. The analysis
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procedure is explained and the studied cohorts are described. The potential survival
benefits of statins in various cardiovascular risk groups at different retirement ages are
presented. The survival models and the estimated effects are assessed and compared
with the results of previous studies.
Chapter 7 discusses the research’ findings. First, the main results are summarised
and the contributions to the existing evidence are presented. Second, the strengths
and limitations of the research are discussed. Third, the implications in medical
management and retirement planning are discussed by addressing the research’ aims.
Fourth, an overall conclusion is provided.
Chapter 2
Review of cardiovascular disease
This Chapter is a literature review of cardiovascular disease (CVD) and its subtype
acute myocardial infarction (AMI), in which the respective survival models are dis-
cussed. The objective of reviewing existing survival models is to survey the current
‘state of the art’ and to identify gaps in CVD research.
The first Section of this chapter defines the medical class CVD and describes
the risk assessment and management of a first cardiovascular event in the United
Kingdom (UK). The second Section defines the CVD subtype AMI, describes the
risk management for secondary prevention of AMI in the UK, and discusses existing
survival models that estimated survival prospects and variations after AMI.
2.1 Cardiovascular disease
CVD is the medical classification for diseases of the circulatory system, and includes:
acute rheumatic fever; chronic rheumatic heart diseases; hypertensive diseases; is-
chaemic heart diseases; pulmonary heart disease and diseases of pulmonary circu-
lation; other forms of heart disease; cerebrovascular diseases; diseases of arteries,
arterioles and capillaries; diseases of veins, lymphatic vessels and lymph nodes; and
other and unspecified disorders of the circulatory system (WHO, 2010). The under-
lying cause of CVD is in most cases atherosclerosis, which is a build-up of plaque
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on the walls of the circulatory system caused by excess cholesterol (Townsend et al.,
2015). As stated in the previous Chapter, CVD is the number two cause of death for
men and women in the UK, accounting for 154,639 deaths in total in 2014 (Townsend
et al., 2015). The greatest contributor to these deaths are ischaemic heart diseases,
such as angina pectoris and AMI, which account for 69,163 deaths (Townsend et al.,
2015).
Most of these cardiovascular events could potentially be prevented by pursuing
a healthy lifestyle including being physically active, having a healthy varied diet,
having a healthy body mass index, drinking alcohol in moderation, and abstaining
from smoking (WHO, 2015a). These healthier lifestyle choices are promoted using
national strategies. Besides lifestyle choices, other modifiable risk factors of CVD are
hypertension and hypercholesterolaemia. These two risk factors are addressed at the
individual level by offering antihypertensive or lipid-lowering drug therapies such as
beta blockers or statins, respectively (NICE, 2011, 2015).
For secondary prevention of CVD, all patients should be offered the following
drug therapy: angiotensin-converting enzyme (ACE) inhibitors, beta blockers, dual
antiplatelet agents of which one is aspirin, and statins (NICE, 2013b). Up to 75% of
recurrent events may be prevented when all these drugs are prescribed in combination
with smoking cessation (WHO, 2015a). For some patients, it is beneficial to have
heart surgery, which includes coronary artery bypass grafts, coronary angioplasty,
valve repair and replacement, heart transplantation, and artificial heart operations
(WHO, 2015a).
2.1.1 Primary risk assessment
The National Institute of Health and Clinical Excellence (NICE), which is a UK na-
tional body providing guidelines on health and social care, recommends the QRISK2
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assessment to calculate the risk of developing a first cardiovascular event in the next
ten years (NICE, 2015). This risk assessment incorporates information on multiple
demographic, medical, and lifestyle factors, see Figure 2.1.
QRISK2 was developed in 2008, using two million UK patient records from 550
general practices that contributed to the QResearch primary care database (Hippisley-
Cox et al., 2008). Using the QResearch and The Health Improvement Network
(THIN) primary care database, the QRISK2 scores were validated against the Fram-
ingham scores, which was the recommended cardiovascular risk assessment at that
time (Collins and Altman, 2009; Hippisley-Cox et al., 2008). The results showed that
the QRISK2 scores estimated cardiovascular risk more accurately than the Fram-
ingham scores. As a result, since 2010 QRISK2 is the recommended tool to assess
cardiovascular risk (NICE, 2015). QRISK2 is updated annually, including the set of
risk factors and the coefficients of the risk factors (Ltd, 2015). The updated version
is in turn externally validated (Collins and Altman, 2012).
The QRISK2 risk assessment shows that men are at a higher risk of developing
CVD than women. Compared to people with a Caucasian background, people with
an Indian, Pakistani, or Bangladeshi background, have higher cardiovascular risk. In
contrast, people with a black Caribbean background or men with a black African
or Chinese background, have lower cardiovascular risk. The risk of CVD increases
with level of deprivation, which has a greater hazardous effect in women than in men.
Although age is the main driver behind cardiovascular risk, the risk factors with the
greatest hazardous effect are, listed in descending order: atrial fibrillation, type 2
diabetes, and family history of ischaemic heart disease.
QRISK2 is used to identify people aged between 25 and 85 who are likely to
be at high risk of developing a first cardiovascular event. These age boundaries are
specified because people younger than 25 have practically no cardiovascular risk, while
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Figure 2.1: QRISK R©2 cardiovascular disease calculator
This tool calculates the risk of developing a first cardiovascular event in the next ten
years for an individual aged between 25 and 85 (ClinRisk Ltd, 2015).
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people aged 85 and older are at high risk no matter their demographic, medical, or
lifestyle background. People who have a QRISK2 score above a certain threshold,
and are thereby classified as being at high risk, are offered statin therapy for primary
prevention of CVD (NICE, 2015). The set risk threshold is based on results from
clinical trials that estimated the effectiveness of the drug in specific risk groups.
2.1.2 Primary risk management
Statins have been widely prescribed for primary and secondary prevention of CVD
since the Scandinavian Simvastatin Survival Study in the 1990s demonstrated ben-
efits of statin therapy in patients with established CVD (4S, 1994). Since then, the
results of many statin trials have been combined into an individual patient-based
meta-analysis of 27 randomised control trials and over 90,000 patients by the Choles-
terol Treatment Trialists’ Collaboration (CTTC) (CTTC, 2012). This meta-analysis
reported that in participants without a history of vascular disease, statins reduced
the overall risk of all-cause mortality by 9% per 1.0 mmol/L reduction in low-density
lipoprotein (LDL). The study, however, could not conclude survival benefits of statins
for the individual risk groups due to the small number of deaths.
Based on the CTTC findings published in 2012, NICE lowered the risk threshold
at which statins should be prescribed from 20% to 10% in July 2014 (NICE, 2015).
This caused a ‘storm of controversy’ about the benefits to people at low risk of CVD
(Parish et al., 2015). The lowered risk threshold translated to an increasing number
of people being eligible for the drugs; that is an additional 4.5 million UK residents
(NICE, 2014b). The risk threshold of 10% recommended by NICE identified similar
numbers of patients as the 2013 American College of Cardiology/American Heart
Association (ACC/AHA) guideline, which recommends statin prescription when the
Pooled Cohort Equations (PCE) estimated 10-year risk of a cardiovascular event is
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≥7.5% (Mortensen and Falk, 2014; Stone et al., 2014). The 2012 European Society
of Cardiology (ESC) guideline recommends considering statins when the Systematic
COronary Risk Evaluation (SCORE) estimated 10-year risk of cardiovascular mor-
tality is ≥5%, but this identifies much fewer patients than the NICE and ACC/AHA
guidelines, because it focuses on mortality rather than events (Mortensen and Falk,
2014; Perk et al., 2012).
The CTTC meta-analysis was one of the most comprehensive sources of evidence
assembled for any medical condition, but still left some major uncertainties about
the survival benefits of statins for those without a history of vascular disease. First,
the strict inclusion criteria of most of the included clinical trials make it difficult to
apply the findings to patients in routine clinical practice, most of whom would not
have been eligible for the trials on the grounds of age or morbidity (Downs et al.,
1998; Nakamura et al., 2006; Ridker et al., 2008; Shepherd et al., 1995). Second, the
risk groups were based on the study’s own prediction of the 5-year risk of a major
vascular event, which makes comparison with the QRISK2, SCORE, or PCE risk
over 10 years, as widely used and recommended in European or American clinical
practice, difficult and uncertain. Third, the average age of a trial participant was
63 years and the trials only included a small number of older participants, making
estimates of effectiveness in different age groups difficult. Fourthly, the follow-up
time of each trial was at most five years, which is much shorter than the monitoring
of many patients in routine clinical practice. The short follow-up time resulted in
a small number of deaths observed, leading to uncertain results for the individual
risk groups; only between 300 and 1,500 deaths were observed in the individual risk
groups of patients with no history of vascular disease. There are also concerns that
anonymised individual patient data from statin trials have not been made available
for independent scrutiny, particularly as statins are among the most widely prescribed
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drugs globally (Parish et al., 2015).
NICE identified several gaps in the research evidence of risk management with
statins when the guidance was updated in 2014, and recommended further research
into the effectiveness of age alone and other routinely available risk factors compared
with formal structured multi-factorial risk assessment to identify people at high risk
of developing CVD, as well as into the effectiveness of statin therapy in older people
in general (NICE, 2015). These identified gaps and the uncertain results of survival
benefits of statins in the individual risk groups led to the current research objective to
estimate the long-term survival benefits of statin prescribed in the general population
with no previous history of CVD, stratified by age and QRISK2 groups. This is
pursued in Chapter 6.
2.2 Acute myocardial infarction
AMI is pathologically defined as myocardial cell death due to prolonged ischaemia
(Swanton and Banerjee, 2009). The risk factors of AMI were established by the
INTERHEART study that took place in 52 countries from 1999 to 2002 and included
roughly 30,000 participants (Yusuf et al., 2004). The study found that the population
attributable risk (PAR) in men and women could be explained up to 90% and 94%,
respectively, by the following risk factors: smoking, alcohol consumption, abdominal
obesity, hypertension, hypercholesterolaemia, diabetes, psychosocial factors (an index
score that combines depression, stress at work/home, financial stress, life events, and
locus of control factors), consumption of fruits and vegetables, and regular physical
activity. This means that if exposure to these risk factors were removed, the incidence
would be reduced by 90% in men and 94% in women. Of the nine risk factors,
hypercholesterolaemia was the most hazardous.
In 2012 in the UK, the average age for men and women to have their first AMI
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episode was 65 and 73 years, respectively, and the case-fatality (here death within
first 30 days) was 8% (NICE, 2013a). Mortality ratios reduce markedly over the first
year following AMI, but start to level off thereafter. The latest population-based
cohort study in England with data from 2004 to 2010, concluded that after seven
years people with a first or recurrent AMI have double or triple the risk of mortality
compared to the general population of equivalent age (Smolina et al., 2012b).
Incidence and mortality rates have declined considerably over the past few decades
in developed countries including the UK (Briffa et al., 2009; Capewell et al., 2000;
Hardoon et al., 2011; Luepker, 2011; Smolina et al., 2012a). The Multinational Mon-
itoring of Trends and Determinants in Cardiovascular Disease (MONICA) project,
which was set up by the World Health Organization, collected data from 38 medi-
cal centres in 21 developed countries from 1985-87 to 1995-97 (Luepker, 2011). The
sample consisted of approximately 10 million subjects aged 25-64. Two thirds of the
decline in mortality after ischaemic heart disease was explained by a decrease in the
incidence rate and a third by a decrease in the case-fatality rate (here death within
first 28 days). A more recent study in England made use of data from the Hospital
Episode Statistics and Mortality Statistics from 2002 to 2010 (Smolina et al., 2012a).
Over that period of time, the incidence and case-fatality rate (here death within first
30 days) of AMI fell both by a third. Both declines contributed approximately the
same to the halved one-year mortality rate.
The European Society of Cardiology and the American College of Cardiology
introduced a new diagnostic criterion of AMI in 2000 (Smolina et al., 2012a). The new
criterion measures the amount of troponin I or T in a blood sample. These proteins
are released when there is heart damage; the more damage, the more of these proteins
can be found (Antman et al., 2000). The new criterion led to more diagnoses of AMI
and thus also to more reported incidence of milder cases. It takes time before a new
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criterion is standardised in the diagnosis of a disease. Studies in Denmark (Abildstrom
et al., 2005), Finland (Salomaa et al., 2006), Australia (Sanfilippo et al., 2008), and
the United States (Roger et al., 2010) showed that the new criterion affects the
incidence rate but not the mortality rate. This is because the new criterion increased
the incidence of AMI in patients aged 70 or older, who have a worse survival rate
than younger patients.
The improved incidence and mortality rates over the past few decades in devel-
oped countries can partly be explained by an increase in coronary revascularisation,
more effective drug therapy, and healthier lifestyles (Bata et al., 2006; Briffa et al.,
2009; Capewell et al., 2000; Hardoon et al., 2011; Smolina et al., 2012a). With respect
to the lifestyles, there was a decrease in smoking, sedentary lifestyle, hypertension,
and hypercholesterolemia. Even though the incidence and mortality rates have im-
proved, a considerable number of people are still affected by AMI and continue to
have worse survival prospects than people without AMI. In 2012 in the UK, there
were approximately one million men and almost half a million women with a history
of AMI (NICE, 2013a).
2.2.1 Secondary risk management
After an AMI, all patients are encouraged to attend a cardiac rehabilitation pro-
gramme (NICE, 2013b). This programme includes exercise plans, health education,
and stress management to reduce their risk of a next cardiovascular event. Patients
are advised to be physically active, stop smoking, regularly consume a moderate
amount of alcohol, eat a Mediterranean-style diet, and manage their weight. All
patients should be offered ACE inhibitors, beta blockers, dual antiplatelet agents of
which one is aspirin, and statins, and be considered for coronary revascularisation.
Survival prospects after an AMI vary by a number of factors, here grouped by
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socio-demographic factors, lifestyle choices, comorbidities, and treatments. Examples
of survival variations by socio-demographic factors are age, sex, socioeconomic status,
and psychosocial factors. Older patients have a higher case-fatality rate and are
at higher risk of a recurrent cardiovascular event (Capewell et al., 2000; Smolina
et al., 2012b). Women tend to have a worse survival rate of AMI in the short-
term but have the same long-term survival prospects as men (Capewell et al., 2000;
Chang et al., 2003; Gottlieb et al., 2000; Koek et al., 2007; Rosengren et al., 2001;
Smolina et al., 2012b; Vaccarino et al., 1999). People with lower socioeconomic status
measured at the individual or neighbourhood level have worse survival prospects
after an AMI. Neighbourhood socioeconomic status possibly captures the residual
confounding factors of unequal hospital resources and social characteristics of an area
such as social cohesion and attitudes towards health (Capewell et al., 2000; Gerber
et al., 2010; Smolina et al., 2012b). Compared to patients with ischaemic heart
disease and no psychosocial factors, patients with ischaemic heart disease suffering
from depression, anxiety, job strain, or lack of social support have a worse survival
rate (Hemingway and Marmot, 1999). Therefore, offering stress management and
psychosocial support to patients who had an AMI could help improve their survival
prospects.
Lifestyle choices that affect survival prospects after an AMI are: smoking, body
mass index, alcohol consumption, and physical activity. There is a smoker’s paradox
in which smokers have a better short-term survival rate than non-smokers (Gerber
et al., 2009; Gourlay et al., 2002). This is partly explained by the fact that smokers
tend to have an AMI at a younger age and therefore fewer additional risk factors. In
the long-term, non-smokers have a better survival rate than ex- and current-smokers.
Smoking cessation either before or after an AMI is associated with improved short-
and long-term survival rates (Gerber et al., 2009). Similarly, obese AMI patients have
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a better survival rate in the first six months compared to AMI patients with a healthy
weight (Nigam et al., 2006). After six months, patients with a healthy weight have a
lower risk of a recurrent event and mortality. The reason for this paradox is not fully
explained, but could be due to the fact that obese patients typically have an AMI
at a younger age and receive more aggressive treatment than patients with healthy
weights. At an older age, overweight patients have a better survival rate than healthy
weight patients even though overweight people are more likely to have cardiovascular
disease (Chapman, 2010). From the age of 65 onwards, the optimal body mass index
was found to be between 27 and 30, and from the age of 75 onwards, obesity has little
to no harmful effects on survival rate.
Comorbidities that affect survival prospects after an AMI are: previous AMI,
angina pectoris, cerebrovascular disease, peripheral vascular disease, heart failure,
cancer, diabetes, renal disease, respiratory disease, hypertension, and hypercholes-
terolaemia. Of these comorbidities, diabetes is the most hazardous. Co-occurrence
of these medical conditions increases with age (van Baal et al., 2011). Considering
AMI, diabetes, cerebrovascular disease, and cancer, the two conditions that occur
most often together in absolute numbers are AMI with diabetes and in relative num-
bers AMI with cerebrovascular disease. The Charlson comorbidity index measured
five years prior to the AMI event is also a strong predictor of survival prospects
(Schmidt et al., 2012). The Charlson comorbidity score is calculated as follows: one
point for AMI, congestive heart failure, peripheral vascular disease, cerebrovascular
disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease,
mild liver disease, and diabetes without end organ damage; two points for diabetes
with end organ damage, hemiplegia, moderate to severe renal disease, non-metastatic
solid tumour, leukaemia, and lymphoma; three points for moderate to severe liver
disease; and six points for metastatic cancer and AIDS (Charlson et al., 1987). This
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score has been extensively validated (O’Connell and Lim, 2000; Schmidt et al., 2012).
Treatment of these conditions should be in line with the respective clinical guidelines
(NICE, 2013b).
As stated above, all patients should be offered drug therapy to reduce the risk of
next cardiovascular event. Non-compliance with the drug therapy could result in a
higher risk of adverse outcomes. Approximately half of patients are non-compliant in
taking aspirin after several years (Graham et al., 2007). A systematic review based on
approximately 50,000 patients showed that this can cause a threefold increased risk of
another cardiovascular event (Biondi-Zoccai et al., 2006). Another study found that
people who stopped taking aspirin within the last six months were worse off compared
to current users with regards to risk of non-fatal AMI or fatal ischaemic heart events
(Garc´ıa Rodr´ıguez et al., 2011). However, people who stopped taking the drug for
more than six months were not significantly better or worse off than current users.
People who stopped because of safety concerns or used over-the-counter aspirin were
also not significantly better or worse off than current users. NICE reported mixed
clinical evidence of the effectiveness of drug therapy versus placebo with regards to
long-term all-cause mortality. Aspirin had inconclusive benefits (CDP, 1976; NICE,
2013a). ACE inhibitors seem to be effective in AMI patients with left ventricular
systolic dysfunction (LVSD; relative risk (RR) of 0.84 (95% confidence interval 0.78-
0.91)) (NICE, 2013a). This evidence is of moderate quality with no serious inconsis-
tency, indirectness, or imprecision. ACE inhibitors, however, seem to be ineffective in
AMI patients with unselected LVSD (RR=1.02 (0.57-1.84)) (NICE, 2013a). This ev-
idence is of low quality due to its imprecision. Patients receiving beta blockers in the
first 72 hours after the onset of AMI or after 72 hours to a year have a lower hazard
of mortality (RR=0.87 (0.67-1.20) and RR=0.76 (0.49-1.16), respectively) (NICE,
2013a). This evidence is of low quality due to its imprecision. Statins in any patient
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or specifically in CVD patients reduced the hazard of all-cause mortality (RR=0.87
(0.84-0.91) and RR=0.87 (0.83-0.91), respectively) (NICE, 2015). This evidence is
of high quality but not clinically important due to the low effect size. The NICE-
recommended drug therapy’s primary objective is to improve survival prospects by
reducing the risk of next cardiovascular event and not per se by reducing the risk
of mortality. If the benefits of a drug in reducing the risk of a next cardiovascular
event outweighs the adverse effects and is not harmful for life expectancy, the drug
could be included in the clinical guideline. The mixed clinical evidence of reduction
in the risk of mortality associated with drug therapy led to the research objective to
estimate the long-term survival benefits of treatments. This is pursued in Chapter 5.
2.2.2 Existing survival models
There are numerous studies that have examined survival prospects and their varia-
tions after AMI by estimating case-fatality, one-year mortality, and long-term mor-
tality. These studies either estimated mortality rates of AMI standardised for age,
sex, deprivation or region (Capewell et al., 2000; Hardoon et al., 2011; Luepker, 2011;
Smolina et al., 2012a,b) or examined survival variations among AMI patients by a
range of risk factors including socio-demographic factors, lifestyle choices, comorbidi-
ties, and treatments (Briffa et al., 2009; Capewell et al., 2000; Chang et al., 2003;
Gerber et al., 2010, 2009; Herzog et al., 1998; Kirchberger et al., 2014; Koek et al.,
2007; Nigam et al., 2006; Quint et al., 2013; Smolina et al., 2012b). The first type of
study is likely to overestimate the hazardous effect of AMI on mortality, because it
was limited in the number of risk factors to adjust for between patients who had an
AMI and who did not have an AMI; while the second type of study cannot estimate
the hazardous effect of AMI on mortality due to the lack of a control group. Thus,
there has not been a study that estimated long-term survival prospects after AMI
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compared to no AMI while adjusting for a range of risk factors. To inform the choice
of risk factors in the survival models developed for this research, existing survival
models that estimated long-term all-cause mortality in AMI patients were reviewed.
The review also included listing the study designs, data sources, and data modelling
techniques used. The survival models reviewed are presented in Table 2.1.
The studies took place in various developed countries: Australia, Canada, Eng-
land, Germany, Israel, the Netherlands, Scotland, and the United States. Either a
city, region, county, or whole country was eligible for the study. All studies had as in-
clusion criteria that patients had to be hospitalised for an AMI. Additional inclusion
criteria were that patients had to survive for a specific period of time (8/11 studies),
the AMI had to be the first one in the medical history (7/11 studies), patients had
to be of a certain age (6/11 studies), and patients had to have an additional medical
condition (2/11 studies). The recruitment periods ranged from 1 to 18 years. Six
studies followed up the patients for longer than that period, resulting in study pe-
riods ranging from 6 to 21 years. Together the studies analysed data from 1977 to
2011. The sample size varied greatly, from less than 1,000 to almost 400,000 patients.
All studies used clinical data from either hospitals or register databases. Five
studies made use of the extra information available in hospital data regarding the
severity of AMI and the treatment given at admission and/or discharge (Briffa et al.,
2009; Chang et al., 2003; Gerber et al., 2010, 2009; Kirchberger et al., 2014). Three
studies obtained additional data from questionnaires or interviews, in which informa-
tion regarding the patient’s socioeconomic status (education, income, employment,
and living with a steady partner), lifestyle (smoking and physical activity), and health
status (self-rated) were asked (Gerber et al., 2010, 2009; Kirchberger et al., 2014).
One study also made use of primary care data, although AMI patients were not
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selected for the study using that source of data (Quint et al., 2013). A study pop-
ulation and survival model based on primary care data could lead to different re-
sults due to the extensive information available on this slightly different population.
Compared to hospital and register data, primary care data has more information on
socio-demographic and lifestyle factors and has a greater coverage of AMI cases in
the UK (Herrett et al., 2013b). Therefore, primary care data could be an important
new source of information on survival prospects of patients who have had an AMI.
All but one study included patients from multiple hospitals. Of these studies,
only one included a random effect of hospitals in the survival model, but found no
significant survival variations between the eight hospitals (Gerber et al., 2009). The
other studies assumed that there were no survival variations by hospital. In case that
this assumption is violated, failing to adjust for clustering by hospital can lead to
false precision (Therneau and Grambsch, 2000).
All studies estimated all-cause mortality from the moment the AMI was diagnosed
by means of a Cox’s proportional hazards regression. Five studies reported checking
the assumption of proportional hazards between the baseline category and the other
categories of a risk factor (Gerber et al., 2010, 2009; Kirchberger et al., 2014; Koek
et al., 2007; Smolina et al., 2012b). In case of violation, the estimated hazard of
mortality associated with a risk factor would be imprecise at specific points in time
as the hazard is an average over the whole study period (Kleinbaum and Klein, 2011).
Moreover, there could be a type-II error, i.e. a false negative, where the risk factor
is protective in one period of time and hazardous in another period of time, like the
smoking paradox in one-year mortality rates as explained above (Gerber et al., 2009;
Gourlay et al., 2002). Therefore, it is important to check the proportional hazards
assumption. All studies assumed uninformative censoring, where patients lost to
follow-up were assumed to have the same mortality rate as patients observed until
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the end of the study (Hosmer et al., 2008). Two studies reported the number of
patients lost to follow-up, which was less than 3% (Herzog et al., 1998; Kirchberger
et al., 2014). The other studies probably had a similar percentage as they made use
of death registers and thus loss to follow-up would only happen in case of emigration.
These low percentages of loss to follow-up were unlikely to affect the results.
Seven studies had missing data in socioeconomic status and lifestyle factors and
one study had missing data in drug prescriptions. One study imputed missing values
in income with the lower of the two categories, which affected only 2% of the sam-
ple (Chang et al., 2003). Five studies performed a complete case analysis thereby
excluding between 4 and 24% of the sample (Capewell et al., 2000; Gerber et al.,
2010, 2009; Kirchberger et al., 2014; Quint et al., 2013). In one study it is unknown
how missing data were addressed (Briffa et al., 2009). When data are missing com-
pletely at random, meaning that there is no systematic difference between observed
and unobserved data, unbiased results are obtained when complete case analysis is
performed (Allison, 2001). It is, however, highly likely that patients with missing
data differ from patients with complete data, as other studies found that recording of
lifestyle factors is associated with health and thereby indirectly associated with sur-
vival rate (Marston et al., 2010; Shephard et al., 2011; Szatkowski et al., 2012). Thus,
the results of the complete case analyses of the reviewed studies could potentially be
biased.
Half of the survival models were built in blocks of risk factors; first sex and age
were included in the model, followed by a group of risk factors, and ending with a
full model (Gerber et al., 2010, 2009; Kirchberger et al., 2014; Koek et al., 2007;
Quint et al., 2013). One study also reported the leanest model possible found by
backward elimination (Kirchberger et al., 2014). The groups of risk factors used
in the survival models were socio-demographic factors, lifestyle choices, severity of
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AMI, comorbidities, treatments, and hospital details. All studies adjusted for age
and sex, and most studies adjusted for socioeconomic status, types of CVD, diabetes,
hypertension, and coronary revascularisation procedures or drug therapy. Two studies
estimated survival variations separately by sex and/or age group (Capewell et al.,
2000; Smolina et al., 2012b), and another two studies tested for interaction effects
with sex, age, and the exposure of interest (diabetes or education level) (Kirchberger
et al., 2014; Koek et al., 2007). Testing interactions between all risk factors could
elucidate different effects in subpopulations and thereby explain survival variations
to a greater extent. Furthermore, given that it is impossible to include all risk factors
in the survival model due to limited recording, all groups of risk factors should be
represented to obtain a holistic estimation of survival prospects.
The estimated hazards of mortality associated with different risk factors are study
specific; the hazards depend on the sample studied, the time-period studied, the
length of the study period, and the adjustment of other risk factors. Compared
to a first AMI, the hazard ratio of mortality associated with a recurrent AMI was
estimated to be 1.2 to 1.8 (Chang et al., 2003; Nigam et al., 2006; Smolina et al.,
2012b). This hazard was greater at a younger age; in people aged 30 to 54 the hazard
ratio was 2.3 while in people aged 85 or older the hazard ratio was 1.4 (Smolina
et al., 2012b). The hazard of mortality associated with diagnosis of AMI decreased
with calendar year; with every 4 to 8 years the hazard of mortality was significantly
lower (Briffa et al., 2009; Capewell et al., 2000; Chang et al., 2003; Herzog et al.,
1998). Of the comorbidities, heart failure, diabetes, and chronic kidney disease, were
with hazard ratios of 1.4 to 2.5, the most hazardous for the survival rate (Briffa et al.,
2009; Capewell et al., 2000; Chang et al., 2003; Herzog et al., 1998; Nigam et al., 2006;
Smolina et al., 2012b). Again, these hazards were greater in younger patients than
in older patients (Smolina et al., 2012b).
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Coronary revascularisation had a survival benefit with a hazard ratio of 0.4 to 0.5
when it was undertaken during hospitalisation (Nigam et al., 2006; Smolina et al.,
2012b) and of 0.8 to 0.9 when it was undertaken prior to the AMI or within the six
months after the AMI (Chang et al., 2003; Herzog et al., 1998). Drug prescriptions had
mixed effects on survival prospects. The greatest survival benefit was by prescription
of antiplatelet drugs, like aspirin, and beta blockers with a hazard ratio of 0.5 to
0.8 (Briffa et al., 2009; Nigam et al., 2006; Quint et al., 2013). In contrast, lipid-
lowering drugs, like statins, and ACE inhibitors were associated with a hazard ratio
of 1.4 to 2.2 (Briffa et al., 2009; Nigam et al., 2006). Survival prospects were better
when patients were prescribed multiple drugs during hospitalisation, but this was not
necessarily true at discharge. The optimal number of prescriptions was three during
hospitalisation and two at discharge (Briffa et al., 2009). Prescription of only one
drug during hospitalisation or more than two different drugs at discharge was not
associated with a significant survival benefit (Briffa et al., 2009).
Men and women did not vary in long-term survival prospects after an AMI, but ex-
perienced different effects of age and deprivation on their survival prospects (Capewell
et al., 2000; Smolina et al., 2012b). Compared to men and women aged under 55, men
and women aged 85 and older had a hazard ratio of 12 to 20 and 11 to 16, respectively
(Capewell et al., 2000; Smolina et al., 2012b). Compared to men and women living
in the least deprived area measured by the index of multiple deprivation (IMD), men
and women living in the most deprived areas had a hazard ratio of 1.3 to 1.4 and
1.2, respectively (Capewell et al., 2000; Smolina et al., 2012b). Lastly, the hazard of
mortality associated with smoking was 1.3 to 1.4 (Briffa et al., 2009; Chang et al.,
2003), and a body mass index of greater than 25 was 0.7 (Nigam et al., 2006).
The identified gaps in the research evidence around survival prospects of AMI
patients led to the research objective to estimate the hazard of mortality associated
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with a history of a single or multiple AMIs at key ages in UK residents based on
primary care records while adjusting for a wide range of risk factors. Additionally, the
widespread model assumptions in the research evidence led to the aim to investigate
possible survival variations by general practice. The research objectives and aims are
pursued in Chapter 5.
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Table 2.1: Existing survival models of all-cause mortality after acute myocardial infarction (AMI)
Lead author
(year
published)
Study period Study population Sample size
(deaths)
Survival
model (as-
sumptions)
Approach to
missing data
(% missing)
Risk factors in model
Briffa
(2009)
1984-2005 Patients aged 35-64
admitted to hospitals in
Perth (Australia) in
1984-1993 with first AMI
and survived first 28 days
4,451 (1,182) Cox’s
regression
(propor-
tional
hazards
assumed)
Imputed null
values
(unknown)
Sex, age, subcohort, diabetes,
hypertension, smoking, ECG
PREDICT score, heart failure,
cardiogenic shock, tachycardia,
systolic blood pressure,
thrombolyisis, antiplatelet drugs,
beta blockers, angiotensin
converting enzyme inhibitors,
lipid-lowering drugs, and
coronary artery bypass graft
Capewell
(2000)
1986-1996 Patients admitted to
hospitals in Scotland in
1986-1995 with first AMI
or angina and survived
first 30 days
96,026
(39,449)
AMI and
37,403
(8,153)
angina
Cox’s
regression by
sex (propor-
tional
hazards
assumed)
Complete
case analysis
(4%)
Age group, deprivation,
cerebrovascular disease, cancer,
ischaemic heart disease, diabetes,
heart failure, peripheral vascular
vascular disease, and respiratory
disease
Chang
(2003)
1993-2000 Patients admitted to
hospitals in Alberta
(Canada) in 1993-2000
with AMI or unstable
angina diagnosis
22,967
(7,014) AMI
and 8,441
(1,718)
unstable
angina
Cox’s
regression
(propor-
tional
hazards
assumed)
Missing
values of
income
imputed
with the
lower
category
(2%)
Sex, age group, year of
admission, diabetes, previous
congestive heart failure, chronic
obstructive pulmonary disease,
previous AMI, previous
angioplasty, chronic renal disease,
anaemia, cardiovascular
specialist, coronary artery bypass
graft capable hospital, health
region, income, revascularisation
Continued on next page
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Lead author
(year
published)
Study period Study population Sample size
(deaths)
Survival
model (as-
sumptions)
Approach to
missing data
(% missing)
Risk factors in model
Gerber
(2009)
1992-2005 Patients aged ≤65
admitted to 8 hospitals in
central Israel in
1992-1993 with first AMI
and survived hospital
admission
1,521 (427) Cox’s
regression
(propor-
tional
hazards
checked)
Complete
case analysis
(24%)
Sex, age, ethnic origin, education,
income, pre-AMI employment,
smoking status, hypertension,
dyslipidemia, diabetes, obesity,
physical activity, Q-wave AMI,
anterior AMI, Killip class,
comorbidity, thrombolysis,
coronary artery bypass graft, and
angioplasty (note: random effect
on hospital was insignificant)
Gerber
(2010)
1992-2005 Patients aged ≤65
admitted to 8 hospitals in
central Israel in
1992-1993 with first AMI
and survived hospital
admission
1,521 (427) Cox’s
regression
(propor-
tional
hazards
checked)
Complete
case analysis
(24%)
Sex, age, ethnic origin,
hypertension, diabetes,
dyslipidemia, smoking, physical
activity, admission to ICU,
anterior AMI, comorbidity index,
Killip class, coronary artery
bypass graft, angioplasty,
self-rated health, education,
income, pre-AMI employment,
living with a steady partner, and
neighbourhood socioeconomic
status
Continued on next page
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Lead author
(year
published)
Study period Study population Sample size
(deaths)
Survival
model (as-
sumptions)
Approach to
missing data
(% missing)
Risk factors in model
Herzog
(1998)
1977-1995 Patients recorded in
United States Renal Data
System with first AMI in
1977-1995 after
renal-replacement
therapy for ≥90 days and
dialysis for ≥60 days
34,189 (ap-
proximately
32,000)
Cox’s
regression
(non-
informative
censoring
(858/2.5%
censored)
and
proportional
hazards
assumed)
Not
applicable
Sex, age, ethnicity, AMI calendar
year, cause of end-stage renal
diagnosis, congestive heart
failure, other cardiovascular
conditions, cancers other than
skin cancer, chronic obstructive
pulmonary disease,
cerebrovascular ischaemia,
peripheral vascular disease,
gastrointestinal disease,
gallbladder disease, liver disease,
duration of end-stage renal
disease, and revascularisation
Kirchberger
(2014)
2000-2011 Patients aged 28-74
admitted to 10 hospitals
in Augsburg region
(Germany) in 2000-2008
with first AMI and
survived first 28 days
4,405 (471) Cox’s
regression
(non-
informative
censoring
(5/0.1%
censored)
assumed and
proportional
hazards
checked)
Complete
case analysis
(22%)
Sex, age group, education level,
living alone, diabetes, angina
pectoris, hypertension,
hyperlipidaemia, stroke, any
reperfusion therapy, AMI type,
left ventricular ejection fraction,
any in-hospital complications, age
group*sex, and age
group*education level (note:
sex*educational level was
insignificant)
Koek
(2007)
1995-2000 Patients admitted to
hospitals in the
Netherlands in 1995 with
first AMI
21,565
(3,149)
Cox’s
regression
(propor-
tional
hazards
checked)
Not
applicable
Sex, age, diabetes, previous
cardiovascular disease, ethnic
origin, age*diabetes, and age*sex
(note: sex*diabetes was
insignificant)
Continued on next page
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Lead author
(year
published)
Study period Study population Sample size
(deaths)
Survival
model (as-
sumptions)
Approach to
missing data
(% missing)
Risk factors in model
Nigam
(2006)
1988-2001 Patients aged <80
residential in Olmsted
County (United States)
admitted to Mayo Clinic
Coronary Care Unit in
1988-2001 with AMI and
survived the first six
months
894 (233) Cox’s
regression
(propor-
tional
hazards
assumed)
Not
applicable
Sex, age, body mass index,
diabetes, systolic blood pressure,
diastolic blood pressure, smoking
status, family history of
ischaemic heart disease, lipid
lowering drugs, beta blockers,
aspirin, and angiotensin
converting enzyme inhibitors
Quint
(2013)
2003-2008 Patients aged ≥18 with
chronic obstructive
pulmonary disease
(COPD) and a first AMI
recorded in MINAP
(Myocardial Ischaemia
National Audit Project,
England) and registered
at a General Practice
Research Database
(GPRD) practice in
2003-2008 and survived
first year
1063 (447) Cox’s
regression
(propor-
tional
hazards
assumed)
Complete
case analysis
(24%)
Sex, age, smoking, family history
of cardiovascular disease, angina,
hypertension, dyslipidaemia,
peripheral arterial disease,
cerebrovascular disease, heart
failure, diabetes, frequency of
exacerbations of COPD, type of
myocardial infarction, diuretics,
anti-arrhythmia drugs,
antiplatelet agents, angiotensin
converting enzyme inhibitors,
beta blockers, statins, nitrates,
and calcium-channel blockers
Smolina
(2012)
2004-2011 Patients admitted to
hospitals in England in
2004-2010 with AMI and
survived first 30 days
387,452
(100,442)
Cox’s
regressions
by sex and
by age group
(propor-
tional
hazards
checked)
Not
applicable
Sex/age group, deprivation,
coronary artery bypass graft,
angioplasty, cancer,
cardiovascular disease, diabetes,
respiratory disease, and renal
disease
Chapter 3
Review of primary care data
This Chapter is a review of primary care data, in particular The Health Improvement
Network (THIN) database, used for this research. The previous Chapter reviewed
survival models of cardiovascular disease (CVD) and revealed that primary care data
were rarely used for model development. This Chapter starts by discussing in what
aspects primary care data could be valuable in developing survival models by com-
paring prospectively collected trial-cohort data with routine data. Next, the main
primary care databases in the United Kingdom (UK) are introduced and the avail-
ability and validity of the data are discussed. This is followed by an overview of the
THIN database. Then, the inclusion and exclusion criteria used to identify eligible
practices and patients for the age-specific cohorts are discussed. Finally, the baseline
measures and the outcomes during follow-up of the cohorts are defined.
3.1 Medical data sources
Important features regarding the usability of a model are that the sample is repre-
sentative of the target population, there is a high volume of person-years of data
to obtain precise estimates, there is high statistical power to test for risk factors,
the most important risk factors are adjusted for to minimise residual confounding,
the appropriate model is chosen to estimate the outcome and the respective model
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assumptions are addressed, and the model is validated. The data source used for
model development determines which outcomes can be studied and the generalisabil-
ity of the results. The data sources used for the CVD survival models can be divided
into prospectively collected trial-cohort data and routine data from primary care,
secondary care, disease registers, or mortality registers (Briffa et al., 2009; Capewell
et al., 2000; Chang et al., 2003; CTTC, 2012; Gerber et al., 2010, 2009; Herzog et al.,
1998; Kirchberger et al., 2014; Koek et al., 2007; NICE, 2013a; Nigam et al., 2006;
Quint et al., 2013; Smolina et al., 2012b). These two types of data sources are com-
pared with respect to the outcome ascertainment, the completeness and accuracy of
risk factors, the representativeness of the sample, and the cost of collecting data.
Randomised control trials (RCTs) and cohort studies that prospectively collect
data are designed to measure specific outcomes, exposures, and risk factors. Study
protocols usually ensure that the data collection is done in a consistent and complete
matter at specific points in time. The data collection, however, might be subject to
recall or interviewer bias. Furthermore, there might not be data collected on certain
risk factors, because at the start of the study these risk factors were deemed not to
be relevant in predicting the outcome.
With routine data, information is recorded at the time the patient enters pri-
mary or secondary care. Therefore, the amount of data available is dependent on
how frequently the patient enters primary or secondary care and what the clinicians
find relevant to record for the patient’s healthcare (MacDonald and Morant, 2008;
Shephard et al., 2011; Wijlaars, 2013a). This could result in a substantial amount
of missing or sporadic entries for the risk factors and outcomes the researcher is
interested in. Furthermore clinicians can code medical conditions and treatments
differently from each other and can have trouble classifying them or even misclassify
them (Hippisley-Cox and Coupland, 2010b; MacDonald and Morant, 2008; Shephard
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et al., 2011). With the introduction of the Quality and Outcomes Framework (QOF)
in 2004, a pay scheme to improve the quality of health care provided by general
practitioners, recording has greatly improved in primary care (Langley et al., 2011;
NICE, 2014a; Szatkowski et al., 2012). There are also lists of clinical codes published
to ensure that different researchers identify the same cases for a medical condition
or treatment, thereby improving reproducibility of results (ClinicalCodes.org, 2016).
Moreover, there are widespread accepted methods to deal with missing data (Allison,
2001; van Buuren and Groothuis-Oudshoorn, 2011). All-cause mortality might be
best recorded in primary care after the mortality register, because general practition-
ers must be informed that their patients have died (HSCIC, 2016a). Furthermore,
because primary care data hold information on the comprehensive medical history and
are not specific to a condition, new factors can be tested for that are not traditionally
collected in secondary care, disease registers, or prospective trial-cohort studies. As
these potential risk factors are already routinely recorded in primary care, there is
greater usability of the developed risk models in routine clinical practice.
RCTs and cohort studies that prospectively collect data might be restricted in
the generalisability of the results due to strict inclusion/exclusion criteria and the
relatively small sample of medical centres participating in the study. Secondary data
and disease registers might only be representative of severe cases. Primary care data
might be the most representative of the UK population, because under the National
Health Service (NHS), 99% of the UK population is registered at a general practice
(NHS, 2013). General practitioners are informed when the patients are picked up
by ambulances and/or enter secondary care (Hall, 2009). This means that primary
care data would be representative of both mild and severe cases. Regarding CVD,
after initial treatment in secondary care, the cardiac rehabilitation programme and
follow-up will take place in primary care (Dalal et al., 2015). This means that the
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risk factors affecting survival prospects of CVD patients are recorded in primary care
medical records. Primary care data thus ideally reflects current clinical practice by
providing an almost complete picture of the medical history of all patients (Wijlaars,
2013a). The medical history is not 100% complete, as for example, the intake of over
the counter medication is unknown (Wijlaars, 2013a). Although primary care medi-
cal records might be representative of the national population, the existing databases
consist of medical records from approximately 6 to 10% of all general practices. Hence
its representativeness may vary by clinical system or region, and therefore it is impor-
tant to validate risk models on data from different general practice groups (Collins
and Altman, 2012).
Data collection is costly for prospective studies because of the ongoing cost during
the study period. The costly data collection can limit the sample size, the amount of
data that is collected, and the length of the study period. Collecting routine data,
on the other hand, has only a high initial cost of setting up the software and training
clinicians to use the software, followed by low maintenance cost of validity checks and
providing feedback on data quality to clinicians. Due to the lower cost of data col-
lection, large study samples with rich, long follow-up data can be obtained relatively
easily (Wijlaars, 2013a). Databases with routine data are frequently updated and
therefore lend themselves to obtaining the most recent statistics (Wijlaars, 2013a).
With an almost complete picture of the medical history of a patient in primary care
data, new combinations of risk factors can be examined on the historic data. Fur-
thermore, primary care data allow the selection of cases and controls from the same
source population, whereas this tends to be a challenge for other data sources (Wi-
jlaars, 2013a).
Thus, while each source of data has its strengths and limitations, primary care data
are suitable for addressing the research objectives of estimating the effect of a history
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of acute myocardial infarction (AMI) on the hazard of mortality in UK residents and
also estimating the potential survival benefits of primary and secondary treatments
of CVD.
3.2 Primary care databases in the United King-
dom
There are three large primary care databases in the UK: QResearch; Clinical Practice
Research Datalink (CPRD), which was previously called General Practice Research
Database (GPRD); and The Health Improvement Network (THIN) (CPRD, 2016;
IMS Health Incorporated, 2015b; QResearch, 2016), see Table 3.1. QResearch in-
cludes medical records from approximately 1,000 practices that use the EMIS clinical
system, whereas CPRD and THIN include records from approximately 600 practices
that use the Vision clinical system (Reeves et al., 2014). The records are from pa-
tients who have at some point been registered at the contributing general practice,
and thus also include non-active patients who have transferred to another practice or
died.
The clinical system in operation allows staff of a general practice to store an
electronic record on the details of a patient’s medical history and the care provided and
planned, including appointments, symptoms, test results, diagnoses, and prescriptions
(Department of Health, 2011). Clinical systems can provide templates for specific
medical conditions or for certain risk groups as reminders of what information needs
to be recorded during a consultation (Department of Health, 2011). For example in
people aged 40 or older, the risk of a first cardiovascular event should be reassessed
on a regular basis (NICE, 2015).
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Table 3.1: Primary care databases and national surveys in the United Kingdom
Sources: CPRD, 2016; HSCIC, 2006, 2013, 2015, 2016b; Herrett et al., 2015; IMS Health Incorporated, 2015b,d; ONS, 2013,
2014; QResearch, 2016. 1Previously known as General Practice Research Database (GPRD). 2Previously known as General
Lifestyle Survey (GLS).
Qresearch CPRD THIN QOF GHS HSE
Full name Qresearch Clinical
Practice
Research
Datalink1
The Health
Improvement
Network
Quality and
Outcomes
Framework
General
Household
Survey2
Health Survey
England
Type Primary care
database
Primary care
database
Primary care
database
Incentive
payment
scheme in
primary care
resulting in
electronic
medical records
database
Repeated
cross-sectional
survey
Repeated
cross-sectional
survey
Study
period
1993-ongoing 1987-ongoing 1987-ongoing 2004-ongoing 1971-2011 1991-ongoing
Study
population
Volunteering
general
practices using
EMIS clinical
system in the
United
Kingdom
Volunteering
general
practices using
Vision clinical
system in the
United
Kingdom
Volunteering
general
practices using
Vision clinical
system in the
United
Kingdom
Volunteering
general
practices in
England
Probability,
stratified
two-stage
sample design
in Great
Britain
Multi-stage
stratified
random sample
in England
Continued on next page
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Table 3.1 – Continued from previous page
Qresearch CPRD THIN QOF GHS HSE
Sample size Over 18 million
patients from
over 1,000
general
practices (in
2015)
Over 11 million
patients from
674 general
practices (in
2015)
Over 12 million
patients from
587 general
practices (in
2015)
Over 56 million
patients from
nearly 8,000
general
practices (in
2015)
18,367
individuals
aged 16+ from
7,937
households (in
2011)
10,080
individuals (in
2014)
Data
collection
Electronic
medical records
Electronic
medical records
Electronic
medical records
Electronic
medical records
Annual
telephone and
face-to-face
interviews
collecting data
regarding
education,
employment
and labour,
health, housing,
social indicators
and quality of
life, use and
provision of
specific social
services
Annual
face-to-face
interviews
collecting data
on physical
health, mental
health and
well-being,
social care,
lifestyle
behaviours, and
physical
measures
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The data from these databases made available to researchers are anonymised
records on the patient’s demographics, consultations, diagnoses, treatments offered,
and lifestyle choices (Wijlaars, 2013b). The anonymisation inter alia includes making
available only part of the date of birth, and postcode of a patient and the general
practice at which the patient is registered. Historical paper records, which are typi-
cally scanned in, are not available to researchers. Free-text comments are sometimes
made available to researchers (Wijlaars, 2013b). Free-text could include extra infor-
mation that are not recorded using the structured Read codes, which could result in
underestimation of diagnoses or treatments when free-text comments are not used by
researchers (Nicholson et al., 2011). With the introduction of the QOF in 2004, the
use of structured Read codes has increased (NICE, 2014a).
When medical records are updated or new ones added to the primary care
database, non-clinical information such as inputs on demographics and registration
are checked (IMS Health Incorporated, 2015c). These validity checks are reported to
clinicians, so that they can improve recording, and to researchers so that they can
adjust the analyses when needed. The validity of clinical information was investigated
by systematic reviews and external validations of primary care research using data
from QResearch, CPRD, THIN, General Household Survey (GHS), and Health Survey
England (HSE) (Blak et al., 2011; Collins and Altman, 2009, 2012; Hall, 2009; Herrett
et al., 2010; Hippisley-Cox et al., 2008; Jordan et al., 2004; Khan et al., 2010), see
Table 3.1. Even though these three primary care databases include different general
practices and patients, the estimated incidence, prevalence, and mortality rates are
similar across the databases and with national surveys when adjusted for sex, age, and
deprivation. Family history of medical conditions, lifestyle choices, and demographics
are, however, not systematically recorded or reassessed in primary care (Hippisley-
Cox and Coupland, 2010b; Hippisley-Cox et al., 2008; Marston et al., 2010; NICE,
50
2014a; Szatkowski et al., 2012). Recording of these factors is related to ill health;
people who are ill, visit a general practice more often and general practitioners are
more likely to ask these patients about their lifestyle compared to healthier patients
(MacDonald and Morant, 2008; Shephard et al., 2011). Recording of lifestyle choices
improved greatly after the introduction of the QOF in 2004. For example, from 2006
onwards the prevalence of smokers in THIN is comparable to that of the GHS, which
is considered the gold standard with regards to prevalence of smoking (Langley et al.,
2011; Szatkowski et al., 2012). Records on smoking status and alcohol consumption
are self-reported in primary care databases. As these are not checked by biochemical
data, there could be reporting bias towards the healthier choice (Langley et al., 2011;
Szatkowski et al., 2012). Primary care does also not hold information on intake of
drugs. This means that actual treatment levels can be lower than prescription records
indicate, and hence the estimated effect of prescribed treatment on an outcome could
be smaller than the actual effect of treatment itself on an outcome (MacDonald and
Morant, 2008).
This research used THIN data, therefore it is useful to check the prevalence of
medical conditions related to CVD in THIN against the other data sources. THIN
had a slightly higher crude prevalence of medical conditions compared to QOF data
from 2006/2007: 0.2% for ischaemic heart disease, 0.2% for chronic kidney disease,
0.1% for hypertension, and 0.8% for obesity (Blak et al., 2011). The prevalence of
diabetes in THIN was 0.2% lower than in QOF in the same year (Blak et al., 2011).
The differences in crude prevalence were likely due to the lack of adjustment for sex,
age, and deprivation (Blak et al., 2011). Compared to HSE, the sex- and age-adjusted
prevalence of diabetes in THIN for 1996-2005 was by 0.2% higher (Masso´ Gonza´lez
et al., 2009). Another study compared the sex- and age-adjusted incidence of chronic
kidney disease in THIN with that of QResearch for 2002-2008 and found similar results
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(Hippisley-Cox and Coupland, 2010b). Prevalence of hypertension and hypercholes-
terolaemia were lower in THIN compared to the national rates of 1998, 2003 and 2006
(MacDonald and Morant, 2008). The rates from the different data sources converged
over time and with increasing age (MacDonald and Morant, 2008). Studies report
terminal digit bias towards zero in blood pressure records from general practices, hy-
pertension clinics, clinical trials, and hypertension screenings (Ali and Rouse, 2002;
Nietert et al., 2006; Thavarajah et al., 2003; Wingfield et al., 2002a,b). In THIN, the
digit bias declined from 71% to 37% in systolic blood pressure and from 64% to 36%
in diastolic blood pressure from 1996 to 2006, respectively (Harrison et al., 2007).
This decline can partly be explained by the shift from manual mercury to digital
sphygmomanometers. The digit bias seems to be associated with lower average blood
pressure records, which could mean underdiagnosis of hypertension when it is solely
based on blood pressure records.
Thus, although researchers do not have access to the complete medical history
of a patient, the available data from primary care databases appear to be valid and
accurate enough to use for model development.
3.3 The Health Improvement Network database
This research made use of data from THIN primary care database. The database was
set up in 2003 by In Practice Systems Ltd (INPS) and Epidemiology and Pharma-
cology Information Core (EPIC) (IMS Health Incorporated, 2015b). INPS developed
the clinical system Vision to store and maintain electronic medical records. The
way information of a patient is recorded, is practically the same across the different
operating clinical systems in the UK (Department of Health, 2011). EPIC collects
the electronic medical records, checks the non-clinical information, anonymises the
records, and adds the records to the database with postcode related indicators. The
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postcode-related indicators are ethnicity, socioeconomic factors such as deprivation,
and environmental factors such as air quality (IMS Health Incorporated, 2015c). This
information is derived from census data of England and Wales, and is thus not added
to the medical records of patients living in Scotland or Northern Ireland. THIN data
is structured by seven ASCII (American Standard Code for Information Interchange)
standardised files, which are (Wijlaars, 2013b):
• Patient: data on demographics.
• Therapy: data on prescriptions.
• Medical: data on medical events.
• Additional Health Data (AHD): data on prevention, lifestyle and diagnostics.
• Postcode Variable Indicators (PVI): data on socioeconomic, ethnicity and en-
vironmental factors
• Consultation: data on location, time, and length of consultation.
• Staff: data on staff who entered the data.
Approximately 1,800 general practices make use of Vision, of which 587 practices
contribute to THIN (IMS Health Incorporated, 2015d). This corresponds to almost
6% of all general practices in the UK contributing to THIN. When a practice signs
up with THIN, previous and current medical records are imported to the database
(IMS Health Incorporated, 2015b). After that, the already imported medical records
are updated and new medical records are imported on a monthly basis (IMS Health
Incorporated, 2015b). THIN consists of over 12 million patient records, of which
almost 4 million are active, i.e. these patients are alive and still registered at the
contributing general practices (IMS Health Incorporated, 2015d). There are roughly
53
86 million patient-years of data, of which 73 million are after the date that general
practices started reporting valid mortality rates (IMS Health Incorporated, 2015d).
THIN holds an approximately equal amount of medical records from men and women,
48 and 52%, respectively (IMS Health Incorporated, 2015d).
The patients included in THIN are representative of the UK with regards to
demographics, prevalence of medical conditions, and mortality rates (Blak et al., 2011;
Hall, 2009). THIN database follows the sex and age distribution of the UK population,
although it includes slightly fewer people aged younger than 25 (Blak et al., 2011),
which is not a problem for this research as it focusses on people around retirement
age. THIN database also includes more people from aﬄuent areas than deprived ones
(Blak et al., 2011). It is therefore important to include sex, age, and deprivation in
model development to obtain representative estimates of the UK population (Blak
et al., 2011; Hippisley-Cox and Coupland, 2010b; MacDonald and Morant, 2008;
Masso´ Gonza´lez et al., 2009).
3.4 Selected age cohorts
Access to THIN data can be through sub-licence, data extracts, and summaries and
reports (IMS Health Incorporated, 2015a). The data cut for this research was re-
stricted to medical records up to the 18th of May 2011 of patients born between 1920
and 1940 from 405 general practices in the UK. Four age cohorts of patients were
selected who turned the target ages (60, 65, 70, and 75) by 2011, see Figure 3.1. Pa-
tients were selected when at the cohort’s age they were registered for at least one year
at an active general practice that coded death dates validly and had no data issues.
Furthermore, the medical records had to include a postcode and be accessed at least
once within the last ten years. These inclusion criteria were specified to ensure that
the patient’s full medical record was available, up-to-date, and valid (Ashman et al.,
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2012; Collins and Altman, 2012). EPIC provided flags on practice level to report is-
sues in data recording and the year when acceptable mortality rate (AMR) recording
was achieved (Research, 2011). Data issues could be due to gaps or limited record-
ing before conversion to Vision, missing consultations in the medical or additional
health data files, or that the general practice split, merged, or changed user number.
The AMR date ensures that general practices reported mortality as expected for the
demographic structure of their patient population (Blak et al., 2011; Maguire et al.,
2009). Between 1987 and 2000, all general practices achieved validated death dates.
Thus, the data available were medical records from 1987 to 2011 of patients born
between 1920 and 1940. These constraints resulted in a recruitment period of 13,
18, 20, and 16 years, and a study period of 24, 24, 21, and 16 years for the 60-, 65-,
70-, and 75-year old cohorts, respectively. The length of the recruitment period and
the calendar years included affected the sample size of the age cohort. More medi-
cal records were available at later years because of AMR dates and inclusion of new
general practices. The sample sizes ranged between 140,241 and 346,410 patients per
age cohort. The selection of medical records was performed in SQL 2012.
Patients observed for more than five years were part of multiple cohorts, see
Figure 3.1. Patients who transferred out of a general practice were lost to follow-up.
When a patient transferred from one general practice to another that contributed to
THIN database, two medical records of the same patient would exist. These medical
records could not be linked due to THIN’s privacy preservation policy. The inclusion
of new patients at the older age cohorts was due to eligibility of general practices and
patients, more specifically due to the AMR dates, the year of birth period, and the
recruitment period.
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Data from The Health Improvement Network (THIN) primary care database with the following restrictions for this research:
* Medical records of patients born between 1920-1940 registered at 405 general practices in the United Kingdom 
* Valid coding of death dates from 1987 onwards
* End of study period on the 18
th
 of May 2011 
Selection patients:
Medical records of patients born between 1920-1940 who turned the cohort’s age between 1987-2011 were selected. The cohort’s ages 
were 60, 65, 70, and 75. At the cohort’s age, patients had to be registered for at least one year at an active general practice that coded 
death dates validly, and their medical records had to be accessed at least once within the last ten years and include a postcode.
Movement of patients across 
age cohorts: 
N = New
D = Deceased
T = Transferred out of general 
       practice (i.e. loss to 
       follow-up)  
A = Alive
E = End of observation and 
      alive
N and A grouped together = 
      studied age cohort
D = 4,281
T = 14,125
D = 6,827
T = 12,378
D = 6,536
T = 6,413
E = 50,692
D = 2,621
T = 1,888
E = 36,480
D = 6,439
T = 15,330
D = 8,966
T = 10,044
E = 29,020
D = 10,107
T = 6,876
E = 50,160
D = 9,619
T = 13,737
E = 1,018
D = 24,260
T = 17,729
E = 60,244
D = 25,252
T = 22,688
E = 35,404
A = 123,835
N = 136,942
A = 104,630
A = 115,173
N = 126,607
A = 40,989
A = 67,143
A = 102,233
N = 83,344
N = 142,241
* Year of birth period
* Recruitment period
* Study period
60 65 75
*1927-1940
*1987-2000
*1987-2011
*1922-1940
*1987-2005
*1987-2011
*1920-1940
*1990-2010
*1990-2011
*1920-1936
*1995-2011
*1995-2011
Sample size 142,241 260,777 346,410 293,709
Cohort’s age 70
Figure 3.1: Selected age cohorts
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3.5 Selected medical history
At the cohort’s age, a snapshot of the patient’s medical history was obtained, after
which it was observed whether and when the patient died from any cause during
follow-up. Patients were censored when they transferred out of their general practice,
as the death date could not be observed. Due to THIN’s privacy preservation pol-
icy, only the year of birth of the patient was known. Therefore, the snapshot of the
patient’s medical history of relevant medical, lifestyle, and socio-demographic infor-
mation was taken at the first of January of the year the patient turned the cohort’s
age. The selected information are listed in Table 3.2. Selection was based on the
literature review discussed in the previous Chapter.
Table 3.2: Information selected from medical records contributing to The Health
Improvement Network (THIN) primary care database
1The read codes in The Health Improvement Network (THIN) primary care database
are comparable to the ICD-10 (International Classification of Disease 10th revision)
codes. 2BNF=British National Formulary. 3All values represented the latest reading
before entering the study, which is the first of January of the year the patient turned
the cohort’s age of 60, 65, 70, or 75.
Category Covariate3
Medical Acute myocardial infarction diagnosis (ICD-10 I21)
conditions1 Angina pectoris diagnosis (ICD-10 I20)
Cerebrovascular disease diagnosis (ICD-10 I60-69)
Chronic kidney disease end stage (ICD-10 N18.5)
Diabetes mellitus diagnosis (ICD-10 E10-14)
Family history of acute myocardial infarction (ICD-10 Z82.4)
Family history of cardiovascular disease (ICD-10 Z82.3 or Z82.4)
Heart failure diagnosis (ICD-10 I50)
Other cardiovascular system disorders diagnosis (ICD-10 I95-99)
Peripheral vascular disease diagnosis (ICD-10 I73)
Valvular heart disease diagnosis (ICD-10 I34-39)
Treatments2 ACE inhibitors prescription (BNF Chapter 2.5.5.1 and 2.5.5.2),
which include: angiotensin-converting enzyme inhibitors and
angiotensin-II receptor antagonists
Aspirin prescription (BNF Chapter 2.9.1)
Beta adrenoceptor blockers prescription (BNF Chapter 2.4)
Continued on next page
57
Table 3.2 – Continued from previous page
Category Covariate3
Calcium-channel blockers prescription (BNF Chapter 2.6.2)
Coronary revascularisation, which include coronary artery bypass
graft and coronary angioplasty
Statins prescription (BNF Chapter 2.12), which include: atorvastatin,
cerivastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin
Clinical Alcohol consumption status, measured as non/ex/current
measurements Diastolic blood pressure in mmHg
& lifestyle Height in meters
choices Hypercholesterolaemia diagnosis
Hypertension diagnosis
Smoking status, measured as non/ex/current
Systolic blood pressure in mmHg
Total cholesterol reading in mmol/L
Weight in kilograms
Demographics Sex
- patient level Year of birth
Demographics
- postcode
level
Air pollution, which includes separate covariates for 2001 estimated
level of nitrogen dioxide, nitrogen oxide, sulphur dioxide, and
particulate matter, measured in quintiles
Ethnicity, which includes separate covariates for proportion of
district population defining themselves as white, mixed, Asian or
Asian British, black or black British, and other, measured in quintiles
Index of multiple deprivation (IMD), measured in quintiles
Limiting long-term illness, health problem, or disability of which
proportion of district population defines as limiting daily activities,
measured in quintiles
Mosaic, which is a consumer classification that captures
demographics, lifestyles and behaviour of a person, see Table 3.3 for
classification
Townsend deprivation score, measured in quintiles
Urbanisation: (1) urban, (2) town and fringe, or (3) village, hamlet
and isolated dwelling
The selected medical conditions were: type of CVD (AMI, angina, cerebrovascular
disease, heart failure, peripheral vascular disease, and other cardiovascular system
disorders), family history of CVD and specifically of AMI, chronic kidney disease,
and diabetes. As a history of AMI is of specific interest to this research, the number
of events was recorded. To separate multiple events, it was specified that the interval
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between events should be at least 30 days.
The treatments investigated were based on the UK National Institute of Health
and Care Excellence (NICE) and the British National Formulary (BNF) recommended
treatments for primary and secondary prevention of CVD during the study period,
which include: coronary revascularisation and prescription of ACE inhibitors, aspirin,
beta blockers, calcium-channel blockers, and statins (Joint Formulary Committee,
2016b; NICE, 2013b). Coronary revascularisation consisted of coronary artery bypass
graft and coronary angioplasty.
The selected clinical measurements and lifestyle choices were: systolic and diastolic
blood pressure, hypertension, total cholesterol reading, hypercholesterolaemia, alcohol
consumption status, height, weight, and smoking status. The ideal blood pressure
is 120/80 mmHg, i.e. a systolic blood pressure (SBP) of 120 mmHg and a diastolic
blood pressure (DBP) of 80 mmHg (NHS, 2014b). Hypertension is diagnosed when
multiple blood pressure readings are 140/90 mmHg or higher, more specifically when
SBP is ≥140 or DBP is ≥90 (NICE, 2011). The ideal total cholesterol level is below 5
mmol/L and is recommended to be below 4 mmol/L in patients with CVD (Thompson
et al., 2008). Hypercholesterolaemia is diagnosed when the cholesterol reading is
above 7.5 mmol/L, although treatment is initiated when total cholesterol is above 5
mmol/L (NICE, 2015; Thompson et al., 2008). Body mass index is a weight to height
measurement and is calculated as weight(kg)/height(m)2 (WHO, 2006).
The selected socio-demographic information at patient level were: sex and year of
birth. The selected socio-demographic information at the postcode level were: air pol-
lution, ethnicity, index of multiple deprivation, Mosaic, limiting long-term illness, and
urbanisation. Apart from Mosaic, the postcode indicators were derived from census
data of England and Wales, and therefore not available for patients living in Scot-
land or Northern Ireland. The postcode indicators were selected to examine possible
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survival variations by general practice in more detail for the respective patients.
Mosaic was selected as a measure of socioeconomic status to adjust for in estimat-
ing survival prospects of patients with a possible history of CVD. Mosaic is a consumer
classification that captures demographics, lifestyles and behaviour of a person (Ex-
perian Ltd., 2009). It is developed by Experian, which is an information services
company (Experian Ltd., 2009). Mosaic consists of 67 categories that are classified
in 15 groups, see Table 3.3. Mosaic codes are assigned to each UK postcode, which
entails circa fifteen households (Experian Ltd., 2009). Mosaic classification is based
on information from 440 covariates. The information comes from multiple sources:
38% is from the UK decennial census and the remaining 62% is from the Experian’s
UK Consumer Dynamics Database (Experian Ltd., 2009). The latter is built on a
number of data sources such as the Electoral Roll, Council Tax property values, house
sale prices, and self-reported lifestyle surveys. Not all sources are known nor the ex-
act calculation of Mosaic classifications due to commercial considerations. Although
this makes it hard to verify the validity of Mosaic, studies have shown that Mosaic
performs well as a measure of socioeconomic status (Douglas and Szatkowski, 2013;
Sharma et al., 2010; Szatkowski et al., 2012). Other measures of socioeconomic status
used in the UK are index of multiple deprivation (IMD), Townsend, and Carstairs
(UKDS, 2006). These measures are country specific whereas Mosaic scores are avail-
able for the whole of the UK. Another advantage of Mosaic over the other measures
of socioeconomic status is that it is based on a greater variety and amount of data
and distinguishes between people to a greater extent, resulting in a higher accuracy
in capturing social disparities (Douglas and Szatkowski, 2013; Sharma et al., 2010).
Finally, actuaries make use of Mosaic in setting out pensions and annuity portfolios
as it was found to be one of the main contributors in explaining longevity variations
in pensioner mortality data next to sex, age, and policy size (Richards, 2008; Ridsdale
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Table 3.3: Mosaic classification
A consumer classification that captures demographics, lifestyles and behaviours of a person
(Experian Ltd., 2009). 1Due to the low prevalence of these categories in the age cohorts,
they were merged together to increase precision in the estimates of the survival models.
Category Description
Alpha territory Most wealthy and influential individuals
Professional rewards Executive and managerial classes
Rural solitude People who live in small villages
Small town diversity People who live in medium sized and smaller towns
Careers and kids Young couples, married or living with their partner
New homemakers Neighbourhoods containing mostly houses that were built in
the last five years
Ex-council community People who are practical and enterprising
Claimant cultures Some of the most disadvantaged people
Upper floor living People who are on limited incomes
Active retirement1 People aged over 65
Suburban mindsets1 People of middle age living together with their children in
family houses
Elderly needs1 Older pensioners who can no longer easily manage household
responsibilities
Industrial heritage1 People who are traditional and conservative, approaching
retirement age
Terraced melting pot1 People who work in relatively menial, routine occupations
and are poorly educated
Liberal opinions1 Young, professional, well educated people
and Gallop, 2010).
Indicators of psychosocial factors such as job strain and lack of social support,
fruit and vegetable intake, and physical activity were not included in the analysis
because THIN does not provide this information.
3.6 Coding of covariates
The prevalence of each medical, lifestyle, and socio-demographic covariate was calcu-
lated. Where appropriate, covariates or categories of covariates that were relatively
rare, approximately a prevalence of less than 5%, were merged together. This was
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done to increase statistical power and precision in the estimates (Greenland and Mor-
genstern, 1990; Hennekens et al., 1987).
With respect to the medical covariates, subtypes of CVD were transformed. A
history of AMI was categorised as having had no, single, or multiple events. This cat-
egorisation was chosen because previous studies found different survival prospects for
patients who had single compared to multiple events, or adjusted for recurrent events
when estimating survival variations in AMI patients (Gerber et al., 2009; Gottlieb
et al., 2000; Kirchberger et al., 2014; Nigam et al., 2006; Smolina et al., 2012b; Vac-
carino et al., 1999). The exact number of events was not used, because only 5% of the
patients who had a history of AMI had more than two events. Different subtypes of
CVD were merged together due to the low prevalence in the youngest cohorts, which
were: diagnosis of cerebrovascular disease, peripheral vascular disease, valvular heart
disease, and other cardiovascular system conditions. The prevalence of these types
were 3.5, 2.4, 0.9, and 4.6% at age 60, respectively, and 10.0, 6.7, 2.8, and 13.2% at
age 75, respectively. The prevalence of the medical conditions combined as ‘cardiovas-
cular system conditions’ was 9.9% at age 60 and 26.0% at age 75. The CVD subtype
heart failure was not included in ‘cardiovascular system conditions’ even though its
prevalence was less than 5% in the youngest cohorts. This was because heart failure
is directly related to prescription of ACE inhibitors, which is a first line treatment
for AMI patients and was studied for this research (NICE, 2013a). ACE inhibitors
are prescribed to reduce the risk of a next cardiac event, in particular heart failure.
With respect to the socio-demographic covariates, year of birth and Mosaic were
transformed. Year of birth was categorised in five year intervals for the matching
procedure, which is explained in Section 4.2.1 in Chapter 4. The Mosaic groups ‘ac-
tive retirement’, ‘suburban mindsets’, ‘elderly needs’, ‘industrial heritage’, ‘terraced
melting pot’, and ‘liberal opinions’ were combined as ‘other’, see Table 3.3. These
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categories were merged together because the prevalence of the former two categories
was less than 5% and the latter four categories less than 1% in the age cohorts.
With respect to the lifestyle covariates, body mass index (BMI) and alcohol con-
sumption status were transformed. BMI values smaller than 15 and greater than 50
were removed to deal with extreme values that were likely due to typographical er-
rors. BMI was categorised to reflects its non-linear effect on the hazard of mortality in
older patients more accurately; overweight patients have a better survival rate com-
pared to healthy weight or obese patients (Chapman, 2010; Gerber et al., 2009; Nigam
et al., 2006; Yusuf et al., 2004). BMI was categorised into underweight/normal weight
(BMI<25), overweight (25≤BMI<30), and obese (30≤BMI) (WHO, 2006). Under-
weight was grouped with normal weight because its prevalence was less than 1% in the
age cohorts. With alcohol consumption status, non- and ex-consumers were combined
as ‘not current consumer’, because the prevalence of ex-consumers was less than 2%
in the age cohorts.
Chapter 4
Review of statistical methods
This Chapter is a review of the statistical methods concerning modelling incomplete
survival data from primary care medical records. Chapter 2 reviewed survival models
of cardiovascular disease (CVD) and revealed some gaps in model development with
respect to addressing the model assumptions and selecting covariates to adjust for in
the model. Chapter 3 reviewed primary care data and revealed that not all medical
records are complete with respect to the covariates of interest for this research. This
Chapter starts with discussing survival analysis in general and the type of survival
model used for this research. Next, the model building is explained that involves
the study design and selection of covariates in the final model. Then, methods to
deal with missing data are described. Finally, the assessment of the final models is
discussed.
4.1 Survival analysis
Survival analysis is the field of statistics concerned with analysing the length of time
until occurrence of an event (Kleinbaum and Klein, 2011). For this research, the
event of interest is death. Although the survival analysis techniques were primarily
developed in the medical and biological sciences, they are now widespread across
the sciences. Only the techniques applicable for this research are described in this
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Section. First survival time is introduced, second descriptive analysis techniques are
reviewed, and third regression analysis techniques are discussed. The main focus is
on the regression analysis techniques.
4.1.1 Survival time
Survival time is the time until the occurrence of an event (Kleinbaum and Klein,
2011). Let T be a non-negative continuous random variable representing survival
time and t be a specific value for T . The probability function of survival time T can
be stated in terms of the survival function, the hazard function, and the cumulative
hazard function (Kleinbaum and Klein, 2011).
The survival function is the probability that the survival time T is greater than
an arbitrary point in time t. This is denoted as (Kleinbaum and Klein, 2011):
S(t) = P (T > t). (4.1)
The survival function is a non-increasing function with S(0)=1 since at the start
of survival time there has not been an event.
The hazard function, also known as the conditional hazard rate, is the probability
that an event occurs within the time interval of t + ∆t, given survival to time t. This
is denoted as (Kleinbaum and Klein, 2011):
λ(t) = lim
∆t→0
P [t ≤ T < t+ ∆t | T ≥ t]
∆t
. (4.2)
The hazard function is a non-negative function with no upper bound. In terms of
the survival function, the hazard function can be written as the probability density
function divided by the probability that an event has not occurred before time t
(Kleinbaum and Klein, 2011):
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λ(t) =
f(t)
S(t)
=
−dS(t)
dt
S(t)
=
−d log(S(t))
dt
. (4.3)
The cumulative hazard function Λ(t) is the integral of the hazard function, i.e.
the ‘sum total’ of the hazards up to time t (Kleinbaum and Klein, 2011):
Λ(t) =
∫ t
0
λ(t)dt = − log(S(t)). (4.4)
Survival time could be incomplete, where the exact timing of the event is unknown.
Presence of incomplete survival times is called censoring. There is left, interval, and
right censoring (Hosmer et al., 2008). With left censoring, the event happened before
the study started and thus the actual survival time is shorter than the observed one.
With interval censoring, the event happened within a time interval with the exact
time unknown. With right censoring, the event did not happen before or during the
study period, and thus the actual survival time is longer than the observed one. Right-
censoring is the most common form of censoring. The main causes of right-censoring
are that the subject was no longer part of the study or the study ended before the
subject could have the event (Kleinbaum and Klein, 2011). In this research, there was
right-censoring data, where the censoring was due to patients transferring to another
general practice during the study period or remaining alive at the end of the study
period.
4.1.2 Descriptive analysis
In the descriptive analysis, survival variations are assessed between subgroups as
specified by the covariate of interest. The most popular descriptive analysis techniques
include the Kaplan-Meier estimator, median survival time, and comparison of survival
functions (Kleinbaum and Klein, 2011). For this research, the goal of the descriptive
analysis was to obtain an overview of the data, to check the coding of the covariates,
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and to be informed about the possible directions and effect sizes associated with the
covariates estimated in the regression analysis.
Let t stand for the observed death times that are sorted in ascending order; di
for the number of deaths at ti; and ni for the number at risk of dying at ti. The
Kaplan-Meier estimator estimates the survival function as (Kaplan and Meier, 1958):
Sˆ(t) =
∏
ti≤t
(
1− di
ni
)
. (4.5)
The Kaplan-Meier estimator Sˆ(t) is a right-continuous step function with jumps
at death times. Not all subjects’ deaths are observed during the study period, which
means they are censored at the last observation. These subjects are included in the
number at risk of dying until censoring, after which they are no longer included in
the survival function. The variance of the Kaplan-Meier estimator Sˆ(t) is estimated
by Greenwood’s formula (Greenwood, 1926):
V̂ar(Sˆ(t)) = Sˆ(t)2
∑
ti≤t
di
ni(ni − di) . (4.6)
The Kaplan-Meier estimator Sˆ(t) is asymptotically normally distributed. Let zα
stand for the critical value at α level from the standard normal distribution, then the
confidence intervals for estimated survival times are calculated as (Kleinbaum and
Klein, 2011):
Sˆ(t)± z1−α/2
√
V̂ar(Sˆ(t)). (4.7)
The estimated median survival time is the estimated survival time at which the
cumulative survival function falls to 0.5 (Kleinbaum and Klein, 2011). The median
rather than the mean survival time is estimated because the distribution is often
highly skewed.
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With the comparison of survival functions, the null hypothesis that the hazard
rates are the same across groups is tested. This involves comparing the observed
and expected number of deaths at each time a death is observed in a subgroup of
subjects as specified by the covariate of interest (Kleinbaum and Klein, 2011). With
the log-rank test, equal weights are given to each time a death is observed, i.e. all
deaths during the study period are of equal importance.
Let i stand for a group of subjects, j for the observed death times that are sorted
in ascending order, Oj for the observed number of deaths across groups, Nj for the
number of subjects at risk of death across groups, and Nij for the number of subjects
at risk of death in group i at time j. Then, the expected number of deaths for group
i at ordered observed death time j is calculated as Eij=OjNij/Nj. For a binary
covariate, the log-rank test Z is defined as (Peto et al., 1977):
Z =
J∑
j=1
(O1j − E1j)√
J∑
j=1
Vj
, (4.8)
where
Vj =
Oj(N1j/Nj)(1−N1j/Nj)(Nj −Oj)
Nj − 1 . (4.9)
For a covariate with K > 2 categories, the test statistic is calculated as u′V −1u,
where u is the vector of observed minus expected deaths for each category, defined
as:
u = (u1, ..., uK)
T , (4.10)
where
uk =
J∑
j=1
(Okj − Ekj), k = 1, ..., K. (4.11)
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And V is the covariance matrix, defined as:
Vil =
J∑
j=1
Oj(N1j/Nj)(Nj −Oj)
Nj − 1
(
δil − Nij
Nj
)
, (4.12)
with δil=1 for i=l and δil=0 otherwise, and i and l goes from 1 to k-1.
The log-rank test follows a χ2-distribution with k-1 degrees of freedom. The
log-rank test might not be informative when the survival functions of subgroups of
subjects are not proportional to each other over time. The proportionality of the
survival functions can visually be assessed by plotting the Kaplan-Meier estimators.
4.1.3 Regression analysis
Unlike the descriptive analysis, the regression analysis can assess the effects of the
covariates associated with survival time simultaneously (Hosmer et al., 2008). This
means that adjusted effects can be obtained, which may result in more precise esti-
mation of the true effects. For this research a Cox’s proportional hazards regression
model was used, which regresses the hazard function on the covariates. The Cox’s
model estimates the hazard λi(t) for subject i by multiplying the baseline hazard
function λ0(t) by the subject’s risk score ri (Cox, 1972):
λi(t, β,Xi) = λ0(t) ri(β,Xi) = λ0(t) e
βXi . (4.13)
The risk score is dependent on the values for the multiple covariates X and their
coefficients β. Taking a ratio of the hazard functions for two subjects i and j who
differ in one covariate x and not in the other covariates, the coefficient βx or the
hazard ratio (HR) eβx of that particular covariate x can be calculated (Hosmer et al.,
2008):
λ(t, β,X) =
λi(t, β,X)
λj(t, β,X)
=
λ0(t)e
βX1
λ0(t)eβX0
=
eβxx1
eβxx0
= eβx(x1−x0). (4.14)
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This means that the baseline hazard λ0(t) does not have to be specified and that
the HR is constant with respect to time t. In other words, the Cox’s model does
not make any assumptions about the shape of the baseline hazard function, but
does assume proportional hazards for the covariates over time t. Evaluation of the
proportional hazards assumption is described later in this subsection.
An adjusted HR is interpreted as the average increased or decreased risk of mortal-
ity when belonging to one category compared to the baseline category of a covariate
during the length of the study period while adjusting for the other covariates (Klein-
baum and Klein, 2011). If the HR is smaller than one, thus the estimated coefficient
βˆ is negative, then there is a decreased hazard of mortality and a longer survival time.
If the HR is greater than one, thus the estimated coefficient βˆ is positive, then there
is an increased hazard of mortality and a shorter survival time. If the HR is equal to
one, thus the estimated coefficient βˆ is zero, then the covariate is not associated with
the hazard of mortality and survival time.
An adjusted HR can be translated to the numbers of years lost or gained in effective
age by dividing the log HR by the log increase in annual hazard of mortality associated
with ageing one year in the population (Brenner et al., 1993). As showed by Gompertz
model applied to numerous populations over time, the increase in annual hazard of
mortality associated with ageing one year is approximately constant between ages 30
and 95 (Brenner et al., 1993; Vaupel, 2010). For England and Wales in 2010-2012,
the increase in the hazard between those ages was approximately 1.1 (Spiegelhalter,
2016). Subsequently, the number of years lost or gained in effective age δt is the log
HR divided by log 1.1:
δt ≈ logHR
log 1.1
. (4.15)
The underlying assumptions of this calculation are that the increase in annual
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hazard of mortality associated with ageing one year is constant with age and that
there are proportional hazards for the covariates over time (Brenner et al., 1993). The
first assumption will most likely hold for this research, because the cohorts studied
consisted of people aged 60, 65, 70 or 75. Evaluation of the proportional hazards
assumption is described later in this subsection.
Using the UK life tables of 2010-2012 (ONS, 2016), the number of years lost
or gained in effective age associated with the covariates can be translated into the
average period expectation of life at the effective age. The average period expectation
of life at the cohort’s ages of 60, 65, 70, and 75 for men are 22, 18, 14, and 11 years,
respectively, and for women are 25, 21, 17, and 13 years, respectively. Covariates that
are associated with an increased hazard of mortality translate in a higher effective
age and therefore a lower period expectation of life. In contrast, covariates that are
associated with a decreased hazard of mortality translate to a lower effective age and
therefore in a higher period expectation of life.
The coefficients β are estimated by maximising the partial log likelihood of the
Cox’s model (Hosmer et al., 2008). The likelihood is called partial, as it is only based
on the m subjects who had the event of interest d during the study period instead of
all n subjects who might or might not have had the event of interest d. The partial
likelihood function is the product of the ith subject’s probability of dying at time t
instead of the other subjects j in the risk set R that comprises of subjects who die
at the specified time or later during the study period. With distinct survival times
sorted in ascending order, the partial likelihood function is given by (Hosmer et al.,
2008):
PL(β) =
m∏
i=1
eβXi∑
j∈R(ti) e
βXj
, (4.16)
The partial log likelihood is (Hosmer et al., 2008):
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l(β) =
n∑
i=1
di
βXi − log
 ∑
j∈R(ti)
eβXj

=
m∑
i=1
βXi − log
 ∑
j∈R(ti)
eβXj
 .
(4.17)
The partial log likelihood is maximised by setting its derivative to zero and solving
it for the unknown coefficients β (Hosmer et al., 2008). The derivative is also called
the score vector, which is calculated as (Hosmer et al., 2008):
U(β) =
∂l(β)
∂β
=
m∑
i=1
(
Xi −
∑
j∈R(ti)Xje
βXj∑
j∈R(ti) e
βXj
)
=
m∑
i=1
Xi − ∑
j∈R(ti)
wij(β)Xj

=
m∑
i=1
(Xi − X¯wi).
(4.18)
The variance of the estimated coefficients is calculated by the inverse of the neg-
ative second derivative of the partial log likelihood function. The negative second
derivative is called the Fisher’s Information Matrix, which is denoted as (Hosmer
et al., 2008):
I(β) = −∂l
2(β)
∂β2
=
m∑
i=1

(∑
j∈R(ti) e
βXj
)(∑
j∈R(ti) X
2
j e
βXj
)
−
(∑
j∈R(ti) Xje
βXj
)2
(∑
j∈R(ti) e
βXj
)2

=
m∑
i=1
∑
j∈R(ti)
wij(β)(Xj − X¯wij)2.
(4.19)
By taking the inverse of the Fisher’s Information Matrix, the variance of the
estimated coefficients is obtained:
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V̂ar(βˆ) = I(βˆ)−1. (4.20)
By means of the Newton-Raphson algorithm the coefficients are obtained through
n iterations as (Therneau and Grambsch, 2000):
βˆ(n+1) = βˆ(n) + V̂ar(βˆ(n))U(βˆ(n)). (4.21)
This iterative process starts with the estimated coefficients set to zero; βˆ(0) = 0.
The end point is convergence in the estimated coefficients, which is when there is
stability in the partial log likelihood; l(βˆ(n+1)) ≈ l(βˆ(n)).
To test the significance of the model, i.e. whether the model with the included
covariates can estimate a subject’s survival time more accurately than taking the av-
erage survival time of the whole sample, the likelihood ratio test statistic is calculated.
This statistic is calculated as (Hosmer et al., 2008):
LRTβ = 2
(
l(βˆ)− l(β(0))
)
, (4.22)
where β(0) stands for the initial values of the coefficients, and βˆ for the estimated
coefficients. The initial values of the coefficients are set to zero as the null hypothesis
is that the covariates are not associated with the hazard of mortality. Therefore,
the likelihood ratio test statistic is essentially twice the difference in the partial log
likelihood of a full and an empty model. The likelihood ratio test statistic follows a
χ2-distribution with the degrees of freedom equal to the difference in the number of
estimated coefficients by the two models (Hosmer et al., 2008).
To test the significance of a specific covariate x, i.e. whether the covariate is sig-
nificantly associated with survival time, the Wald statistic z is calculated. With this
statistic, it is tested whether the covariate’s estimated coefficient βˆx is significantly
different from zero. The statistic z is calculated as (Hosmer et al., 2008):
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z =
βˆx
ŝe(βˆx)
, (4.23)
where se stands for the standard error and is calculated as the square root of the
variance of the estimated coefficient x. The Wald statistic z follows a standard normal
distribution (Hosmer et al., 2008). The confidence interval (CI) of the estimated
coefficient βˆx is calculated as (Hosmer et al., 2008):
CI(βˆx) = βˆx ± z1−α/2ŝe(βˆx), (4.24)
where zα stands for the critical value at a specific α level from the normal distri-
bution. If the confidence interval for the estimated coefficient does not include zero,
then the covariate is associated with a significant increased or decreased hazard of
mortality.
The regression techniques of the basic Cox’s model, as described above, can be
extended to fit various scenarios. For this research, the assumptions of no time-tied
events, uninformative censoring, homogeneous population, and proportional hazards
were addressed.
Assumption of no time-tied events
The partial log likelihood of the basic Cox’s model, as described above, assumes that
survival time is continuous and thus that there are no time-tied events (Therneau,
2014). The data used for this research included death dates, making survival time
discrete. Multiple deaths could be observed on the same day in which the order of
the deaths is unknown, resulting in time-tied events.
There are three main methods to deal with time-tied events in the Cox’s model:
Breslow’s or Efron’s approximation of the partial log likelihood or the exact partial
log likelihood (Therneau, 2014). The three methods are explained by means of an
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example.
Let there be three subjects in the risk set R and each has the event at a different
time. Then based on Equation (4.16), the partial log likelihood for the subject who
first had the event would be:
PL1 =
eβX1∑
j∈R(ti) e
βXj
=
r1
r1 + r2 + r3
. (4.25)
Now let the first time of an event be a time-tied event for two subjects. Then the
partial log likelihood for the first two subjects with the events could be one of the
following if time was continuous:
PL1&2 =
(
r1
r1 + r2 + r3
)(
r2
r2 + r3
)
,
PL1&2 =
(
r2
r1 + r2 + r3
)(
r1
r1 + r3
)
.
(4.26)
It is unknown which partial log likelihood is the correct one. Breslow’s and Efron’s
approximations estimate the average of the two possible partial log likelihoods. With
Breslow’s approximation, the fractions with the largest risk pool for each time-tied
event are used (Breslow, 1972). The partial log likelihood for the two subjects would
thus be:
PL1&2−Breslow =
(
r1
r1 + r2 + r3
)(
r2
r1 + r2 + r3
)
. (4.27)
Generalising this to the whole sample, Breslow’s approximation can be written as
(Hosmer et al., 2008):
PL(β)Breslow =
m∏
i=1
eβXi+∑
j∈R(ti)(e
βXj)di
, (4.28)
where di is the number of events at time ti, D(ti) is the set of subjects who have the
event at time ti, and Xi+ is the summed values for the covariates, Xi+ =
∑
j∈D(ti) Xj.
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The problem with Breslow’s approximation is that di-1 subjects are included in the
denominator too many times. The more subjects have the event at the same time,
the less accurate Breslow’s approximation is. This leads to a conservative bias and
thus underestimation of the coefficients (Cox and Oakes, 1984).
A more accurate approximation of the partial log likelihood was proposed by
Efron (1977). With his approximation, the risk scores of the subjects with time-tied
events in subsequent risk sets are multiplied by the probability they would be in the
subsequent risk set (Hosmer et al., 2008). Coming back to the previous example,
with Efron’s approximation, the risks of the two subjects with time-tied events are
multiplied by 50% in the second risk set. The idea behind this is, that subject 1 and
2 are for sure in the first risk set, but have 50% chance each to be in the second risk
set. Thus, the partial log likelihood for the two subjects would be:
PL1&2−Efron =
(
r1
r1 + r2 + r3
)(
r2
(0.5)r1 + (0.5)r2 + r3
)
. (4.29)
Generalising this to the whole sample, Efron’s approximation can be written as
(Hosmer et al., 2008):
PL(β)Efron =
m∏
i=1
eβX(i)+
di∏
k=1
(∑
j∈R(ti) e
βXj − k−1
di
∑
j∈D(ti) e
βXj
) . (4.30)
As stated above, the exact partial log likelihood for time-tied events assumes time
to be discrete and thus expects time-tied events. A Cox’s model with discrete-time
is based on the logistic model, where the risk score is multiplied with the odds ratio
of the baseline hazard instead of the baseline hazard itself (Therneau and Grambsch,
2000):
hˆi(t)
1 + hˆi(t)
=
(
hˆ0(t)
1 + hˆ0(t)
)
eβXi . (4.31)
76
Coming back to the previous example, the exact partial log likelihood calculates
the probability that subject 1 and 2 are part of the group with time-tied events instead
of any other selection of the subjects in the risk set. Thus, the partial log likelihood
for the two subjects would be:
PL1&2−Exact =
r1r2
r1r2 + r1r3 + r2r3
. (4.32)
Generalising this to the whole sample, the exact partial log likelihood is (Klein
and Moeschberger, 2003):
PL(β)Exact =
m∏
i=1
eβXi+∑
q∈Q(ti) e
βXq
, (4.33)
where Q are all the combinations of selected subjects for the group with time-tied
events, q is one combination of selected subjects, di is the number of events at time
ti, and Xq is the summed values for the covariates, Xq =
∑di
j=1 Xj. The exact partial
log likelihood is accurate but time-consuming in its computation.
For each method, the same steps are taken to estimate the coefficients β as with
the partial log likelihood that assumed no time-tied events (Hosmer et al., 2008). In
case of no time-tied events, all three methods provide the same results. In case of
time-tied events, the default setting is to use Efron’s approximation as it is more
accurate than Breslow’s approximation and more efficient than the exact partial log
likelihood (Hosmer et al., 2008). For this research, Efron’s approximation was used.
Assumption of uninformative censoring
Survival models assume uninformative censoring, which means that the distribution
of time-to-event and the distribution of time-to-censorship do not inform each other
(Hosmer et al., 2008). As stated above, this research had right-censoring data, where
the censoring was due to patients transferring to another general practice during the
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study period or remaining alive at the end of the study period. Censoring due to
end of study period is believed to be random and thus uninformative of time-to-
event distribution. Censoring due to transfer to another general practice could be
non-random and affect the distribution of time-to-event.
Previous studies identified two groups of people who move at an older age in
the United Kingdom (Pennington, 2013; Uren and Goldring, 2007). The first group
moves to match the desired lifestyle during retirement. For example, people move
to an area more suitable for active retirement or move to a more secure area with
respect to proximity to health and social care, and support from nearest family. This
move tends to take place between ages 60 to 70, and is mostly done by households
from aﬄuent areas. The second group moves due to ill-health. This move tends to
take place after age 70, and is mostly done by households from deprived areas.
If these trends are observed in the studied age cohorts for this research, the haz-
ard of mortality could be overestimated before age 70, when transferring to another
general practice is associated with excellent health. Similarly, the hazard of mortality
could be underestimated after age 70, when transferring to another general practice is
associated with ill-health. For this research, patients who did not transfer from their
general practice were compared with patients who transferred before or after age 70
with respect to health status, lifestyle choices, and socio-demographic factors.
Assumption of homogeneous population
The basic Cox’s model assumes that the sample comes from a homogeneous popula-
tion. The data used for this research are medical records of patients from multiple
general practices. Practices vary in health outcomes due to differences in their patient
population and provision of patient care (Rasbash et al., 2012). Patients from one
practice are thus not independent from each other, instead they have a shared risk
(Hosmer et al., 2008). The shared risk is also called shared frailty, where patients of
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one practice are more frail than patients from another practice, and this excessive risk
translates in worse health outcomes (Therneau and Grambsch, 2000). The differences
between shared frailties result primarily from the fact that it is impossible to adjust
for all covariates on subject level in the analysis. This could be due to financial,
legal, or ethical restrictions in identifying and measuring the covariates. Even if all
covariates were to be measured, there could be too many of them to adjust for in the
model due to limited computational or statistical power.
To adjust for the cluster effect of general practices due to unmeasured covariates,
a shared frailty term is specified in the Cox’s model. This means that the Cox’s model
is multilevel, modelling data on patient and general practice level. The unmeasured
covariates are modelled by a random effect in the analysis. The multilevel Cox’s
model estimates the hazard λij for patient j in general practice i by multiplying the
shared frailty term of the general practice Zi by the baseline hazard λ0(t) and the
patient’s risk score rij (Hosmer et al., 2008):
λij(t, Zi, β,Xij) = λ0(t)Zi rij(βXij) = λ0(t)Zi e
βXij , (4.34)
where
Zi ∼ i.i.d. Γ(1, θ). (4.35)
The shared frailties Zi’s are assumed to be identical and independently distributed
random factors that follow a Gamma distribution with mean 1 and variance θ. A
Gamma distribution is chosen instead of a Gaussian distribution, because the frailty
terms should only be able to take positive values since the hazard function is a non-
negative function (Hosmer et al., 2008). The variance θ quantifies the degree of
variability among the clusters and the degree of correlation within a cluster. In
other words, a greater variance means that the cluster effects are more dispersed and
the correlation within clusters is stronger. Inter-cluster correlation, calculated by
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Kendall’s τ , is θ/(2 + θ) in the model (Therneau, 2014).
In case of no cluster effects (θ = 0 and Z = 1), i.e. patients from the same
general practice are independent from each other, the multilevel Cox’s model reduces
to the standard Cox’s model specified in Equation (4.13). In case of cluster effects
(θ 6= 0), a shared frailty of a general practice greater than one means that patients
from that practice are more frail and thus have a shorter than average survival time.
Similarly, a shared frailty of a general practice smaller than one, means that the
patients registered at that practice are less frail and thus have a longer than average
survival time.
The multilevel Cox’s model is estimated by maximising the partial log likelihood
function. Let there be G general practices where the ith general practice has ni
patients. Let Di =
ni∑
j=1
dij stand for the number of events in the i
th general practice
and Λ0(t) stand for the cumulative baseline hazard. The partial log likelihood is
formulated as (Klein and Moeschberger, 2003):
l(θ, β) =
G∑
i=1
[Diln(θ)− ln [Γ (1/θ)] + ln [Γ (1/θ +Di)]
− (1/θ +Di)ln
[
1 + θ
ni∑
j=1
Λ0(t)e
βXij
]
+
ni∑
j=1
dij {βXij + ln [λ0(t)]}].
(4.36)
The partial log likelihood is maximised by applying the Estimation-Maximization
(EM) method, which entails the following steps (Klein and Moeschberger, 2003):
1. Fit the basic Cox’s model and obtain the estimated coefficients βˆ.
2. (E step) Estimate the shared frailty terms Zˆi.
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3. (M step) Update the estimated coefficients βˆ by fitting the Cox’s model with
the estimated shared frailty terms Zˆi.
4. Iterate between E and M steps until convergence in the estimates Zˆi and βˆ.
To assess whether there is a cluster effect of general practices, it is tested whether
the variance of the shared frailty terms θ is significantly different from zero. This is
done by calculating the likelihood ratio test (LRT) statistic (Hosmer et al., 2008):
LRTθ = 2
(
l(θˆ, βˆ)− l(0, βˆ)
)
, (4.37)
where
l(θ = 0, βˆ) =
G∑
i=1
ni∑
j=1
dij {βXij + ln [λ0(t)]} −
G∑
i=1
Di. (4.38)
The likelihood ratio test statistic is thus twice the difference between the partial
log likelihood of the multilevel Cox’s model and the partial log likelihood of the basic
Cox’s model. The test statistic follows a χ2-distribution with one degree of freedom
(Hosmer et al., 2008).
Assumption of proportional hazards
The underlying assumption of the Cox’s model is that the hazards are proportional
over time between subgroups of subjects (Therneau, 2014). The model is adequate
when this assumption holds. Popular techniques used to assess the proportional
hazards assumption are visual assessment of Kaplan-Meier plots or numerically by
Grambsch and Therneau’s test (Persson, 2002). Graphs are not as objective as sta-
tistical tests, and are therefore not recommended to rely solely on (Persson, 2002).
The Grambsch and Therneau’s test is based on the scaled Schoenfeld residuals.
Schoenfeld residuals are obtained from the first derivative of the partial likelihood as
specified in Equation (4.18). Recall that m is the number of subjects who had the
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event during the study period, Xi stands for the values of the covariates for subject
i with ordered survival time ti, and X¯wi stands for the risk set conditional means of
the covariates for subject i with ordered survival time ti. The Schoenfeld residual for
the kth covariate equals (Hosmer et al., 2008):
rˆk =
m∑
i=1
(Xik − X¯wik). (4.39)
From this, the Schoenfeld residual for the kth covariate for the ith subject who had
the event of interest during the study period equals (Hosmer et al., 2008):
rˆik = Xik − X¯wik . (4.40)
The sum of the Schoenfeld residuals should equal zero, as the coefficients β were
obtained by setting the derivative of the partial log likelihood to zero. As the partial
log likelihood is only based on the subjects who had the event of interest during the
study period, the Schoenfeld residuals for censored subjects will be missing and will
thus not be informative for the fit of the model. Grambsch and Therneau proposed to
scale the Schoenfeld residuals by its estimated variance to obtain a more informative
measure (Therneau, 2014). Let rˆ′i be a vector of Schoenfeld residuals for the i
th
subject who had the event of interest during the study period, as (Hosmer et al.,
2008):
rˆ′i = (rˆi1, rˆi2, ..., rˆik). (4.41)
The variance of the Schoenfeld residuals can be approximated by the covariance
matrix of the estimated coefficients V̂ar(βˆ) multiplied by the number of events m,
so that the scaled Schoenfeld residuals for the ith subject are computed as (Hosmer
et al., 2008):
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r∗i =
r′i
mV̂ar(βˆ)
. (4.42)
Let transformed survival time be a vector ranking subjects in the order of events,
such that t∗ = (1, 2, ...,m) (Therneau, 2014). The Grambsch and Therneau’s test
estimates the correlation between the scaled Schoenfeld residual of a covariate and
the transformed survival time (Therneau, 2014). The correlation statistic follows a
χ2-distribution with one degree of freedom. A correlation statistic of a covariate that
is significantly different from zero indicates that the proportional hazards assumption
is violated for that covariate.
If the proportional hazard assumption is violated, the covariate should be specified
differently. For this research, such covariates were assumed to be time-dependent.
Follow-up time was split in intervals in which the assumption was no longer violated.
The time intervals of 10, 5, or 1 year were tested. When the coefficients of a covariate
were not significantly different in multiple time intervals, the time intervals were
merged together.
4.2 Missing data
Most studies that make use of observational data, have a proportion of the data miss-
ing. There are three types of missing data: missing completely at random (MCAR),
missing at random (MAR), and missing not at random (MNAR) (Graham, 2009).
With MCAR data, there is no systematic difference between observed and unob-
served data (Graham, 2009). For instance, cholesterol readings might be missing due
to breakdown of equipment. With MAR data, there is a systematic difference be-
tween observed and unobserved data and this difference can completely be explained
by the observed data (Graham, 2009). For instance, given that the data consist of
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cholesterol readings and age, recorded cholesterol readings might be higher than miss-
ing cholesterol readings only because older patients are more likely to have a record
of cholesterol readings. With MNAR data, there is a systematic difference between
observed and unobserved data and this difference is at least partly explained by unob-
served data (Graham, 2009). For instance, given that the data consist of cholesterol
readings and drug therapy, patients with high cholesterol readings who do not ad-
here to drug therapy might be less likely to go to doctor appointments. This could
mean that missing cholesterol readings are higher than recorded cholesterol readings
of patients who do adhere to drug therapy.
The next subsections discuss the type of missing data present in primary care
records, methods to deal with this type of missing data to obtain unbiased results,
and the specification of the multiple imputation process that was carried out for this
research to deal with the missing data.
4.2.1 Missing data in primary care records
With primary care data, it is established that there is a systematic difference between
observed and unobserved data (Hippisley-Cox and Coupland, 2010b; Hippisley-Cox
et al., 2008; Marston et al., 2010; NICE, 2014a; Szatkowski et al., 2012). Recording of
medical, lifestyle, and socio-demographic information are related to ill health; people
who are ill, visit the general practice more often and general practitioners are more
likely to record background information of these patients compared to healthier pa-
tients (MacDonald and Morant, 2008; Shephard et al., 2011). Women are more likely
to have a complete medical record than men, as they tend to be sicker and visit the
general practice more often (Bartley, 2004). Information on lifestyle is predominantly
recorded because of its association with medical conditions (Marston et al., 2010).
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Over time, the incentives and methods for recording information other than the med-
ical condition or treatment by general practitioners have changed (Marston et al.,
2010). For example, with the introduction of the Quality and Outcomes Framework
(QOF) in 2004, a pay scheme to improve the quality of the health care provided by
general practitioners, recording has greatly improved in primary care (Langley et al.,
2011; NICE, 2014a; Szatkowski et al., 2012).
For this research, patients with and without complete medical records were com-
pared to each other in respect to the medical history of relevant medical, lifestyle, and
socio-demographic covariates as described in Chapter 3 Section 5. It was assumed
that patients who had no record of a medical diagnosis or treatment, did not have the
medical condition or receive the treatment. This means that there were only missing
records in the lifestyle covariates, i.e. in cholesterol level, blood pressure, body mass
index, alcohol consumption status, and smoking status. It was assessed whether there
was a significant difference in the proportion of missing records in a lifestyle covariate
by the medical conditions, treatments, socio-demographic factors, and other lifestyle
covariates. This was assessed by the χ2-test of independence, of which the statistic is
calculated as (Kleinbaum and Klein, 2011):
χ2 =
r∑
i=1
c∑
j=1
(Oij − Eij)2
Eij
(4.43)
where r and c are the numbers of rows and columns in the contingency table,
respectively, Oij stands for observed count in row i column j, and Eij for expected
count in row i column j. The expected count Eij is calculated as OiOj/N , where N
is the sample size. This test follows a χ2-distribution with (r − 1)(c − 1) degrees of
freedom. The underlying assumptions of the test are that the sample size is sufficiently
large and the smallest expected count is greater than five (Kleinbaum and Klein,
2011). These assumptions were met.
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In the studied age cohorts for this research, the proportion of missing records in
lifestyle covariates decreased with age, see Tables A.1 to A.4 in the Appendix. The
proportion of missing records was the greatest in cholesterol readings with 83% at
age 60 and 50% at age 75. Due to the high proportion of missing records, cholesterol
reading was substituted by the diagnosis of hypercholesterolaemia in the analysis.
The proportion of missing records was the lowest in blood pressure and smoking
status with 28% at age 60 and 13% at age 75. The proportion of missing records
in body mass index and alcohol consumption status was 37% at age 60 and 20% at
age 75. Excluding cholesterol readings, 49% of the youngest cohort and 29% of the
oldest cohort had incomplete medical records. A study using QResearch primary care
database reported similar proportions of missing records (Hippisley-Cox et al., 2008).
The results of the χ2-test of independence confirm that patients with and without
complete medical records systematically differ from each other, see Tables A.1 to
A.4 in the Appendix. There were significantly more incomplete records among men,
patients born in earlier years, and patients without a medical diagnosis or treatment
(p<.001). The exceptions to these trends were that there was no significant difference
in the proportion of missing smoking status across sexes (χ2(1)<.01, p=.97) and body
mass index categories (χ2(2)=1.55, p=.46) in the 70-year old cohort, and in blood
pressure across sexes (χ2(1)=1.76, p=.18) in the 75-year old cohort.
4.2.2 Methods to deal with missing data
Over time, the approach to handling missing data has changed; when a significant
proportion of data is missing (>5%), it is widely acknowledged that it is not accept-
able to perform: complete case analysis, exclude covariates with missing data from
the analysis, create a category for missing observations, or substitute a missing obser-
vation with a reasonable guess (Allison, 2001; Marshall et al., 2010; Sterne et al., 2009;
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van Buuren and Groothuis-Oudshoorn, 2011). With complete case analysis, subjects
with incomplete information are excluded from the analysis. This means that the
sample size and thereby the statistical power of tests are reduced. In addition, if
the reason for missing data is associated with the outcome of interest, the analysis
would provide biased estimates because the estimates of coefficients would be biased
towards the subset of sample that is observed instead of the entire sample. Excluding
covariates with missing data from the analysis could mean that important covariates
in predicting the outcome are not adjusted for, resulting in biased estimates. Creating
a category for missing observations would also result in biased estimates because it
would distort correlations with the other covariates.
Substituting a missing observation with a reasonable guess is called single im-
putation. Typically, missing observations of a given covariate are substituted with
the mean of the observed values for that covariate. As with creating a category for
missing observations, imputing missing observations with the mean of observed obser-
vations would distort correlations with the other covariates and thus provide biased
estimates of coefficients. A more appropriate imputation is to substitute missing ob-
servations of a given covariate with the predicted values of that covariate given by a
regression model that regresses that covariate on the other covariates that are part
of the analysis. Imputation by a regression model provides unbiased estimates given
that the covariates associated with the reason for having missing data are included in
the regression model. The imputation, however, underestimates the standard errors,
leading to false precision of the results.
When there is up to 50% of the data missing, the widely accepted method to
deal with that is to perform multiple imputation (Allison, 2001; Marshall et al., 2010;
Sterne et al., 2009; van Buuren and Groothuis-Oudshoorn, 2011). With this method,
values are imputed for missing observations multiple times, creating multiple datasets
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with varying values. The results estimated on each of the datasets are then pooled
using Rubin’s rules, which take into account the variance of the coefficient within and
between imputed datasets (Rubin, 1987). The goal of multiple imputation is to make
valid statistical inferences by reflecting the uncertainty in missing data, and not to
impute the true values (Rubin, 1987). The next subsection describes the process of
multiple imputation in greater detail.
Multiple imputation involves several stages of model development and respective
assumptions about the missing data, where any incorrect decisions could lead to
biased estimates. The most important assumption is that the data are missing (com-
pletely) at random (Allison, 2001), as defined in the introduction to this Section. The
type of missing data cannot be directly tested, however understanding why the data
might be missing may support or oppose the use of multiple imputation.
Multiple imputation carried out on primary care data was shown to be an effective
method of obtaining unbiased estimates in the presence of missing data (Carlin et al.,
2007; Marston et al., 2010). For this research it was, therefore, assumed that the
reason for missing records could fully be explained by the observed data on medical
conditions, treatments, socio-demographic factors, and lifestyle factors, and thus that
the missing data were missing at random. There was more than 5% and less than
50% missing data in the age cohorts, hence multiple imputation was chosen to deal
with bias and imprecision caused by the presence of missing data.
4.2.3 Multiple imputation
The imputation model should consist of all covariates that are included in the anal-
ysis model and covariates that are associated with missing data (van Buuren, 2012).
It might, however, not be possible to include all covariates in the imputation model
because of multicollinearity or limited computational power to handle the complexity
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of the imputation model. The optimal number of included covariates is up to 30, al-
though more than 15 hardly increases the explained variance in the imputed covariate
(van Buuren, 2012). When the imputation model includes more covariates than the
analysis model, the results of the analysis model could be biased if the imputation
model is incorrect (Schafer and Graham, 2002). When the analysis model includes
more covariates than the imputation model, the results of the analysis model are
valid but could underestimate the effects of the covariates that were excluded from
the imputation model, given that the analysis model is correct (Schafer and Graham,
2002).
The imputation model for each covariate with missing data is depended on its
measurement scale. Continuous covariates are imputed using a linear regression.
The imputed covariate does not have to be normally distributed because the aim of
the imputation model is to provide a range of plausible values and not to impute
the values that would have been observed if the data were not missing (van Buuren,
2012). Binary covariates are imputed using a logistic regression. Covariates with more
than two categories are imputed using a multinomial regression. Covariates should
be imputed on their original measurement scale and transformed after imputation to
obtain unbiased estimates (von Hippel, 2009). Any covariates derived from covariates
with missing records should be imputed as well instead of calculated based on the
imputed values (i.e. passive imputed) (van Buuren, 2012). This is to ensure that the
imputed values are consistent with the analysis model.
As described above, the studied age cohorts for this research had multiple covari-
ates with missing values. These covariates were measured on different scales, where
blood pressure and body mass index were continuous, and alcohol consumption and
smoking status were categorical. There was a general missing pattern, meaning that
the data could not be ordered in such a way that if there were missing values for
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one covariate then there were also missing values for another covariate (van Buuren
and Groothuis-Oudshoorn, 2011). The data had a hierarchical structure as patients’
medical records were clustered by general practice. Until recently, the only software
that could specify an imputation model for mixed continuous-categorical data with
a hierarchical structure and a general missing pattern was REALCOM-Imputation
(Centre for Multilevel Modelling, 2016). This software imputes missing data by joint
modelling.
Joint modelling assumes that the data come from a multivariate distribution, most
commonly being a Gaussian distribution, which is what the software REALCOM-
Imputation specifies (Allison, 2001; Centre for Multilevel Modelling, 2016). Imputa-
tions based on this distribution have been shown to be robust to non-normal data
(van Buuren and Groothuis-Oudshoorn, 2011). Joint modelling imputes per pattern
of missing data on a row to row basis (Allison, 2001). For example if there are two
covariates with missing observations and the missing is at random, then the patterns
of missing data are: subjects/rows with no missing data, subjects/rows with missing
observations in the first covariate and no missing observations in the second covariate,
subjects/rows with no missing observations in the first covariate and missing obser-
vations in the second covariate, and subjects with missing observations in the first
and second covariates.
Multiple imputation is an iterative process that consists of the following steps
(Allison, 2001):
1. Obtain the observed sample means and covariance matrix.
2. For each pattern of missing data, use the means and covariance matrix to es-
timate the regression coefficients for equations in which each covariate with
missing data is regressed on all other covariates of interest.
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3. Based on the estimated regression coefficients, predict the values for the sub-
jects with missing data and add a residual term as specified by the Gaussian
distribution. Without adding a residual term, the imputation process would
be deterministic, resulting in underestimated variances of the covariates with
missing data.
4. With the new dataset of observed and imputed values, recalculate the sample
means and covariance matrix.
5. Use the recalculated means and covariance matrix to obtain a random draw
from the posterior distribution of means and covariances.
6. Iterate by going through steps 2 to 5 continuously until convergence of the
estimated regression coefficients.
The iteration process until convergence in the estimated regression coefficients is
called the ‘burn-in length’. Convergence of the coefficients can be checked by plotting
the coefficients of the imputation model against the iterations. Each iteration results
in a new dataset of observed and imputed values. To obtain independent imputed
datasets, the datasets should be separated by a number of iterations. The number of
iterations for the burn-in length and between imputed datasets can be as little as five
iterations (van Buuren, 2012). The default setting in REALCOM-impute is a burn-
in length of 100 iterations and 100 iterations between imputed datasets (Centre for
Multilevel Modelling, 2016). Having more iterations than necessary, does not affect
the results (van Buuren, 2012).
The number of imputed datasets is recommended to be roughly the percentage of
missing records in the dataset (von Hippel, 2009). Although imputing more than five
times will most likely not change the inferences made on five imputed datasets (van
Buuren, 2012). For this research, the default setting of REALCOM-impute was used,
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which is 10 imputed datasets (Centre for Multilevel Modelling, 2016). The imputed
values were checked by bar and density plots. Assuming that the missing data were
missing at random, the imputed values should have a similar distributions as the
recorded observations (van Buuren, 2012).
The imputed datasets were analysed separately, i.e. the covariate selection was
done on each imputed dataset. As described in subsection 4.2.2, a general, non-age
specific model was selected to have the same interpretation of the effects at each
age. If an interaction effect was found in the majority of the models (≥50%), it was
included in the final model. Given age cohort, this final model was then estimated
on each imputed dataset and combined using Rubin’s rules. Let there be m imputed
datasets, where the jth imputed dataset has estimated coefficients βˆj. Let Ŵj be
the estimated variances of estimated coefficients βˆj of the j
th imputed dataset, Ŵ be
the average within imputation variance of estimated coefficients βˆ across m imputed
datasets, and B̂ be the between variance of estimated coefficients βˆ. Using Rubin’s
rules, the coefficients βˆ and variances V̂ar(βˆ) are calculated as (Rubin, 1987):
βˆ =
1
m
m∑
j=1
βˆj, (4.44)
V̂ar(βˆ) = Ŵ +
(
1 +
1
m
)
B̂,where
Ŵ =
1
m
m∑
j=1
Ŵj,
B̂ =
1
m− 1
m∑
j=1
(βˆj − βˆ)2.
(4.45)
If one dataset is analysed, the variances of the coefficients V̂ar(βˆ) would be equal to
the within imputation variance Ŵ . The between imputation variance B̂ is the result
of having missing data. The addition of the term B̂/m is the result of estimating the
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coefficients on a limited number of imputed datasets.
To test whether the coefficient βˆ is significantly different from zero, the t-statistic
is calculated as (Rubin, 1987):
t =
βˆ
ŝe(βˆ)
, (4.46)
where se stands for the standard error of the estimated coefficient βˆ. The t-
statistic follows a t-distribution with degrees of freedom equal to (Rubin, 1987):
df = (m− 1)
(
1 +
1
r
)2
,where
r =
B̂(1 + 1/m)
Ŵ
.
(4.47)
4.3 Model building
4.3.1 Study design
For this research, two survival models were developed. The first model was developed
to estimate the hazards of all-cause mortality associated with a history of AMI and
related treatments while adjusting for other risk factors. The second model was devel-
oped to estimate the hazard of all-cause mortality associated with statins prescribed
as primary prevention of CVD while adjusting for other risk factors. The models
were specified on slightly different age cohorts. For the first model all patients in
the cohorts were eligible for participation while for the second model patients with a
history of CVD were excluded from the cohorts.
The prevalence of AMI was relatively rare, especially in the youngest cohort. At
ages 60, 65, 70, and 75, the prevalence of AMI in women was 1.1, 1.9, 2.7, and
3.7%, respectively, and in men 4.8, 6.6, 8.3, and 10.0%, respectively. To create more
balanced cohorts with respect to the exposure of interest, patients with a history of
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AMI were selected and each matched to three controls without this history on sex,
year of birth category, and general practice.
A balanced dataset means that the groups being compared are of the same size
and have similar characteristics with the exception of the exposure and outcome of
interest (Greenland and Morgenstern, 1990; Hennekens et al., 1987). A more balanced
cohort created by matching, translates in increased statistical power and efficiency
(Greenland and Morgenstern, 1990; Hennekens et al., 1987). The statistical power of
a test is the probability that the null hypothesis is correctly rejected, i.e. the power to
identify an effect that truly exists. This is maximised when the subgroups of patients
are of the same size. Statistical efficiency refers to the optimal use of the data, where
a more efficient test or estimator needs fewer patients to reject the null hypothesis.
Efficiency is maximised when the variance is minimised.
To improve statistical power and efficiency, the matched factor must be a con-
founder, which is a covariate that is associated with both the exposure and outcome
and does not lay on the causal pathway (Hennekens et al., 1987; Rothman et al.,
2008). If the matched factor is not a confounder, overmatching can take place, which
in turn could harm the statistical efficiency and the validity of the results. Matched
factors that are typically used are sex and age (Hennekens et al., 1987; Rothman
et al., 2008). When a study includes multiple medical centres, the medical centres
are also matched on. This is because patients of one centre are more alike compared
to patients from another centre (Rasbash et al., 2012). By matching on medical cen-
tre, cases and controls are similar in unmeasured factors that are clustered in medical
centres. For this research, cases and controls in the age cohorts were matched on sex,
year of birth category, and general practice. Matching on year of birth category takes
into account possible advances in medical management over time (Kleinbaum and
Klein, 2011). Year of birth was categorised with categories being 1920-25, 1926-30,
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1931-35, and 1936-40, because not all cases could be matched to a control when a
specific year was used as a matching factor.
The traditional matching methods are individual or frequency matching (Rothman
et al., 2008). With individual matching, matching is carried out case by case, whereas
with frequency matching, it is carried out per stratum of cases. In a situation when
not enough controls per case can be found, alternative matching methods are carried
out such as partial, marginal, counter, probability, and propensity score matching
(Caliendo and Kopeinig, 2008; Cologne et al., 2004; Langholz and Clayton, 1994).
An optimal matching ratio is to match the cases with one to ten controls, although
five or more controls hardly increases the statistical efficiency (Raboud and Breslow,
1989). The majority of studies use less than five controls per case due to feasibility
and the limited increased statistical efficiency when there would be more controls
(Cepeda et al., 2003). For this research, the matching ratio was set to the maximum
number of controls that could be matched per case in each age cohort with the limit
being five controls per case. This resulted in a matching ratio of 1 case to 3 controls.
Frequency matching was carried out as this is more efficient than individual matching
when there are multiple cases with the same values for the matched factors (Rothman
et al., 2008).
4.3.2 Selection of covariates
The selection of medical, lifestyle, and socio-demographic covariates for this research
was based on the literature review discussed in Chapter 2. This means that all
covariates were previously shown to be risk factors that contributed in explaining
survival variations in AMI patients or primary cardiovascular risk groups. Interaction
effects within and between all groups of risk factors were not studied before, except
for limited interactions with the main exposure, sex, and age. For this research,
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all second-order interactions were tested to examine survival variations in greater
detail. To obtain the leanest model possible where the prediction error is minimised,
a selection procedure was carried out to select the most important interaction effects.
The prediction error is the difference in observed and predicted outcome values
(Harrell, 2001; Hosmer et al., 2008). The prediction error includes the bias between
observed and predicted outcome values and the variance of the predicted outcome
values. The minimal prediction error is observed with the true underlying model
of the data. A model that includes less covariates than the true model ‘underfits’
the data by not capturing the underlying trend of the data. In other words, this
model excludes important covariates in predicting the outcome and therefore has
high bias and low variance of the predicted outcome values. A model that includes
more covariates than the true model ‘overfits’ the data by not only capturing the
underlying trend but also the noise of the data. In other words, this model includes
important and unimportant covariates in predicting the outcome, and therefore has
low bias and high variance of the predicted outcome values. To find the true model,
several stepwise methods were proposed.
Stepwise methods select the most important covariates to include in a model solely
based on their significance that is specified by some mathematical criterion (Harrell,
2001; Hosmer et al., 2008). Forward selection starts with an empty model and adds
one covariate at the time where the covariate that is added first explains the greatest
percentage of (the remaining unexplained) variation in the outcome. This process
is continued until no covariate significantly contributes to the model in explaining
the variation in the outcome. Backward elimination starts with a full model that
includes all covariates and removes one covariate at the time where the covariate that
is removed first contributes the least to the model. This process is continued un-
til all the covariates in the model contribute significantly in explaining variations in
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the outcome. Bidirectional elimination starts with an arbitrary model and considers
adding, removing, or swapping a covariate with each step until the model does not
change. This stepwise method is thus a combination of forward selection and back-
ward elimination. All methods have the risk of excluding important and/or including
unimportant covariates (Harrell, 2001; Hosmer et al., 2008). Backward elimination is
preferred over the other stepwise methods because it is the least likely to exclude im-
portant covariates that are only significant in relation with other covariates (Harrell,
2001; Hosmer et al., 2008).
Stepwise methods are based on some mathematical information criterion. This
information criterion is an estimate of the prediction error. With the model selection
process, the model with the lowest information criterion would be selected. There
are numerous information criteria of which Akaike information criterion (AIC) and
Bayesian information criterion (BIC) are most commonly used, and defined as (Hastie
et al., 2009):
AIC = −2LL+ 2k, (4.48)
BIC = −2LL+ k ln(m), (4.49)
where LL is the partial log likelihood of the Cox’s model, k is the number of
coefficients estimated by the model, and m is the limiting sample size, which is the
number of events in survival analysis (Harrell, 2001; Hastie et al., 2009). As the sample
size increases to infinity, model selection based on AIC has a non-zero and model
selection based on BIC has a zero probability of overfitting the data, i.e. selecting
unimportant covariates thereby making the model too complex (Hastie et al., 2009).
However, with a finite limiting sample size, model selection based on BIC could select
too few covariates, making the model too simple. As the stepwise method based on
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some information criterion is an automated process, it is important to check whether
the resulting survival model is biologically plausible (Hosmer et al., 2008).
For this research, backward elimination of second-order interaction effects was
carried out. For the automated process, BIC was used as information criterion. It
was assumed that only interaction effects would be removed from the model and not
main effects as their significance in explaining survival prospects were established
in previous studies. The automated backward elimination process where BIC was
minimised, resulted per age cohort in a survival model with 20 to 25 interaction effects
with p-values ranging from <.001 to .500. Backward elimination was continued until
all interaction effects were significant at 1% level in the decomposition of Cox’s model
by ANOVA (analysis of variance). Due to large sample sizes, the significance level
was set at 1% to obtain only the interaction effects that contribute the most to the
model in explaining survival variations. The low significance level comes with the
cost that interaction effects between covariates that have relatively rare categories
will most likely be excluded. This manual backward elimination process resulted per
age cohort in a survival model with three to eight interaction effects. A common set
of effects in the survival models was chosen to have the same interpretation of the
effects at each age cohort. If an interaction effect was found in the majority of the
models (≥50%), it was included in all models. For the analysis that makes use of
multiple imputation, the variable selection had a two-step approach. At the first step,
interaction effects found in the majority of the models on the imputed datasets of an
age cohort, were included in the age-specific model. At the second step, interactions
found in the majority of the age-specific models, were included in the final overall
model. It was checked whether the interaction effects were biologically plausible by
comparing them with previous studies and clinical guidelines.
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4.4 Model assessment
The final survival models were assessed in respect to overall performance, discrimi-
nation, and external validation, using Royston’s R-square (Royston, 2006), Harrell’s
concordance (Harrell et al., 1996), and the shrinkage slope (Steyerberg et al., 2010),
respectively. Furthermore, the results were compared internally with the complete
case analysis, and externally with previous studies.
Royston’s R-square
Overall model performance was assessed by calculating Royston’s R-square, which is
the percentage of variation in the outcome explained by the survival model (Royston,
2006). This is based on the goodness-of-fit measures proposed by Nagelkerke (1991)
and O’Quigley et al. (2005).
Nagelkerke’s ρ2n is the most commonly calculated goodness-of-fit measure of a
Cox’s model (Steyerberg et al., 2010). The statistic ρ2n is calculated by dividing the
likelihood ratio test statistic of the empty versus full model, as specified in Equation
(4.22), by the sample size N (Nagelkerke, 1991):
ρ2n = 1− exp
(
LRTβ
N
)
. (4.50)
This statistic ranges from zero to one, where zero means that the survival model
could not determine survival time for any subject and one means that the model could
perfectly determine survival time for each subject. Nagelkerke’s ρ2n is biased towards
zero when there is censoring during the study period (Royston, 2006). O’Quigley, Xu,
and Stare (2005) therefore suggested to replace the sample size N in the denominator
by the number of events M :
ρ2k = 1− exp
(
LRTβ
M
)
. (4.51)
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This statistic is a measure of explained variation, where zero means that the
survival model could not explain the variation in survival time for any subject and
one means that the model could perfectly explain the variation in survival time for
every subject. Royston (2006) suggested to rewrite the statistic ρ2k as a measure of
explained variation. Let the model variance Varm be ρ
2
k/(1−ρ2k), the residual variance
Varr be pi
2/6, and the total variance Vart be the sum of the model variance Varm
and the residual variance Vart (Royston, 2006). Then the percentage of variation in
survival time explained by the model is the model variance Varm divided by the total
variance Vart (Royston, 2006):
ρ2r =
V
pi2/6 + V
=
ρ2k
ρ2k + (pi
2/6)(1− ρ2k)
. (4.52)
This statistic ranges from zero to one, where zero means that the survival model
could not explain any of the survival variation between subjects and where one means
that the survival model could perfectly explained survival variation between subjects.
Harrell’s concordance
The degree of discrimination between subjects by the model was assessed by cal-
culating Harrell’s concordance, which is the percentage of correspondence between
the estimated hazard score and observed survival time for all combinations of two
selected subjects (Steyerberg et al., 2010). Harrell’s concordance CH is calculated as
(Steyerberg et al., 2010):
CH =
C + T/2
C +D + T
, (4.53)
where C stands for concordant pairs, D for discordant pairs, and T for tied pairs.
A concordant pair is when the subject with the lower risk score has the longer survival
time. A discordant pair is when the subject with the lower risk score has the shorter
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survival time. A tied pair is when it is unknown which of two subjects had the event
first. This happens when two subjects have time-tied events, when both are censored,
or when one subject is censored before the other subject had the event.
The concordance statistic ranges between zero and one, where one stands for
perfect discrimination between two randomly selected subjects (Therneau, 2014). A
concordance of .5 means that the model is as good as flipping a fair coin in its
discrimination. In survival analysis, the concordance measure is typically between .6
and .7 (Therneau, 2014).
Shrinkage slope
External model validation was assessed by calculating the shrinkage slope, which
assesses the agreement between observed and expected outcomes. Predictions could
be systematically too low or too high, reflecting overfitting or underfitting of a model
(Harrell et al., 1996). The shrinkage slope is the factor by which the coefficients
may need to be shrunk due to overfitting or rise due to underfitting of the model
(Harrell et al., 1996). In other words, this factor indicates how well the model would
perform on new data and how well the results of the sample are generalisable to a
wider population.
For this research, the shrinkage slope was calculated by a ten-fold cross-validation
(Refaeilzadeh et al., 2009). Cross-validation estimates the expected extra prediction
error due to sampling, where the prediction error is the difference between observed
and predicted outcome values. The prediction error  is calculated as (Hastie et al.,
2009):
 = E[Y − Yˆ ] = 1
N
N∑
i=1
(yi − yˆi), (4.54)
where subject i has observed outcome yi and predicted outcome yˆi, and N is the
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total number of subjects. With K-fold cross-validation, the sample is randomly split
in K folds of equal sizes. The model is fitted on K-1 folds and the prediction error
of the fitted model on the excluded fold is calculated. In other words, the model is
trained on K-1 folds and validated on the excluded fold. This process is repeated K
times, so that each fold has been validated once. The cross-validation estimate of the
prediction error CV (ˆ) is the average of the K prediction errors (Hastie et al., 2009):
CV (ˆ) =
1
K
1
n
K∑
i=1
n∑
i=1
(y
−k(i)
i − yˆ−k(i)i ),
=
1
N
N∑
i=1
(yi − yˆ−k(i)i ),
(4.55)
where yˆ−k is the predicted outcome for the kth excluded fold and n the number of
subjects in the kth fold. A ten-fold cross-validation is typically chosen because there
are multiple performance statistics and the training fold is large enough to generalise
over the whole sample while the validation fold is not too small to obtain an accurate
performance statistic (Refaeilzadeh et al., 2009).
The shrinkage slope is one minus the prediction error (Hastie et al., 2009). A
shrinkage slope of one means that the coefficients were correctly estimated by the
model (Harrell et al., 1996). In most cases, the shrinkage will be smaller than one,
which means that the coefficients were overestimated by the model and that the true
coefficients are likely to be smaller than estimated. In rare cases, a shrinkage slope
will be greater than one, which means that the coefficients were underestimated by
the model and that the true coefficients are likely to be greater than estimated. The
closer the shrinkage slope is to one, the more accurate the survival model is predicting
survival time.
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Comparing results
The final models were compared to the models obtained from the complete case
analysis. The comparison included the covariates and interactions adjusted for, the
estimated hazard ratios, and the model diagnostics with respect to overall perfor-
mance, discrimination, and external validation. This comparison within the study
would inform how missing data affected the results and the validity of the multiple
imputation.
The estimated hazard ratios from the final models were also compared with the
ones estimated by models developed by previous studies. These studies were sum-
marised in Chapter 2 in Table 2.1, which included what covariates and interactions
were adjusted for. The previous studies did not report on model diagnostics, and
thus these cannot be compared.
Chapter 5
Survival models for acute
myocardial infarction
This Chapter presents the development of the survival models for acute myocardial
infarction (AMI). The survival models estimated the adjusted hazards of all-cause
mortality associated with a history of AMI and related treatments, comorbidities,
lifestyle factors, and demographics in residents of the United Kingdom (UK) at re-
tirement age. Survival variations by general practice were also examined. The findings
were published in BMJ Open (Gitsels et al., 2017).
This Chapter starts with explaining the analysis procedure including the study
design, selected medical history, and model development. This is followed by a de-
scription of the age cohorts. Next, the survival models are presented. Then, the
survival models are evaluated with respect to model performance, internal validation,
and external validation. Finally, recommendations based on the findings are provided.
5.1 Analysis procedure
5.1.1 Study design
The research objectives of investigating how a history of AMI affects longevity at
retirement age and which treatments improve longevity, were addressed by a retro-
spective cohort design. Four cohorts of patients aged 60, 65, 70, and 75 were followed
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up. The data restrictions and the identification of eligible general practices and pa-
tients from The Health Improvement Network (THIN) primary care database, were
discussed in Chapter 3 Section 4. The prevalence of AMI was relatively rare, espe-
cially in the youngest cohort. At ages 60, 65, 70, and 75, the prevalence of AMI in
women was 1.1, 1.9, 2.7, and 3.7%, respectively, and in men 4.8, 6.6, 8.3, and 10.0%,
respectively. To create more balanced cohorts with respect to the exposure of inter-
est, patients with a history of AMI were selected and each matched to three controls
without this history on sex, year of birth category, and general practice, see Figure
5.1.
The analysis of the age cohorts was performed in two stages, where the first stage
of complete case analysis informed the second stage of full data analysis. Frequency
matching was carried out once on complete medical records and once irrespective of
completeness of records. The reason for this was to ensure that the balance in the
cohorts created by matching would not be cancelled when excluding patients with
missing data from the complete case analysis. Moreover, this led to optimal use of
the available data by maximising the sample size of the complete case analysis and
thereby increasing the statistical power. Patients could be part of multiple cohorts,
where cases could be matched to different controls. Matching was done in Python
version 3.4.2.
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Data from The Health Improvement Network (THIN) primary care database with the following restrictions for this research:
* Medical records of patients born between 1920-1940 registered at 405 general practices in the United Kingdom 
* Valid coding of death dates from 1987 onwards
* End of study period on the 18
th
 of May 2011 
Selection patients:
Medical records of patients born between 1920-1940 who turned the cohort’s age between 1987-2011 were selected. The cohort’s ages 
were 60, 65, 70, and 75. At the cohort’s age, patients had to be registered for at least one year at an active general practice that coded 
death dates validly, and their medical records had to be accessed at least once within the last ten years and include a postcode.
Movement of patients across 
age cohorts: 
N = New
D = Deceased
T = Transferred out of general 
       practice (i.e. loss to 
       follow-up)  
A = Alive
E = End of observation and 
      alive
N and A grouped together = 
      studied age cohort
D = 4,281
T = 14,125
D = 6,827
T = 12,378
D = 6,536
T = 6,413
E = 50,692
D = 2,621
T = 1,888
E = 36,480
D = 6,439
T = 15,330
D = 8,966
T = 10,044
E = 29,020
D = 10,107
T = 6,876
E = 50,160
D = 9,619
T = 13,737
E = 1,018
D = 24,260
T = 17,729
E = 60,244
D = 25,252
T = 22,688
E = 35,404
A = 123,835
N = 136,942
A = 104,630
A = 115,173
N = 126,607
A = 40,989
A = 67,143
A = 102,233
N = 83,344
N = 142,241
* Year of birth period
* Recruitment period
* Study period
60 65 75
*1927-1940
*1987-2000
*1987-2011
*1922-1940
*1987-2005
*1987-2011
*1920-1940
*1990-2010
*1990-2011
*1920-1936
*1995-2011
*1995-2011
Sample size 142,241 260,777 346,410 293,709
Cohort’s age 70
Matched study design, where 
cases with a history of acute 
myocardial infarction (AMI) 
were matched to three 
controls on sex, year of birth 
category, and general 
practice.
C1 = Cases with AMI 
C2 = Controls without AMI
C   = Cases + controls 
C1 =   4,186
C2 = 12,558
C   = 16,744
C1 = 10,882
C2 = 32,646
C   = 43,528
C1 = 18,432
C2 = 55,296
C   = 73,728
C1 = 19,098
C2 = 57,294
C   = 76,392
Figure 5.1: Selected age cohorts for acute myocardial infarction matched by sex, year of birth, and general practice
This Figure is an extended version of Figure 3.1 with information on the matched study design. Patients could be part of multiple
cohorts, where cases could be matched to different controls.
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5.1.2 Selected medical history
At the cohort’s age, a snapshot of the patient’s medical history was obtained. Addi-
tionally, the patient’s survival was recorded during the follow-up. Chapter 3 Section
5 described the raw information selected from the medical records for the entire re-
search. This Section describes the edited information selected for the survival models
aimed at estimating the hazards of mortality associated with acute myocardial in-
farction and related treatments.
The primary exposure was AMI. Multiple events were required to be separated by
30 days. Information on the type of AMI was not available. However, a study that
linked information from the Myocardial Ischaemia National Audit Project (MINAP)
and the General Practice Research Database (GPRD), which has 60% of practices in
overlap with THIN, found that 46% of AMIs were ST-elevated (ST segment elevation
myocardial infarctions, STEMIs) in England and Wales in 2003-2008 (Herrett et al.,
2013a). The selected variables of the medical records were based on the literature
review, and consisted of: sex, year of birth, socioeconomic status, angina, heart
failure, cardiovascular system conditions (cerebrovascular disease, peripheral vascular
disease, valvular heart disease, and other cardiovascular system disorders), chronic
kidney disease, diabetes, hypertension, hypercholesterolaemia, alcohol consumption
status, body mass index (BMI), and smoking status, see Appendix B Table B.1.
Socioeconomic status was measured by Mosaic, which is based on demographics,
lifestyles, and behaviour of people at a postcode level (Experian Ltd., 2009).
The treatments investigated were based on the UK National Institute of Health
and Care Excellence (NICE) recommended first line treatments to AMI patients dur-
ing the study period, which includes: coronary revascularisation and prescription of
ACE inhibitors, aspirin, beta blockers, calcium-channel blockers, and statins (NICE,
2013b). Coronary revascularisation consisted of coronary artery bypass graft and
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coronary angioplasty. Since 2007, calcium-channel blockers are only recommended
to treat hypertension or angina in AMI patients (NICE, 2013b). Since 2013, dual
antiplatelet therapy (DAPT: aspirin plus another antiplatelet agent) is recommended
to AMI patients (NICE, 2013b). Owing to the low prevalence of DAPT in the age
cohorts, the survival effect of the therapy was not estimated, see Appendix B Table
B.2.
The values of all variables represented the latest reading before entering the study,
which was at the 1st of January of the year the patient turned the cohort’s age. Family
history of AMI and family history of cardiovascular disease (CVD) were not included
in the analysis because of the very low rates of recording in primary care (Hippisley-
Cox et al., 2008). Indicators of psychosocial factors such as job strain and lack of
social support, fruit and vegetable intake, and physical activity were not included in
the analysis because THIN does not hold information on them.
There were missing values in alcohol consumption status (proportion range across
the four age cohorts 17-37%), BMI (18-37%), and smoking status (10-29%). The
fraction of incomplete medical records decreased with age; 45% of the youngest cohort
and 23% of the oldest cohort had incomplete records. Incomplete records were more
common in patients without medical conditions or treatments and in patients born
at an earlier year, see Appendix B Table B.3. This is in accordance with previous
research that reported that recording is associated with sickness and has improved
since the introduction of Quality and Outcomes Framework (QOF) in 2004 (Marston
et al., 2010; Shephard et al., 2011; Taggar et al., 2012).
Missing values were dealt with by multiple imputation. The joint imputation
model consisted of all factors from the snapshot of medical history including time to
death and was two level to adjust for the correlation between patients from the same
general practice. Imputations were done in REALCOM-Imputation software. The
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Monte Carlo Markov Chain (MCMC) estimation had a burn-in length of 100 iterations
and was in total 1,000 iterations long. The imputed values of every 100th iteration
were used. This resulted in ten imputed datasets. The distribution of recorded and
imputed values of variables with missing data were similar, see Appendix B Table
B.4.
Postcode classification indices other than Mosaic were only available for patients
living in England or Wales. The following classification indices were selected to ex-
amine the hazard of mortality associated with general practice in more detail: index
of multiple deprivation (IMD), level of urbanisation, quintile of limiting long-term ill-
ness, quintile of various ethnic groups, and quintile of various air pollution measures,
see Appendix B Table B.1.
5.1.3 Model development
A Cox’s proportional hazards regression model was fitted to estimate the effect of
a history of AMI and respective treatments on the hazard of all-cause mortality
at different ages. The outcome variable was time to death in days, that is, from
the 1st of January of the year the patient turned the cohort’s age to the date of
death. Starting from a model with second-order interaction effects of all variables
with the main exposure AMI and the matching factors sex and year of birth category,
backward elimination was performed to obtain the most parsimonious model possible.
Interaction effects found in the complete case analysis, which were not restricted to the
main exposure and matching factors, were also included in the backward elimination
process. The extra interactions were hypercholesterolaemia with statin prescription,
and BMI with smoking status. A unified model for all ages was chosen, to have
the same interpretation of the hazards. This model consisted of the factors that
were found significant in the majority of models with the alpha level set to 5% for
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fixed effects and 1% for interaction effects. The model also included a random effect of
general practice to adjust for the correlation between patients from the same practice.
The Cox’s regression assumes no time-tied deaths, uninformative censoring, and
proportional hazards. Time-tied deaths were handled by Efron’s approximation. Cen-
soring due to loss of follow-up was examined by comparing patients who did and did
not transfer out of their general practice with respect to health status and lifestyle
factors. For the youngest two age cohorts, distinction was made between patients
observed until age 70 or for longer. This was because previous studies indicated that
there are two groups of people who move at an older age, where the younger group
comes from more aﬄuent areas and move in good health and the older group comes
from more deprived areas and move in worse health (Pennington, 2013; Uren and
Goldring, 2007). These trends were not observed in the age cohorts, see Appendix
B Table B.5, and therefore uninformative censoring was assumed. The assumption
of proportional hazards was checked by Grambsch and Therneau’s test. When the
assumption was violated for a variable, being significant at alpha level set to 1%, the
variable’s effect on survival time was made time-variant. Follow-up time was split in
intervals in which the assumption was no longer violated, where the time intervals of
10, 5, or 1 year were tested.
The final model included sex, year of birth, socioeconomic status, AMI, angina,
heart failure, cardiovascular system conditions, chronic kidney disease, diabetes, hy-
pertension, hypercholesterolaemia, coronary revascularisation, ACE inhibitors, as-
pirin, beta blockers, calcium-channel blockers, statins, alcohol consumption status,
BMI, smoking status, and general practice. Chronic kidney disease was not adjusted
for at ages 60 and 65 due to a low prevalence of less than 1%. There were five in-
teractions: AMI with angina, AMI with beta blockers, AMI with calcium-channel
blockers, hypercholesterolaemia with statins, and BMI with smoking status. Angina
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is, like AMI, a subtype of ischaemic heart disease (IHD) and has a similar treatment
regime as AMI (NICE, 2013a,b). With the way these subtypes interact, a new factor
representing IHD was generated that had the following levels: no history, angina only,
single AMI with possibly angina, or multiple AMIs with possibly angina. Similarly,
with the way hypercholesterolaemia and statins interact, a new factor representing
cholesterol was generated that had the following levels: no diagnosis or drugs, hy-
percholesterolaemia only, and statins with possibly hypercholesterolaemia. Variables
with time-varying hazards were cardiovascular system conditions and coronary revas-
cularisation at all ages, and hypertension by ages 70 and 75. The contribution of each
variable to the model in explaining survival variations was assessed by decomposing
the Cox’s regression by ANOVA (analysis of variance).
It was examined whether the adjusted hazard of mortality associated with gen-
eral practice could be explained by postcode related indicators. These variables were
not included in the original survival models because they were only available for pa-
tients living in England or Wales. Even though the additional variables explored
were measured on district level, the relation between them and general practice was
examined on patient level. This was because a practice could serve patients from a
range of districts and an average calculated in the cohorts would not be representative
of the practice as it would be biased to the older and sicker patients. High density
scatterplots were made and Spearman’s rank tests were performed to estimate the
correlation of the postcode related indicators and the hazard of mortality associated
with general practice. The correlation statistic ranges from -1 to 1, where 0 stands
for no correlation and -1 or 1 for perfect correspondence between the two variables
(Harrell et al., 1996). The probability values were not consulted because the cor-
relation tests between aggregate measures were performed at patient level, thereby
underestimating the variance and leading to false precision.
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The number of years lost or gained in effective age associated with a history of
AMI and related treatments, comorbidities, lifestyle factors, and demographics were
calculated. The models were assessed on overall performance, discrimination, and ex-
ternal validation, using Royston’s R2, Harrell’s concordance, and the shrinkage slope,
respectively. Furthermore, the results were compared internally with the complete
case analysis and externally with previous studies. The analyses were performed in
R version 3.1.1, using the packages ‘hmisc’, ‘rms’, and ‘survival’.
5.2 Description of cohorts
Four cohorts of patients who were either 60, 65, 70, or 75 years old at baseline were
studied. The age cohorts included cases with history of AMI who were matched to
three controls on sex, year of birth, and general practice. The profile of cases and con-
trols with respect to comorbidities, treatments, and lifestyle and socio-demographic
factors differed by age and changed over time, see Table 5.1, Figure 5.2 and Appendix
B Figures B.1-B.2.
The prevalence of comorbidities was higher among AMI cases than controls, and
increased with age, see Table 5.1. Angina was the most common comorbidity in
AMI patients (prevalence range across the four age cohorts 46-48%), followed by
cardiovascular system conditions (23-43%), diabetes (11-20%), heart failure (5-12%),
and chronic kidney disease (0-10%). From 1995 to 2011, the prevalence of diabetes
in AMI patients increased by 14-18%, while the prevalence of angina decreased by
5-10%, and the prevalence of the other comorbidities remained approximately the
same over time, see Appendix B Figure B.1.
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Table 5.1: Characteristics of cases and controls in matched age cohorts
The age cohorts included cases with history of acute myocardial infarction (AMI) who were matched to three controls on sex, year
of birth, and general practice. 1Missing values in alcohol consumption status, body mass index, and smoking status were dealt with
by multiple imputation. The reported prevalences of these variables are the means across ten imputed datasets. The prevalences of
comorbidities and lifestyle factors at the cohort’s age were affected by calendar year, see Appendix B Figures B.1-B.2.
Age 60 Age 65 Age 70 Age 75
Cases Controls Cases Controls Cases Controls Cases Controls
Number of patients 4,186 12,558 10,882 32,646 18,432 55,296 19,098 57,294
Total person-years of
follow-up (mean)
46,686
(11.2)
150,471
(12.0)
93,056
(8.6)
299,841
(9.2)
114,700
(6.2)
370,006
(6.7)
91,884
(4.8)
298,140
(5.2)
Deaths during follow-up
(%)
1,220
(29%)
2,008
(16%)
3,070
(28%)
5,782
(18%)
5,186
(28%)
10,557
(19%)
5895
(31%)
12,674
(22%)
Transfers during follow-up
(%)
900
(22%)
3,035
(24%)
1,986
(18%)
6,597
(20%)
2,693
(15%)
8,781
(16%)
2,733
(14%)
8,971
(16%)
Male (%) 3,367
(80%)
10,101
(80%)
8,402
(77%)
25,206
(77%)
13,567
(74%)
40,701
(74%)
13163
(69%)
39,489
(69%)
Angina (%) 1,924
(46%)
594
(5%)
5,161
(47%)
2,445
(7%)
8,623
(47%)
5,528
(10%)
9,122
(48%)
7,472
(13%)
Heart failure (%) 205
(5%)
61
(0%)
676
(6%)
338
(1%)
1,568
(9%)
982
(2%)
2,198
(12%)
1,674
(3%)
Cardiovascular system
conditions (%)
979
(23%)
681
(5%)
3,154
(29%)
2,941
(9%)
6,591
(36%)
7,672
(14%)
8,205
(43%)
11,674
(20%)
Chronic kidney disease (%) 1
(0%)
0
(0%)
4
(0%)
8
(0%)
965
(5%)
1,392
(3%)
1872
(10%)
3,039
(5%)
Diabetes (%) 449
(11%)
624
(5%)
1,622
(15%)
2,297
(7%)
3,398
(18%)
5,573
(10%)
3,726
(20%)
6,876
(12%)
Hypercholesterolaemia (%) 1,634
(39%)
1,907
(15%)
4,228
(39%)
7,423
(23%)
6,392
(35%)
14,936
(27%)
6,395
(33%)
15,814
(28%)
Continued on next page
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Table 5.1 – Continued from previous page
Age 60 Age 65 Age 70 Age 75
Cases Controls Cases Controls Cases Controls Cases Controls
Hypertension (%) 1,168
(28%)
1,991
(16%)
3,750
(34%)
7,608
(23%)
7,411
(40%)
17,955
(32%)
8,579
(45%)
22,330
(39%)
Alcohol consumption status
recorded (%)
7,679
(61%)
2,874
(69%)
23,183
(71%)
8,663
(80%)
42,571
(77%)
15,746
(85%)
46,359
(81%)
16,894
(88%)
Alcohol consumer1 (%) 3,385
(81%)
10,997
(88%)
8,780
(81%)
28,130
(86%)
14,494
(79%)
45,962
(83%)
14,293
(75%)
45,504
(79%)
Body mass index recorded
(%)
7,664
(61%)
2,973
(71%)
23,023
(71%)
8,793
(81%)
42,655
(77%)
15,876
(86%)
46,048
(80%)
16,919
(89%)
Overweight1 (%) 2,427
(58%)
7,239
(58%)
5,866
(54%)
17,609
(54%)
9,406
(51%)
28,253
(51%)
9,264
(49%)
28,030
(49%)
Obese1 (%) 750
(18%)
1,418
(11%)
2,295
(21%)
4,687
(14%)
4,107
(22%)
9,180
(17%)
3,848
(20%)
9,365
(16%)
Smoking status recorded
(%)
8,692
(69%)
3,244
(77%)
25,498
(78%)
9,493
(87%)
46,766
(85%)
16,817
(91%)
50,665
(88%)
17,884
(94%)
Ex-smoker1 (%) 1,274
(30%)
2,398
(19%)
4,611
(42%)
10,903
(33%)
8,335
(45%)
19,305
(35%)
8695
(46%)
20,641
(36%)
Smoker1 (%) 1,163
(28%)
3,507
(28%)
2,203
(20%)
6,544
(20%)
3,079
(17%)
8,973
(16%)
2,545
(13%)
7,660
(13%)
114Figure 5.2: Prevalence of treatments by cohort’s age in patients with acute myocardial infarction
The age cohorts differed in recruitment period. The prevalence prior to 1995 is not presented due to the small numbers of medical
records available.
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The clinical and lifestyle factors hypertension, hypercholesterolaemia, obesity
(BMI≥30 kg/m2), and ex-smoking were more common among AMI cases than con-
trols, see Table 5.1. Overweight (BMI 25-30 kg/m2) and smoking was as common
among cases as controls. Alcohol consumption was less common among cases than
controls. Given calendar year, the prevalence of obesity and smoking in AMI pa-
tients decreased with increasing age, see Appendix B Figure B.2. Given calendar
year, the prevalence of overweight and ex-smoking in AMI patients remained approx-
imately the same with increasing age, while the prevalence of alcohol consumption
decreased, and the prevalence of hypertension increased. The prevalence of hyperc-
holesterolaemia was more common in younger AMI patients prior to 2000, and was
approximately the same across age thereafter. From 1995 to 2011, the prevalence
of alcohol consumption and overweight in AMI patients remained approximately the
same; the prevalence of hypertension, ex-smoking, and obesity increased; and the
prevalence of smoking decreased. Interestingly, the prevalence of hypercholestero-
laemia increased from 1995 to 2000/2002 and decreased after that. This trend was
the most pronounced in the oldest cohort, in which the prevalence increased from
15% in 1995 to 43% in 2002, after which it decreased to approximately 30% in 2011.
The decrease in hypercholesterolaemia could reflect the cholesterol lowering effect by
the more widespread prescription of statins. The prevalence order of the clinical and
lifestyle factors in AMI patients changed over time and this varied by age, although
smoking remained the least prevalent and alcohol consumption the most prevalent.
From 2005 onwards, the prevalence of smoking was between 10-20%; obesity and
hypercholesterolaemia between 20-40%; ex-smoking, overweight, and hypertension
between 40-60%; and alcohol consumption between 60-80%.
The prevalence of coronary revascularisation and drug therapy was higher among
patients who had multiple AMIs compared with patients who had a single AMI,
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see Table 5.2. The rates across the four age cohorts for coronary artery bypass
graft (CABG) and percutaneous coronary intervention (PCI) were 16-19% and 3-8%,
respectively, see Appendix B Table B.6. Men were approximately twice as likely to
have had coronary revascularisation as women were, which could not be explained
by age, deprivation, or diabetes, see Figure 5.3 and Appendix B Table B.7. Men
and women were equally likely to be prescribed drugs. From 1995 to 2011, the
prevalence of coronary revascularisation and drug therapy increased substantially,
with the exception of prescription of calcium-channel blockers that decreased over
the years, see Figure 5.2. The difference in treatment prevalence by the four initial
ages converged over time. In 2010 the most widely prescribed drugs to AMI patients
were statins and aspirin (both 94%) followed by ACE inhibitors (85%), beta blockers
(65%), and calcium-channel blockers (25%). In the same year, 38% of the AMI
patients have had coronary revascularisation; the prevalence was greater in patients
living in the most aﬄuent areas (IMD category 1: 45%) than in patients living in the
most deprived areas (IMD category 5: 32%; trend χ2(1)=5.06, p=.20).
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Table 5.2: Baseline treatments by ischaemic heart disease
The age cohorts included cases with history of acute myocardial infarction (AMI) who were matched to three controls on sex, year of
birth, and general practice. History of ischaemic heart disease was a factor categorised as: no history, angina only, single AMI with
possibly angina, or multiple AMIs with possibly angina. Thus, the former two categories consisted of the controls and the latter two
categories consisted of the cases. The prevalences of treatments by the cohort’s age were affected by calendar year, see Figure 5.2.
Ischaemic Size Coronary Drug therapy
heart disease revascularisation
Men Women Aspirin ACE Beta Statins Ca-channel
inhibitors blockers blockers
Age 60 No 11,964 0 (0%) 0 (0%) 271 (2%) 678 (6%) 1,156 (10%) 208 (2%) 615 (5%)
Angina 594 97 (19%) 7 (8%) 211 (36%) 95 (16%) 238 (40%) 148 (25%) 264 (44%)
Single AMI 3,465 486 (18%) 77 (11%) 1,467 (42%) 768 (22%) 1,482 (43%) 951 (27%) 1,080 (31%)
Multiple AMIs 721 194 (32%) 20 (18%) 386 (54%) 256 (36%) 314 (44%) 247 (34%) 290 (40%)
Age 65 No 30,201 0 (0%) 0 (0%) 2,548 (8%) 3,299 (11%) 3,727 (12%) 2,194 (7%) 2,709 (9%)
Angina 2,445 512 (25%) 30 (7%) 1,400 (57%) 701 (29%) 1,036 (42%) 1,164 (48%) 1,024 (42%)
Single AMI 8,796 1532 (23%) 334 (16%) 5,751 (65%) 3,452 (39%) 4,011 (46%) 4,722 (54%) 2,762 (31%)
Multiple AMIs 2,086 594 (35%) 67 (17%) 1,532 (73%) 1,072 (51%) 946 (45%) 1,272 (61%) 722 (35%)
Age 70 No 49,768 0 (0%) 0 (0%) 8,698 (17%) 9,756 (20%) 7,176 (14%) 8,863 (18%) 6,820 (14%)
Angina 5,528 1,263 (28%) 125 (12%) 3,851 (70%) 2,204 (40%) 2,376 (43%) 3,335 (60%) 2,235 (40%)
Single AMI 14,847 2,811 (26%) 730 (18%) 11,269 (76%) 7,770 (52%) 6,989 (47%) 9,638 (65%) 4,461 (30%)
Multiple AMIs 3,585 1,012 (36%) 172 (22%) 2,918 (81%) 2,202 (61%) 1,721 (48%) 2,524 (70%) 1,219 (34%)
Age 75 No 49,822 0 (0%) 0 (0%) 12,592 (25%) 12,633 (25%) 7,945 (16%) 11,318 (23%) 8,574 (17%)
Angina 7,472 1,652 (29%) 225 (13%) 5,642 (76%) 3,430 (46%) 3,188 (43%) 4,780 (64%) 2,952 (40%)
Single AMI 15,319 2,705 (26%) 835 (17%) 12,487 (82%) 9,226 (60%) 7,036 (46%) 10,395 (68%) 4,676 (31%)
Multiple AMIs 3,779 954 (35%) 230 (23%) 3,295 (87%) 2,574 (68%) 1,759 (47%) 2,767 (73%) 1,228 (32%)
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Figure 5.3: Prevalence of ischaemic heart disease (IHD) and coronary
revascularisation given IHD, by deprivation
The age cohorts included cases with history of acute myocardial infarction (AMI) who
were matched to three controls on sex, year of birth, and general practice. History of
IHD consisted of AMI and angina. Patients of both subtypes of IHD could be eligible
for coronary revascularisation. Deprivation was measured by index of multiple deprivation
(IMD) quintiles.
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5.3 Survival models
The survival models developed for ages 60, 65, 70, and 75 are presented in forest plots.
The results on AMI and related treatments across the age cohorts can be found in
this Section Figures 5.4 and 5.5, respectively. The results of the survival models by
age cohort can be found in Appendix B Figures B.3-B.6.
The adjusted hazard of all-cause mortality for AMI patients was constant during
follow-up of 24 years; it did not matter how many years the cases had already survived,
they were still at a higher risk of dying than the controls. This relative hazard was
the greatest in the youngest cohort while the absolute hazard was the greatest in the
oldest cohort, see Figure 5.4 and Appendix B Figure B.7.
Due to the way AMI and angina interacted, a factor representing IHD was gen-
erated as described above. Compared with no history of IHD by age 60, 65, 70,
or 75, having had one AMI was associated with a hazard of mortality of 1.80 (95%
confidence interval 1.60-2.02), 1.71 (1.59-1.84), 1.50 (1.42-1.59), or 1.45 (1.38-1.53),
respectively. This translates to an increase in effective age of 5.9 (4.7-7.0), 5.4 (4.6-
6.1), 4.1 (3.5-4.6), or 3.7 (3.2-4.3) years, respectively. Compared with no history of
IHD by age 60, 65, 70, or 75, having had multiple AMIs was associated with a hazard
of mortality of 1.92 (1.60-2.29), 1.87 (1.68-2.07), 1.66 (1.53-1.80), or 1.63 (1.51-1.76),
respectively. This translates to an increase in effective age of 6.5 (4.7-8.3), 6.2 (5.2-
7.3), 5.1 (4.3-5.9), or 4.9 (4.1-5.6) years, respectively. The hazard of mortality did not
differ between cases with or without a history of angina. Cases and controls differed
in survival benefits of prescriptions of beta blockers and calcium-channel blockers,
which are described below. There were no other interactions with a history of AMI,
meaning that the effect of AMI on the hazard of mortality was the same for different
subgroups of patients, such as for men and women.
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Figure 5.4: Unadjusted and adjusted hazards of all-cause mortality associated with ischaemic heart disease
The age cohorts included cases with history of acute myocardial infarction (AMI) who were matched to three controls on sex, year of
birth, and general practice. Due to the way AMI and angina interacted, a factor representing ischaemic heart disease was generated
that had the following levels: no history, angina only, single AMI with possibly angina, or multiple AMIs with possibly angina. The
hazard ratios (95% confidence interval) were adjusted for sex, year of birth, socioeconomic status, heart failure, cardiovascular system
conditions, chronic kidney disease (only at ages 70 and 75), diabetes, hypertension, hypercholesterolaemia, coronary revascularisation,
ACE inhibitors, aspirin, beta blockers, calcium-channel blockers, statins, alcohol consumption status, body mass index, smoking
status, and general practice.
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The comorbidities that had the greatest impact on survival were cardiovascular
system conditions and heart failure, see Appendix B Figures B.3-B.6. The hazard
of mortality associated with a history of medical conditions was constant over time;
it did not matter how many years patients have had the history, they were still
at a higher risk of dying than patients without the history. The exception to this
was cardiovascular system conditions, where the relative hazard decreased over time
and thus the survival prospects improved over time. In general, the relative hazard
associated with the comorbidities was greatest in the youngest cohort. On average
the comorbidities led to an additional increase in effective age of 3.5 to 7.0 years at
all ages.
The lifestyle factor that had the greatest impact on survival was smoking, see
Appendix B Figures B.3-B.6. The hazard of mortality associated with smoking com-
pared with non-smoking was greater in normal weight patients than in overweight or
obese patients. This translates to an increase in effective age across the four age co-
horts of 7.5 to 10.0 and 5.5 to 8.0 years, respectively. The relative hazard was greatest
in the youngest cohort. In non-smokers, the survival prospects of overweight patients
were not significantly different from normal weight patients. Alcohol consumption
was associated with improved survival benefits, translating to a decrease in effective
age of 0.5 to 1.5 years at all ages.
Coronary revascularisation was associated with a significant improvement in the
survival prospects in the short-term, see Figure 5.5. Compared with no history of
coronary revascularisation by age 60, 65, 70, or 75, having had revascularisation
was associated with a hazard of mortality of 0.80 (0.61-1.05), 0.72 (0.63-0.82), 0.73
(0.67-0.80), or 0.78 (0.73-0.84), respectively, in the first five years of follow-up. This
translates to a decrease in effective age of 2.3 (-0.5-5.0), 3.3 (2.0-4.7), 3.1 (2.2-4.0),
or 2.5 (1.7-3.2) years, respectively. After five years of follow-up, a history of coronary
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revascularisation was no longer associated with a significant improvement in the sur-
vival prospects. These prospects were the same for different subgroups of patients,
such as for men and women.
Drug therapy was associated with mixed survival prospects and could differ by
subgroups of patients, see Figure 5.5. The drug therapy that was associated with
the greatest improved survival prospects was prescription of statins; the prescription
translated to an average decrease in effective age of 2.5 years at all ages. The haz-
ard of mortality associated with statin prescription did not differ between patients
with or without a history of hypercholesterolaemia. Prescription of beta blockers
was associated with mixed survival prospects; prescription translated to an average
decrease in effective age of 2.0 years at all ages in AMI patients versus no decrease in
patients without AMI. Prescription of calcium-channel blockers was also associated
with mixed survival prospects; prescription translated to no decrease in effective age
in AMI patients versus an average increase in effective age of 2.0 years in patients
without AMI. Prescription of aspirin or ACE inhibitors was associated with worsened
survival prospects; the prescription translated to an average increase in effective age
of 1.0 or 1.5 years, respectively, at all ages. There were no significant differences in
the effects of the treatments by other subgroups of patients than described above,
such as for men and women.
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Figure 5.5: Adjusted hazards of all-cause mortality associated with treatments for
ischaemic heart disease
The age cohorts included cases with history of acute myocardial infarction (AMI) who were
matched to three controls on sex, year of birth, and general practice. The hazard ratios (95%
confidence interval) were adjusted for sex, year of birth, socioeconomic status, ischaemic
heart disease, heart failure, cardiovascular system conditions, chronic kidney disease (only
at ages 70 and 75), diabetes, hypertension, hypercholesterolaemia, alcohol consumption
status, body mass index, smoking status, general practice, and the listed treatments. The
hazard associated with coronary revascularisation was split at five years of follow-up after
the cohort’s age. The hazard associated with statin was the same in patients with and
without hypercholestolaemia.
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Survival prospects also differed by socioeconomic status, in which the difference
was greater at a younger age. The Mosaic category 5 (‘neighbourhood with mainly
young couples’) was associated with the worst survival prospects for patients aged
60 and older, this ranged from a hazard of mortality of 1.73 (1.42-2.10) at age 60 to
1.33 (1.22-1.44) at age 75, see Appendix B Figures B.3-B.6. This translates to an
increase in effective age of 5.5 years at age 60 and 3.0 years at age 75. In addition,
survival prospects varied considerably between general practices. The 95% tolerance
interval of the hazard of mortality associated with general practice was (0.79 to 1.21)
at age 60 and (0.55 to 1.45) at an older age. This translates to a maximum of 4.5
and 10 years difference in effective age between general practices, respectively. A
general practice could serve a range of patients with regards to health status, ethnic
background, deprivation, urbanisation, and pollution. These factors, however, were
not correlated with the hazard of mortality associated with general practice, see
Appendix B Table B.8. Moreover, adjusting for these factors in the final survival
models did not attenuate the hazard of mortality associated with general practice.
The variables contributing the most to the survival models in explaining survival
variations in the age cohorts were IHD, cardiovascular system conditions, interaction
between BMI and smoking status, and general practice. The variables contributing
the least to the survival models were hypertension, prescription of aspirin and calcium-
channel blockers, and alcohol consumption status.
5.4 Evaluation
5.4.1 Performance statistics
The final survival models explained 20 to 29% of survival differentials. There was
68 to 70% concordance between the estimated hazard of mortality and survival time.
The shrinkage slopes indicated that the adjusted effects were overestimated by less
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than 3%. These performance statistics are typical for survival analysis and the small
shrinkage slopes suggest that the results are robust.
The survival models that only included history of IHD estimated 1.08 and 1.19
times higher hazards of mortality associated with single and multiple AMIs, respec-
tively, see Figure 5.4. These models explained less than 1% of survival differentials
and had between 56-59% concordance between the estimated hazard of mortality and
survival time. The difference between the unadjusted and adjusted estimates and
the respective model performances demonstrate the importance of adjusting for con-
founders when estimating the effects of medical conditions and treatments associated
with the hazard of mortality.
5.4.2 Internal validation
The complete case analysis, estimated on only complete medical records, provided
similar results as the final survival models that were estimated on both complete and
incomplete records, see Appendix B Figures B.3-B.6. Both types of analyses adjusted
for the same variables. The complete case analysis did not find a significant difference
in the hazard of mortality associated with calcium-channel blockers in AMI patients
compared with other patients, and also did not find a significant difference in the
hazards of hypertension over time in the oldest two cohorts.
Both analyses estimated similar hazard ratios with overlapping confidence inter-
vals. In the youngest cohort, the difference in estimates was the greatest in socioe-
conomic status, BMI, and smoking status. The complete case analysis estimated the
hazard ratio of socioeconomic status on average 0.17 lower and the hazard ratios of
BMI and smoking status on average 0.15 higher. The difference in these estimates
decreased with increasing age, where the HR difference in the oldest cohort was only
0.03 and 0.01, respectively. In the oldest cohort, the difference in estimates was the
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greatest in AMI and cardiovascular system conditions after five years of follow-up,
where the complete case analysis estimated a HR of 0.10 to 0.23 greater.
The overall performance, discrimination, and validation statistics of the two types
of analyses were also alike, see Appendix B Table B.9. The survival models devel-
oped in the complete case analysis explained 23 to 30% of the survival variations,
determined 69 to 70% concordance between the estimated hazard of mortality and
survival time, and overestimated the effects by 1 to 4%.
5.4.3 External validation
This matched cohort study estimated the adjusted hazards of all-cause mortality
associated with a history of AMI and respective treatments by age 60, 65, 70, or 75
in UK residents using medical records from primary care between 1987 and 2011. In
accordance with the literature, this study found that AMI survivors have a long-term,
increased hazard of mortality, in which younger survivors and survivors of multiple
events were worse off (Briffa et al., 2009; Capewell et al., 2000; Chang et al., 2003;
Gerber et al., 2010, 2009; Herzog et al., 1998; Kirchberger et al., 2014; Koek et al.,
2007; Nigam et al., 2006; Quint et al., 2013; Smolina et al., 2012b). However, this
study estimated lower hazards of mortality than previously estimated. The lower
estimated hazards of mortality associated with a history of AMI reported by this
study compared with previous studies could be due to the different data source used
and the range of confounders adjusted for. This study made use of primary care data,
whereas most studies used hospital and register data. Research showed that the 1-year
mortality rate of AMI is lower in primary care probably because of a lower proportion
of severe cases (Herrett et al., 2013b). Furthermore, this study adjusted for a range
of confounders, which attenuated the estimated hazards of mortality associated with
a history of AMI. There is a smaller difference between the unadjusted estimates of
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this study and the sex-standardised and age-standardised mortality ratios estimated
in residents of England based on hospital and register data from 2004 to 2010 by
Smolina et al. (2012b). That study concluded that after 7 years, people with a first or
recurrent AMI had double or triple the risk of mortality, respectively, compared with
the general population of equivalent sex and age (Smolina et al., 2012b). It is unlikely
that the lower estimated hazards of mortality reported by this study are due to the
shifting epidemiological trends in CVD because there were no interactions between
a history of AMI and year of birth category or other risk factors with the exception
of angina, beta blockers, and calcium-channel blockers. The medical advances and
shifting prevalence of risk factors over time were adjusted for in the analysis and had
no different survival effects in AMI patients compared with patients without AMI.
This study tested all second-order interaction effects between AMI and the con-
founders and found only a significant interaction with angina, beta blockers, and
calcium-channel blockers at all initial ages. Two studies that estimated the long-term
survival prospects after angina or AMI also found that angina was less hazardous than
AMI, however the studies did not estimate the survival prospects when both types
of ischaemic heart diseases were present (Capewell et al., 2006; Chang et al., 2003).
This study found a borderline insignificant interaction between AMI and heart failure.
The insignificance could be due to the low prevalence of heart failure and therefore
not having enough power to test the interaction. This study did not find a sex differ-
ence in survival prospects after AMI. This is supported by some studies (Chang et al.,
2003; Gottlieb et al., 2000; Koek et al., 2007; Rosengren et al., 2001) but contradicted
by another (Smolina et al., 2012b). The difference could be explained by (the lack
of) adjustment for comorbidities and treatments.
This study found that the lower uptake of coronary revascularisation by women
could not be explained by age, diabetes, or deprivation, as suggested by a previous
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study (Chang et al., 2003). A study with data from the UK from 2003 to 2008,
showed that coronary revascularisation was more prevalent in non-STEMIs than in
STEMIs (Herrett et al., 2013a). As non-STEMIs are more common among women
than among men (Herrett et al., 2013a), it seems that type of AMI could not explain
the sex difference in uptake of surgery present in this study. In 2012, the European
Society for Cardiology reviewed the sex differences in treatment after AMI, taking
into account sex differences in risk profiles, and concluded that sex differences exist
(Chieffo et al., 2012). Patients from deprived areas had also lower uptake of coronary
revascularisation.
This study also found that a history of coronary revascularisation was no longer
associated with a significantly improved survival prospects after 5 years of follow-up.
This is in accordance with another study that reported a protective effect in the 1-year
mortality rate but an insignificant effect in the 5-year mortality rate of AMI (HR=0.76
(0.67-0.85) and HR=0.91 (0.78-1.08), respectively) (Chang et al., 2003). The findings
suggest that coronary revascularisation might mainly be beneficial in reducing early
mortality. No sex difference in survival after coronary revascularisation was found in
this study, which is supported by some studies (Chang et al., 2003; Smolina et al.,
2012b) but contradicted by another (Lagerqvist et al., 2001).
This study found no difference in drugs prescriptions by sex by 2010. A previous
study that looked at treatment after AMI in the UK from 1991 to 2002 did report
differences in prescription (Hardoon et al., 2011). It seems that the sex difference in
drugs prescription converged over time. The current study found that survival was
better in those who were prescribed statins or beta blockers, but worse in those pre-
scribed aspirin or ACE inhibitors, and unchanged in those prescribed calcium-channel
blockers. The estimated hazards of mortality associated with these treatments were
almost the same at each age, implying that the effectiveness of treatments does not
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differ by age. The findings of this study agree with the clinical evidence reviewed
by NICE (2013a) on the effectiveness of statins and calcium-channel blockers, but
disagree with the effectiveness of ACE inhibitors, aspirin, and beta blockers.
This study found that prescription of ACE inhibitors was associated with in-
creased hazard of mortality, whereas the NICE review estimated a protective effect
in AMI patients with left ventricular systolic dysfunction (LVSD; relative risk (RR)
of 0.84 (0.78-0.91)) and an inconclusive effect in AMI patients with unselected LVSD
(RR=1.02 (0.57-1.84)) (NICE, 2013a). The studies included used data from 1986-
1993 (AIRE Study, 1993; Borghi et al., 1998; Køber et al., 1995; Pfeffer et al., 1992;
SOLVD Investigators, 1992). A study using data from the same period found incon-
clusive effects of ACE inhibitors in AMI patients with diabetes (HR=1.15 (0.79-1.66))
and hazardous effects in AMI patients with no diabetes (HR=1.52 (1.15-2.01)), which
the authors explained by confounding in respect to heart failure and the use of old
data from 1985-1992 (Lo¨wel et al., 2000). Two studies that made use of longer follow-
up also found hazardous effects of ACE inhibitors in AMI patients: a hazard of 1.54
(1.07-2.23) was found using data from 1988-2001 of the United States (Nigam et al.,
2006), and a hazard of 1.91 (1.64-2.27) or 2.23 (1.89-2.62) for ACE inhibitors initiated
in hospital or at discharge, respectively, were found using data from 1984-2005 of Aus-
tralia as part of the MONICA study (Briffa et al., 2009). The authors of MONICA
study suggested that these findings on the hazardous effects of ACE inhibitors might
be due to confounding by indication. The current study controlled for heart failure,
which lowered the HR of ACE inhibitors by ∼0.05, and made use of more recent data
from 1987 to 2011, thereby suggesting that ACE inhibitors might in fact be harmful
to survival.
This study found that prescription of aspirin was associated with increased hazard
of mortality, whereas the NICE review only included one study that estimated an
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inconclusive protective effect of the drug versus placebo on all-cause mortality (NICE,
2013a). That study included men with a recent AMI aged 30-64 in 1972-1974 (CDP,
1976). The current study made use of more recent data with longer follow-up of older
patients of both sexes. Aspirin is associated with an increased risk of bleeding, where
the risk increases with age (NICE, 2013a). Since the elderly are excluded from most
clinical trials, it could be that aspirin might actually be harmful in the elderly as
the findings of the current study suggest. Since 2013, DAPT is recommend as a first
line treatment to AMI patients (NICE, 2013b). Studies included in the NICE review
reported that DAPT is more effective than aspirin on its own (NICE, 2013a). For
example, a study in Australia estimated a hazard of 0.77 (0.65-0.90) or 0.74 (0.64-
0.85) for antiplatelet drugs initiated in AMI patients in the hospital or at discharge,
respectively (Briffa et al., 2009).
This study found that prescription of beta blockers was associated with significant
survival benefits, whereas the NICE review reported uncertain survival benefits in
AMI patients who received the drugs in the first 72 hours (RR=0.87 (0.67-1.20)) or
after the first 72 hours to a year (RR=0.76 (0.49-1.16)) (NICE, 2013a). The studies
included in the review used data from 1976 to 1985 (BHAT Research Group, 1982;
LIT Research Group, 1987; Olsson et al., 1985; Pedersen, 1983; Roberts et al., 1984;
Roque et al., 1987). Studies using more recent data estimated significant survival
benefits associated with beta blockers: a study in Germany using data from 1985-1992
estimated a hazard of 0.62 (0.45-0.85-0.85) or 0.64 (0.52-0.78) in AMI patients with
diabetes or no diabetes, respectively (Lo¨wel et al., 2000); a study in the United States
using data from 1988-2001 estimated a hazard of 0.60 (0.45-0.80) in AMI patients; a
study in Australia using data from 1984-2005 estimated a hazard of 0.55 (0.48-0.63)
or 0.56 (0.50-0.64) for beta blockers initiated in AMI patients in the hospital or at
discharge, respectively (Briffa et al., 2009); and a study in England using data from
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2003-2008 estimated a hazard of 0.59 (0.44-0.79) or 0.50 (0.36-0.69) for beta blockers
initiated in patients with chronic obstructive pulmonary disease (COPD) before or
after AMI, respectively (Quint et al., 2013).
Finally, this study found that survival prospects varied greatly across general
practices, which was independent from health status, ethnic background, deprivation,
urbanisation, and air pollution. A study by Gerber et al. (2010) estimated the effect
of neighbourhood and individual socioeconomic status on survival after AMI and
suggested that higher level measured socioeconomic status might capture residual
confounding of unequal hospital resources and social characteristics of an area such
as social cohesion and attitudes towards health. Other studies on survival prospects
after AMI assumed that there were no survival variations by hospitals (Briffa et al.,
2009; Capewell et al., 2000; Chang et al., 2003; Herzog et al., 1998; Kirchberger
et al., 2014; Koek et al., 2007; Quint et al., 2013; Smolina et al., 2012b), although the
study by Chang et al. (2003) did adjust for cardiovascular specialist, hospitals capable
of performing coronary artery bypass graft, and health region. Failing to adjust for
survival variations by care provider could result in false precision of survival prospects
(Therneau and Grambsch, 2000).
5.4.4 Strengths and limitations
This study used routinely collected primary care data that were representative of the
UK (Blak et al., 2011; Hall, 2009). The advantage of using primary care data was that
there was more information on socio-demographic and lifestyle factors available and
there was a higher coverage of AMI cases (Herrett et al., 2013b). Another strength
could be found in the study design; the matched cohort study design allowed to es-
timate the effect of a history of AMI on mortality compared with no history of AMI
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while adjusting for a wide range of confounders. The confounders included comorbidi-
ties, treatments, lifestyle factors, and demographics, and interactions between these
factors. This has not been done before; previous studies were either population-based
which has a tendency to overestimate the hazardous effect of AMI on survival, or
previous studies only included AMI cases which meant that only survival variations
among AMI survivors could be estimated. An additional strength of the study was
that by estimating the survival prospects given a possible history of AMI at differ-
ent ages, the results could be used for planning ongoing medical management and
planning resources allocation in the UK population. Finally, the study had a long
follow-up of almost 25 years.
Data on the type of AMI were not available in THIN. This meant that the study
could not distinguish between STEMI and non-STEMI and thus could not provide
specific survival prospects for them. Although the major confounders of AMI were
adjusted for, there could potentially be some residual confounding by a number of
other factors such as family history of AMI or CVD, psychosocial factors, fruit and
vegetable intake, and physical activity. These factors were not adjusted for in the
survival models due to the unsystematic or no recording in the medical records. AMI
severity indicators, such as left ventricular function, were also not included in the
survival models because this information was only available for the cases and not
the controls. Another limitation of the study was incomplete medical records with
respect to lifestyle factors. Missing data were dealt with by multiple imputations,
which is a widely accepted method to deal with bias and imprecision when missing
data are present (van Buuren, 2012). An additional limitation of the study was
that adherence to drug therapy was unknown and therefore the survival prospects
associated with prescription of drug therapy might not accurately reflect the effect of
the drugs themselves on the hazard of mortality. Furthermore, no dose-response effect
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could be estimated as the prescribed doses were not included in the survival models.
Finally, there might be bias by indication in which patients receiving treatment were
somehow sicker than those not receiving the treatment, despite the adjustment for
important confounders.
5.5 Conclusions
The findings of this study suggest that surviving an AMI was associated with a per-
manent increased hazard of mortality and that coronary revascularisation, statins
prescription, and beta blockers prescription could reduce this hazard. This is of clin-
ical importance, because not every AMI survivor received these treatments. In 2010,
beta blockers were not widely prescribed to AMI survivors; the survival prospects of
35% of the AMI survivors might be improved by such a prescription.
This study also found that the prescription of aspirin and/or ACE inhibitors was
associated with an increased hazard of mortality. This might be of potential concern
as the previous explanations for similar findings on the hazardous effects associated
with ACE inhibitors on survival, such as confounding by heart failure and use of old
data, were addressed by this study. By 2010, 94% and 85% of AMI survivors were
prescribed aspirin and ACE inhibitors, respectively. Further research is required to
assess the effectiveness of aspirin and ACE inhibitors in the light of these findings
that such commonly used medications may be of little benefit, or even cause harm.
Furthermore, the findings of this research suggest that there were sex and depri-
vation inequalities in uptake of coronary revascularisation while all subgroups benefit
equally from it. Further research is needed to assess whether there might be a barrier
in access to surgery or whether the difference in uptake is due to confounding by
indication such as by prognosis of CVD.
Finally, this research found there were up to ten years difference in effective age
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between general practices and these differences could not be explained by the socio-
demographic factors, health status, and environmental characteristics of the districts
their patients resided. Further research is needed to explore the reasons for the
unexplained survival variations between general practices and how the differences
can be minimised.
Chapter 6
Survival models for statin
prescription
This Chapter presents the development of the survival models for statin prescription.
The survival models estimated the adjusted hazard of all-cause mortality associated
with statins prescribed as primary prevention of cardiovascular disease (CVD) by key
ages in residents of the United Kingdom (UK). The findings were published in PLoS
One (Gitsels et al., 2016).
This Chapter starts with explaining the analysis procedure including the study
design, selected medical history, and model development. This is followed by a de-
scription of the age cohorts. Next, the survival models are presented. Then, the
survival models are evaluated with respect to model performance, internal validation,
and external validation. Finally, recommendations based on the findings are provided.
6.1 Analysis procedure
6.1.1 Study design
The research objective of investigating how prescription of statins affects longevity
in the general population with no previous history of CVD, was addressed by a
retrospective cohort design. Four cohorts of patients aged 60, 65, 70, and 75 were
followed up. These are key ages at which individuals and general practitioners would
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make a decision about statin uptake. Before the age 60, the initiation rate of statin
prescription for primary prevention of CVD in the UK is less than 3% (O’Keeffe et al.,
2015). The age cohorts were split by the estimated cardiovascular risk at baseline.
The risk groups consisted of patients with a QRISK2 of <10%, 10-19%, or ≥20% risk
of a first cardiovascular event in the next ten years. These risk groups were chosen
because the UK National Institute for Health and Clinical Excellence (NICE) recently
lowered the QRISK2 estimated risk threshold at which to prescribe statins from 20%
to 10% (NICE, 2015). As discussed in Chapter 2 Section 1, the effectiveness of the
drug in the recently eligible patients is uncertain.
The data restrictions and the identification of eligible general practices and pa-
tients from The Health Improvement Network (THIN) primary care database, were
discussed in Chapter 3 Section 4. For this particular research objective, patients
with a history of CVD (acute myocardial infarction, angina, cerebrovascular disease,
heart failure, peripheral vascular disease, valvular heart disease, or other cardiovas-
cular system disorders) were excluded from the analysis. The prevalence of CVD at
ages 60, 65, 70, and 75, was 8.7, 13.5, 18.6, and 24.5%, respectively. Patients with
a missing Townsend deprivation score were also excluded from the analysis because
this information was needed to calculate the baseline risk of CVD using QRISK2.
The Townsend scores in THIN were derived from the 2001 census data of England
and Wales (UKDS, 2006). This means that patients living in Scotland and North-
ern Ireland were excluded from the analysis. Only a small percentage of patients
from England and Wales had a missing Townsend score. The prevalence of missing
Townsend score at ages 60, 65, 70, and 75, was 7.8, 11.6, 12.3, and 12.4%, respec-
tively, with less than 0.2% contributed by patients from England and Wales. Patients
with and without a Townsend score were similar to each other with respect to the
mortality rate and prevalence of statin prescription, see Appendix C Table C.1.
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Patients were part of multiple age cohorts if they remained at the same general
practice for more than five years and did not develop CVD during that time, see
Figure 6.1. Patients were followed up for maximum 24 years and the oldest patients
were 91 years old by the end of study.
6.1.2 Selected medical history
At the cohort’s age, a snapshot of the patient’s medical history was obtained. Addi-
tionally, the patient’s survival was recorded during the follow-up. Chapter 3 Section
5 described the raw information selected from the medical records for the entire re-
search. This Section describes the edited information selected for the survival models
aimed at estimating the hazard of mortality associated with statin prescription pre-
scribed as primary prevention of CVD.
To obtain cardiovascular risk group, the baseline risk of the patient needed to be
calculated. The NICE guideline on lipid modification recommends using QRISK2 to
calculate the 10-year risk of a first cardiovascular event (NICE, 2015). The QRISK2
algorithm is available online (http://svn.clinrisk.co.uk/opensource/qrisk2/).
It incorporates information on multiple demographic, medical, and lifestyle factors
to estimate the risk (Hippisley-Cox et al., 2008), see Chapter 2 Figure 2.1. Not all
this information was available in THIN or in its subset used in this research, leading
to a number of substitutions or exclusions in the algorithm, see Appendix C Table
C.2. The QRISK2 was calculated for all patients with complete information in JAVA
version 8.
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Data from The Health Improvement Network (THIN) primary care database with the following restrictions for this research:
* Medical records of patients born between 1920-1940 registered at 405 general practices in the United Kingdom 
* Valid coding of death dates from 1987 onwards
* End of study period on the 18
th
 of May 2011 
Selection patients:
Medical records of patients born between 1920-1940 who turned the cohort’s age between 1987-2011 were selected. The cohort’s 
ages were 60, 65, 70, and 75. At the cohort’s age, patients had to be registered for at least one year at an active general practice that 
coded death dates validly, and their medical records had to be accessed at least once within the last ten years and include a postcode.
Movement of patients across 
age cohorts: 
N = New
C = Cardiac event
D = Deceased
T = Transferred out of general 
       practice (i.e. loss to 
       follow-up)  
A = Alive
E = End of observation and 
      alive
N and A grouped together = 
      studied age cohort
* Year of birth period
* Recruitment period
* Study period
60 65 75
*1927-1940
*1987-2000
*1987-2011
*1922-1940
*1987-2005
*1987-2011
*1920-1940
*1990-2010
*1990-2011
*1920-1936
*1995-2011
*1995-2011
Initial sample size 142,241 260,777 346,410 293,709
Cohort’s age 70
Final sample size 118,700 199,574 247,150 194,085
Exclusion patients with: 
* History of cardiac event
* Missing Townsend score
*12,405 (8.7%)
*11,136 (7.8%)
*35,093 (13.5%)
*26,110 (11.6%)
*64,537 (18.6%)
*34,723 (12.3%)
*72,064 (24.5%)
*27,560 (12.4%)
D = 3,019
T = 12,121
D = 4,448
T = 9,954
D = 3,907
T = 4,778
E = 37,459
D = 1,491
T = 1,276
E = 25,500
A = 97,199 A = 76,915 A = 28,267N = 118,700
C = 6,361 C = 5,882 C = 2,504
D = 3,989
T = 11,932
D = 5,222
T = 7,151
E = 18,038
D = 5,879
T = 4,695
E = 33,994
N = 102,375 A = 79,600 A = 44,568
C = 6,854 C = 4,621
D = 5,702
T = 10,124
E = 694
D = 14,639
T = 12,234
E = 39,555
D = 15,293
T = 15,865
E = 23,610
N = 90,635 A = 66,482
N = 54,768
C = 7,633
Figure 6.1: Selected age cohorts without cardiovascular disease
This Figure is an altered version of Figure 3.1, where only patients with no history of cardiovascular disease by an initial
age were followed up.
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Ethnicity was not recorded in THIN and could therefore not be included in the
QRISK2 calculation. The QRISK2 calculator has white ethnicity as the reference
category. 93% of the UK population is white and the QRISK2 score risk would be
underestimated for people with an Indian, Pakistani, or Bangladeshi background and
overestimated for people with a black Caribbean background and for black African
and Chinese men (Hippisley-Cox et al., 2008). The QRISK2 calculator uses Townsend
deprivation score measured on a continuous scale. The data cut from THIN, however,
provided the Townsend score in quintiles. Based on the 2001 census data, the associ-
ated median values for each quintile were used for calculating the cardiovascular risk
(UKDS, 2006). The selected medical history for this research did not include atrial
fibrillation and rheumatoid arthritis. It was assumed that the patients in the studied
cohorts did not have these medical conditions. This would be true for the major-
ity of the patients, as the prevalence of atrial fibrillation and rheumatoid arthritis is
less than one percent in the United Kingdom (Collins and Altman, 2012; Hippisley-
Cox et al., 2008). Family history of CVD substituted family history of ischaemic
heart disease in the QRISK2 calculation. Family history of CVD is also used by the
JBS3, another accepted risk calculator developed by the Joint British Societies for
the prevention of cardiovascular disease (Joint Formulary Committee, 2016a). With
the studied cohorts, it was assumed that diabetes was type two, which would be
true for 90% of the cases (NHS, 2014a). It was also assumed that current smokers
smoked moderately (10 to 19 cigarettes a day), which would be true for the majority
(ONS, 2014). The diagnosis of hypercholesterolaemia was used instead of a specific
cholesterol level, because it was only recorded in the minority of primary care records
(27 to 50% recordings) (Hippisley-Cox et al., 2008). When a patient did not have a
diagnosis of hypercholesterolaemia, a ratio of total cholesterol to high density lipids
of four was ascribed. This is the default value of the online QRISK2 calculator when
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no ratio is given. When a patient had a diagnosis of hypercholesterolaemia, a ratio
value of five was ascribed.
For the survival analysis, the outcome of interest was time to death and the
primary exposure was statin prescription prior to the cohort’s age. The selected
confounders of the potential survival benefit associated with statin prescription were
based on the literature review, and consisted of: sex, year of birth, socioeconomic
status, chronic kidney disease, diabetes, hypertension, hypercholesterolaemia, blood
pressure regulating drugs, body mass index, and smoking status, see Appendix C
Table C.3. Socioeconomic status was measured by Mosaic, which is based on de-
mographics, lifestyles, and behaviour of people at a postcode level (Experian Ltd.,
2009).
There were missing values in systolic blood pressure (15-28%), smoking status (14-
30%), and body mass index (22-37%). The fraction of incomplete medical records
decreased with age; 46% of the youngest cohort and 29% of the oldest cohort had
incomplete records. The proportion of complete records was greater among partici-
pants born at a later year, with a medical condition, or who were prescribed drugs,
see Appendix C Table C.4. This is in agreement with previous research that found
that recording is likely be related to ill health and that recording improved since the
introduction of the Quality and Outcomes Framework (QOF) in 2004 (Marston et al.,
2010; Shephard et al., 2011; Taggar et al., 2012).
Incomplete medical records were dealt with by multiple imputation. The joint
imputation model consisted of all factors included in the QRISK2 calculation and the
outcome variable of the analysis model which was time to death. The imputation
model was multilevel to adjust for the correlation between patients from the same
general practice. QRISK2 score was imputed instead of being calculated based on
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the imputed values to ensure that the imputed values were consistent with the anal-
ysis model (van Buuren, 2012). Imputations were done in REALCOM-Imputation
software. The Monte Carlo Markov Chain (MCMC) estimation had a burn-in length
of 100 iterations and was in total 1,000 iterations long. The imputed values of every
100th iteration were used. This resulted in ten imputed datasets. The distribution of
recorded and imputed values for systolic blood pressure, body mass index, smoking
status, and QRISK2 scores were similar, see Appendix C Table C.5.
6.1.3 Model development
A Cox’s proportional hazards regression was fitted to estimate the effect of statin
prescription on the hazard of all-cause mortality for different risk groups at various
ages, with the outcome variable being time to death in days. All-cause mortality was
used as the primary outcome because multiple previous studies showed the protective
effect of statins on the risk of cardiovascular events and related deaths, but reported
uncertain overall survival benefit (CTTC, 2012). The exposure was any statin pre-
scription at any time before the participant reached the baseline age. The analysis on
statins excluded patients who were prescribed other lipid-lowering therapy to ensure
that the effect of statins was not mediated by those drugs. The number of patients
excluded at age 60, 65, 70, and 75 were 876 (0.7%), 1,718 (0.9%), 2,840 (1.1%), and
2,475 (1.3%), respectively. A separate analysis was performed to estimate the effect
of lipid-lowering therapy prescription including and excluding statins. The analysis
was on an intention to treat basis, as it was based on the prescription of drugs and
not intake of them. The models were fitted to each age and risk group. The ages were
60, 65, 70, and 75 years old. The risk groups consisted of patients with a QRISK2
of <10%, 10-19%, or ≥20% risk of a first cardiovascular event in the next ten years.
This would mean that twelve age-risk groups would be studied. However, as only a
143
few patients were at low risk by age 70 (n=325) and none by age 75, these two groups
were not studied.
Starting from a model with second-order interaction effects of all factors with the
main exposure statin prescription, sex, and age, backward elimination was performed
to obtain the most parsimonious model possible. The final model consisted of the
factors that were found significant with the alpha level set to 5% for fixed effects and
1% for interaction effects. The survival models were multilevel on general practice
and patient level, to adjust for the interdependence of patients from the same general
practice.
The Cox’s regression assumes no time-tied deaths, uninformative censoring, and
proportional hazards. Time-tied deaths were handled by Efron’s approximation. Cen-
soring due to loss of follow-up was examined by comparing patients who did and did
not transfer out of their general practice with respect to health status and lifestyle
factors. For the youngest two age cohorts, distinction was made between patients
observed until age 70 or for longer. This was because previous studies indicated that
there are two groups of people who move at an older age, where the younger group
comes from more aﬄuent areas and move in good health and the older group comes
from more deprived areas and move in worse health (Pennington, 2013; Uren and
Goldring, 2007). These trends were not observed in the age cohorts, see Appendix
C Table C.6. Patients who transferred were similar to patients who did not transfer
with respect to medical conditions and lifestyle factors. However, patients who trans-
ferred after age 70 were approximately half as likely to be prescribed lipid-lowering
therapy as patients who transferred before age 70 or who did not transfer at all, even
though the QRISK2 scores between the groups were not significantly different. Unin-
formative censoring was assumed because transfers did not differ in health status and
lifestyle factors other than prescription of lipid-lowering therapy. The assumption
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of proportional hazards was checked by Grambsch and Therneau’s test. When the
assumption was violated for a variable, being significant at alpha level set to 1%, the
variable’s effect on survival time was made time-variant. Follow-up time was split in
intervals in which the assumption was no longer violated, where the time intervals of
10, 5, or 1 year were tested.
A unified model for all risk groups and ages was attempted in order to have the
same interpretation of the hazards. However, some factors could not be adjusted
for because only one subgroup of patients specified by the factor was present in the
particular risk group at the specific age. All men were either at moderate or high risk
of CVD by age 65 and 99% were at high risk by age 75. There were no patients with
diabetes in the low risk group at ages 60 and 65, and in the moderate risk group at
ages 65, 70, and 75. Furthermore there were no patients with hypercholesterolaemia
in the moderate risk group at age 75. Where possible, the final models adjusted
for sex, year of birth, socioeconomic status, diabetes, hypercholesterolaemia, blood
pressure regulating drugs, body mass index, smoking status, and general practice.
There were no interactions with statin prescription, sex, or age, and no time-varying
hazards of variables. The contribution of each variable to the model in explaining
survival variations was assessed by decomposing the Cox’s regression by ANOVA
(analysis of variance).
The number of years lost or gained in effective age associated with statin pre-
scription were calculated. The models were assessed on overall performance, discrim-
ination, and external validation, using Royston’s R2, Harrell’s concordance, and the
shrinkage slope, respectively. Furthermore, the results were compared internally with
the complete case analysis and externally with previous studies. The analyses were
performed in R version 3.1.1, using the packages ‘hmisc’, ‘rms’, and ‘survival’.
145
6.2 Description of cohorts
Four cohorts of patients who were either 60, 65, 70, or 75 years old and who had no
history of CVD at baseline were studied. The profile of the patients with respect to
medical conditions, treatments, and lifestyle factors differed by age and changed over
time, see Table 6.1, Figure 6.2 and Appendix C Figure C.1.
The older the cohort, the more prevalent the outcome death, the exposure statin
prescription, and the medical conditions were. The prevalences of these factors were
lower than in the general population because the cohorts excluded patients with a
history of CVD. Family history of CVD, however, was exceptionally low in the age
cohorts, with prevalence less than one percent.
From the age of 60 to 75, the annual death rate per 1,000 individuals for men
increased from 12.8 to 41.0, and for women from 8.7 to 28.4. Likewise, the 10-year
risk of a first cardiovascular event in men increased from 13.3 to 33.2%, and in women
from 7.8 to 25.8%. Of the medical conditions, diabetes was the most common; from
the age of 60 to 75, its prevalence in men increased from 4.1 to 10.6% and in women
from 3.0 to 8.0%. From 1995 to 2011, the prevalence of diabetes increased by 6-9%
across age cohorts, see Appendix C Figure C.1.
From the age of 60 to 75, prescription of lipid-lowering therapy in men increased
from 2.0 to 20.0%, and in women from 2.6 to 19.2%. Statins were the most common
prescribed type of lipid-lowering therapy; 70% of lipid-lowering therapy prescription
was a statin at age 60 and this increased to 94% at age 75. These prevalences were
affected by calendar year as statins became more popular over time, see Figure 6.2.
Since 2006, all patients with a cardiovascular risk of 20% or greater are eligible for
statin therapy (NICE, 2016). In 2010, only 45% of this group were prescribed statins.
Given risk group and calendar year, statins were prescribed less in older patients
and in men, see Table 6.2 and Figure 6.2. Given age-risk group, 50% of the therapy
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durations started between one and four years prior to the cohort’s age, 75% under six
years, and only 10% more than eight years, see Appendix C Figure C.2. The majority
of the prescriptions (87-93%) were in the year prior to the cohort’s age.Adherence of
treatment arm was ascertained for patients who were observed in multiple cohorts.
Assuming that patients who were lost to follow-up stayed in the initial treatment
arm, 88 to 98% of the cases and 78 to 92% of the controls never switched treatment
arm, see Appendix C Table C.7. Five percent of the patients changed treatment arms
multiple times.
Given calendar year, the prevalence of the clinical and lifestyle factors hyperten-
sion and ex-smoking increased with age, while smoking decreased, and overweight and
obesity remained approximately the same, see Appendix C Figure C.1. The preva-
lence of hypercholesterolaemia was more common in younger patients prior to 2000,
and was approximately the same across age after 2000. From 1995 to 2011, hyper-
tension, obesity, and ex-smoking became more prevalent, while smoking became less
prevalent, and overweight remained approximately at the same level. Interestingly,
the prevalence of hypercholesterolaemia increased from 1995 to 2005, after which it
levelled off. This trend was the most pronounced in the oldest cohort, in which the
prevalence increased from 6% in 1995 to 40% in 2005, after which it levelled off at
42% in 2011. The prevalence order of the clinical and lifestyle factors in patients
with no history of CVD changed over time and this varied by age. In 2000, over-
weight was with a prevalence of approximately 42% the most common while diabetes
with a prevalence of approximately 7% was the least common at all ages. In 2010,
the prevalence of hypertension was between 40-60%; hypercholesterolaemia and over-
weight between 40-45%; ex-smoking and obesity between 20-40%, and smoking and
diabetes between 10-20%.
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Table 6.1: Characteristics of men and women in age cohorts without cardiovascular disease
1Missing values in smoking status, body mass index, and consequently QRISK2 score, were dealt with by multiple imputation.
The reported prevalences of these variables are the means across ten imputed datasets. The prevalences of comorbidities and
lifestyle factors at the cohort’s age were affected by calendar year, see Appendix C Figure C.1.
Age 60 Age 65 Age 70 Age 75
Women Men Women Men Women Men Women Men
Number of patients 61,715 56,985 106,633 92,941 138,355 108,794 114,434 79,651
Total person-years of
follow-up data (mean)
759,967
(12.3)
676,579
(11.9)
1,045,437
(9.8)
857,273
(9.2)
1,033,903
(7.5)
754,810
(6.9)
681,791
(6.0)
438,204
(5.5)
Deaths (%) 6,628
(10.7%)
8,668
(15.2%)
12,975
(12.2%)
15,873
(17.1%)
19,515
(14.1%)
21,184
(19.5%)
19,379
(16.9%)
17,977
(22.6%)
Loss to follow-up (%) 14,992
(24.3%)
14,844
(26%)
21,415
(20.1%)
20,620
(22.2%)
23,747
(17.2%)
18,541
(17.0%)
20,707
(18.1%)
13,363
(16.8%)
Family history of
cardiovascular disease (%)
86
(0.1%)
51
(0.1%)
363
(0.3%)
198
(0.2%)
820
(0.6%)
398
(0.4%)
664
(0.6%)
308
(0.4%)
Chronic kidney disease (%) 4
(0.0%)
1
(0.0%)
60
(0.1%)
18
(0.0%)
3,324
(2.4%)
2,099
(1.9%)
5,528
(4.8%)
3,151
(4.0%)
Diabetes (%) 1,825
(3.0%)
2,363
(4.1%)
5,050
(4.7%)
6,024
(6.5%)
9,174
(6.6%)
9,864
(9.1%)
9,148
(8.0%)
8,462
(10.6%)
Hypercholesterolaemia (%) 8,760
(14.2%)
7,638
(13.4%)
25,656
(24.1%)
19,129
(20.6%)
42,483
(30.7%)
26,649
(24.5%)
36,792
(32.2%)
18,914
(23.7%)
Treated hypertension (%) 11,617
(18.8%)
8,144
(14.3%)
29,873
(28.0%)
21,311
(22.9%)
50,742
(36.7%)
34,854
(32.0%)
51,864
(45.3%)
30,612
(38.4%)
Reported systolic blood
pressure (%)
47,535
(77.0%)
37,802
(66.3%)
86,916
(81.5%)
68,466
(73.7%)
115,548
(83.5%)
88,023
(80.9%)
98,494
(86.1%)
67,259
(84.4%)
Reported smoking status
(%)
44,689
(72.4%)
37,844
(66.4%)
85,080
(79.8%)
70,020
(75.3%)
115,189
(83.3%)
89,115
(81.9%)
98,553
(86.1%)
68,394
(85.9%)
Ex-smoker1 (%) 14,097
(22.8%)
19,990
(35.1%)
24,493
(23.0%)
34,030
(36.6%)
32,850
(23.7%)
42,624
(39.2%)
26,247
(22.9%)
31,703
(39.8%)
Continued on next page
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Table 6.1 – Continued from previous page
Age 60 Age 65 Age 70 Age 75
Women Men Women Men Women Men Women Men
Smoker1 (%) 10,469
(17.0%)
12,403
(21.8%)
16,128
(15.1%)
18,288
(19.7%)
16,989
(12.3%)
17,034
(15.7%)
11,923
(10.4%)
10,599
(13.3%)
Reported BMI (%) 41,759
(67.7%)
33,110
(58.1%)
79,055
(74.1%)
62,168
(66.9%)
105,789
(76.5%)
80,251
(73.8%)
89,174
(77.9%)
61,381
(77.1%)
BMI1 mean (sd) 26.3 (4.1) 26.3 (3.0) 26.6 (4.4) 26.4 (3.3) 26.7 (4.5) 26.5 (3.5) 26.5 (4.9) 26.2 (3.5)
Calculated QRISK2 score
(%)
36,325
(58.9%)
27,586
(48.4%)
70,023
(65.7%)
52,799
(56.8%)
96,015
(69.4%)
72,252
(66.4%)
81,980
(71.6%)
56,273
(70.6%)
QRISK21 mean score (sd) 7.8 (3.3) 13.3 (4.0) 12.1 (4.4) 18.9 (5.2) 18.0 (5.5) 25.5 (6.3) 25.8 (6.4) 33.2 (6.9)
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Figure 6.2: Prevalence of statin prescription by cohort’s age in patients without
cardiovascular disease
The prevalence in a given year was the percentage of patients who turned the cohort’s age
in that year and were prescribed statins prior to that age. The reported QRISK2 risk group
is the mean 10-year risk of a first cardiovascular event across ten imputed datasets.
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Table 6.2: Prevalence of statin prescription by cohort’s age, cardiovascular risk
group, and sex
The age cohorts included patients with no history of cardiovascular disease. The prevalence
of statin prescription by the cohort’s age was affected by calendar year, see Figure 6.2. The
number of patients per QRISK2 group is the mean 10-year risk of a first cardiovascular
event across ten imputed datasets.
QRISK2 Women Men Total
score (% Statins) (% Statins) (% Statins)
Age 60 <10% 50,668 (1.2%) 9,234 (0.4%) 59,902 (1.1%)
10-19% 9,834 (3.8%) 44,037 (1.3%) 53,871 (1.8%)
≥20% 692 (12.3%) 3,359 (5.3%) 4,051 (6.5%)
Total 61,194 (1.7%) 56,630 (1.4%) 117,824 (1.6%)
Age 65 <10% 40,749 (2.2%) 0 (0.0%) 40,749 (2.2%)
10-19% 58,475 (7.5%) 64,203 (3.2%) 122,678 (5.2%)
≥20% 6,274 (27.8%) 28,155 (12.5%) 34,429 (15.3%)
Total 105,498 (6.6%) 92,358 (6.0%) 197,856 (6.4%)
Age 70 <10% 325 (0.9%) 0 (0.0%) 325 (0.9%)
10-19% 102,938 (9.6%) 16,587 (5.4%) 119,525 (9.1%)
≥20% 33,196 (28.8%) 91,263 (17.5%) 124,459 (20.5%)
Total 136,459 (14.3%) 107,850 (15.7%) 244,309 (14.9%)
Age 75 10-19% 14,345 (4.6%) 1 (0.0%) 14,346 (4.6%)
≥20% 98,365 (19.9%) 78,899 (19.2%) 177,264 (19.6%)
Total 112,710 (17.9%) 78,900 (19.2%) 191,610 (18.5%)
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6.3 Survival models
Survival models were developed for the ten different age, and cardiovascular risk
groups and the results on statin prescription are presented in Figure 6.3. The sur-
vival models estimated no survival benefit from statin prescription by any age in
patients with a cardiovascular risk lower than 10%. There was also no survival ben-
efit associated with statin prescription in patients younger than 60, no matter how
high their cardiovascular risk was. In patients with a risk of 10 to 19% and aged
over 60, statin prescription had uncertain survival benefit. In these patients, statin
prescription by age 65, 70, or 75 was associated with a hazard of mortality of 1.00
(95% confidence interval 0.91-1.11), 0.86 (0.81-0.99), or 0.79 (0.52-1.19), respectively.
Patients with a risk of 20% or greater and aged over 60, had a significant survival
benefit from statin prescription. In these patients, statin prescription by age 65, 70,
or 75 was associated with a hazard of mortality of 0.86 (0.79-0.94), 0.83 (0.79-0.88),
or 0.82 (0.79-0.86), respectively. This translates to a decrease in effective age of 1.5
(0.6-2.4), 1.9 (1.3-2.4), or 2.0 (1.5-2.4) years, respectively, compared with patients
without statin prescription by those ages.
There were no interactions found with statin prescription. This means that the
potential survival benefit associated with statin prescription was the same for differ-
ent subgroups of patients, such as for men and women. As no interaction between
statin prescription and year of birth category was found, the results suggest that
the effectiveness of statin prescription does not vary by year of prescription category.
Lastly, there was no survival benefit from lipid-lowering therapy excluding statins by
any age for any risk group. This resulted in smaller estimated survival benefit of
lipid-lowering therapy as a whole compared with its subclass of statins, see Appendix
C Figure C.3.
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Figure 6.3: Unadjusted and adjusted hazards of all-cause mortality associated with statin prescription
The age cohorts included patients with no history of cardiovascular disease. The hazard ratios (95% confidence interval) were
adjusted for sex, year of birth, socioeconomic status, diabetes, hypercholesterolaemia, blood pressure regulating drugs, body mass
index, smoking status, and general practice. QRISK2=10-year risk of first cardiovascular event. LLT=lipid-lowering therapy.
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The variables contributing the most to the survival models in explaining survival
variations in the age cohorts were smoking status and general practice. The variables
contributing the least to the survival models were statins, sex, and year of birth
category.
6.4 Evaluation
6.4.1 Performance statistics
The final survival models for each age and cardiovascular risk group performed sim-
ilarly with the exception of the model estimated on patients aged 60 at high risk,
see Appendix C Table C.8. The survival model estimated on this group of patients
performed worse than the others. This might be due to only 0.3% of patients at
that age had a cardiovascular risk of 20% or greater (n=4,051). The survival model
explained 5% of the survival variations, had 59% concordance between the estimated
hazard of mortality and survival time, and overestimated the effects by 22%. The
high percentage of overestimation, i.e. the large shrinkage slope, suggests that the
results are not robust and may not be trusted. It may be the case that with a larger
sample size, results would show that statins prescription is associated with a survival
benefit for this age-risk group. The survival models for the other age-risk groups
explained 11 to 13% of the survival variations, had 62 to 63% concordance between
the estimated hazard of mortality and survival time, and overestimated the effects by
less than 2%. These performance statistics are typical for survival analysis and the
small shrinkage slope suggest that the results are robust.
The unadjusted hazards of mortality indicate that prescription of statins is bene-
ficial for survival by age 65 in patients with a cardiovascular risk of 10% or greater,
see Figure 6.3. The difference in unadjusted and adjusted survival benefits is greater
in patients with a risk of 10 to 19% than in patients with a risk of 20% or greater, the
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difference was on average 12% and 4%, respectively, in no particular direction. The
unadjusted model explained 0% of the survival variations, had only 51% concordance
between the estimated hazard of mortality and survival time, and had an unstable
shrinkage slope. These performance statistics support the importance of controlling
for confounders when estimating the effect of a drug on the hazard of mortality. The
stratification on cardiovascular risk groups alone was not sufficient, even though the
risk calculation was based on multiple demographic, medical, and lifestyle factors.
The risk groups were based on the risk of cardiovascular event whereas the study was
concerned with the risk of premature death.
6.4.2 Internal validation
The complete case analysis, estimated on only complete medical records, provided
similar results and performance statistics as the final survival models that were es-
timated on both complete and incomplete records, see Appendix C Table C.8 and
Figure C.4. The complete case analyses estimated 3 to 5% greater survival benefits
associated with statin prescription. This could maybe be explained by the fact that
completeness of medical records was associated with ill health, indicating that sicker
patients might benefit more from the drugs. The complete case models explained 9 to
14% of survival variations, had 61 to 65% concordance between the estimated hazard
of mortality and survival time, and overestimated the effects by 5%. Again, the sur-
vival model estimated on patients aged 60 at high risk performed worse; the model
explained 6% of the survival variations, had 60% concordance between the estimated
hazard of mortality and survival time, and overestimated the effects by 26%.
6.4.3 External validation
This large population-based cohort study estimated the hazard of mortality associ-
ated with statin prescription for groups with <10%, 10-19%, or ≥20% risk of a first
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cardiovascular event in the next ten years, using QRISK2, over almost 25 years. It
shows that there was no mortality reduction associated with statin prescription in
the 60-year old cohort, and in participants at less than 10% risk aged 65, 70, or
75 at baseline. Participants aged 70 or 75 at baseline and who were at moderate
risk (QRISK2 score 10-19%) showed uncertain mortality reduction associated with
statin prescription. Participants aged 65, 70, or 75 at baseline and who were at high
risk (QRISK2 score ≥20%) showed significant mortality reduction associated with
statin prescription. The hazard ratios reduce with increasing age, with the greatest
benefit seen in the oldest cohort. In keeping with previous research, there was no
difference between men and women in mortality associated with statin prescription
(Kostis et al., 2012).
These findings reinforce the considerable benefits of statin treatment in high-risk
groups (where this study found substantial and important undertreatment) reported
by the extremely influential Cholesterol Treatment Trialists’ Collaboration (CTTC)
meta-analysis on 27 randomised control trials (RCTs) (CTTC, 2012). However, the
findings of this cohort study clearly differ from the CTTC results for those at low risk
of CVD. Where this cohort study found no benefit, despite widespread treatment of
patients (particularly women) at low risk, the CTTC reported an overall reduction
in all-cause mortality (rate ratio 0.91) in patients without a history of cardiovascular
disease, and concluded that statins ‘are effective for people with a 5-year risk of
major vascular events lower than 10%’ (CTTC, 2012). The use of statins in primary
prevention remains controversial and contested, perhaps at least in part due to the
limitations of RCTs discussed in the Chapter 2, including lack of generalisability
due to strict inclusion criteria, lack of comparability with clinical risk scores such
as QRISK2 due to trials use of observed events as a comparator (the CTTC trial
5-year risk of major vascular events lower than 10% is hard to compare to a general
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population QRISK2 score of 10% and is not equivalent), the small number of older
patients in trials, and the relatively short follow-up time of 4-5 years in trial (compared
with 6-12 years in the age cohorts studied here), and perhaps most importantly, the
concerns that anonymised individual patient data from statins trials have still not
been made available for independent scrutiny, and remain under the control of a single
group of respected researchers, whilst statins are among the most widely prescribed
drugs globally (Krumholz, 2016; Parish et al., 2015). Large scale observational studies
of the effects of statins in everyday diverse clinical practice over many years are an
under-explored source of information on the effects of statins on mortality. No data
source is perfect and there are well rehearsed uncertainties and unanswered questions
arising from both observational and trial data, as set out in previous chapters. This
analysis of cohort data fills in some of the gaps and provides an important new source
of information on the possible effects of statins in routine practice.
6.4.4 Strengths and limitations
One of the study’s strengths was that it used routinely collected primary care data
that were representative of the UK population and widely available. The large sample
size included a great number of patients aged over 80 and many patients at low risk
of a cardiovascular event, with almost 25 years of follow-up data. The 10-year risk
of a first cardiovascular event was calculated by QRISK2, which is recommended by
NICE and widely used in routine practice, and broadly comparable to other widely
used risk assessment tools such as SCORE and PCE (Mortensen and Falk, 2014; Perk
et al., 2012; Stone et al., 2014). The use of all-cause mortality, meant that the overall
effect of statin prescription on mortality could be assessed as opposed to estimating
the possible shift of the hazard of mortality from one medical condition to another.
Estimating the effect of statin prescription by age group meant that age-group specific
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recommendations could be given.
The analysis was performed on an intention to treat basis to more accurately
assess the effect of routine current practice in the general population. THIN had
information on prescription of drugs, and not on dispense and intake of them. This
means that the actual statin uptake could be lower than THIN records indicated.
Therefore, the benefits of statin intake might be greater than the estimated benefits
of statin prescription. The analysis did not include the duration of therapy as a pos-
sible predictor of survival. As the majority of the patients had started statin therapy
within the six years prior to each key age for each risk group, it seems more likely
that the benefit of statins is age-dependant rather than duration-dependant. In other
words, it is unlikely that the younger patients did not experience a survival benefit
from statins due to a shorter duration of therapy. Limitations of a prevalence-user
(rather than new-user) study design are that bias might be introduced when the ex-
posure’s effect on the outcome varies by time and alters other health indicators (Ray,
2003). As the hazard of mortality associated with statin prescription did not differ
by time, it is unlikely that underascertainment of deaths between the time statin
therapy is initiated and the target age is reached would have biased the results. Due
to limitations of the data, the QRISK2 score could only be approximated. Although
there were missing data, sensitivity analyses showed that it was unlikely they influ-
enced the results. Finally, a limitation of using routinely collected observational data
to estimate the effects of interventions is that the results might be affected by unex-
plained confounding. This was minimised by stratifying by cardiovascular risk group
and age, and by controlling in the regression models for a wide range of potential
confounders.
158
6.5 Conclusions
This large population-based cohort study estimated the adjusted hazard of all-cause
mortality associated with statin prescription by age and CVD risk groups, using
QRISK2. As expected, patients at high risk (QRISK2 score of 20% or greater) had
reduced mortality associated with statin prescription. This is of clinical importance,
because not every patient receives the drug. In 2010, statins were not widely pre-
scribed to patients at high risk of CVD; the survival prospects of 55% of these patients
might be improved by such prescriptions.
In addition, the newly eligible patients who are at moderate risk (QRISK2 score of
10 to 19%) showed uncertain mortality reduction associated with statin prescription.
Furthermore, the study found no mortality reduction associated with statin prescrip-
tion in patients younger than 60 years, and in patients at less than 10% risk. Further
research is needed on the effects of statins over the long-term for younger patients at
low risk of a first cardiovascular event. The recent revision of guidelines to extend
treatment to younger and lower risk groups may need to be reconsidered. Clinicians
may want to use this new information when discussing the risks and benefits of statins
initiation with their patients.
Chapter 7
Discussion
This thesis concerns the development of survival models using primary care data to
estimate all-cause mortality hazard indices of cardiovascular disease (CVD) and to
evaluate related treatments in routine clinical practice in the United Kingdom (UK).
This Chapter discusses these newly developed models, focussing on their validity and
utility in medicine and retirement planning. First, the main findings are summarised
and the contributions to the existing clinical evidence are provided. Second, the
strengths and limitations of this research are reviewed. Third, this research’ aims are
addressed and the implications in medical management and retirement planning are
discussed. Finally, the overall conclusions are presented.
7.1 Main findings
For this research, medical records from 1987 to 2011 from general practices contribut-
ing to The Health Improvement Network (THIN) database were used to develop two
survival models specified at ages 60, 65, 70, and 75. The first model was developed to
estimate the hazards of all-cause mortality associated with a history of acute myocar-
dial infarction (AMI) and related treatments while adjusting for other risk factors.
As the prevalence of AMI was relatively rare, especially in the youngest age cohort,
patients with a history of AMI were selected and each matched to three controls
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without this history on sex, year of birth category, and general practice. The second
survival model was developed to estimate the hazard of all-cause mortality associated
with statins prescribed as primary prevention of CVD while adjusting for other risk
factors. The age cohorts excluded patients with a history of CVD.
7.1.1 Survival models for acute myocardial infarction
This research found that AMI survivors had a long-term, increased hazard of all-
cause mortality, in which younger survivors and survivors of multiple events were
worse off. These hazards were lower than estimated by previous studies (Briffa et al.,
2009; Capewell et al., 2000; Chang et al., 2003; Gerber et al., 2010, 2009; Herzog et al.,
1998; Kirchberger et al., 2014; Koek et al., 2007; Nigam et al., 2006; Quint et al., 2013;
Smolina et al., 2012b). The difference could be due to this study’s sample included a
wider range of AMI patients and this research adjusted not only for sex and age but
also for comorbidities, treatments, lifestyle choices, and socio-demographic factors,
resulting in more accurate estimates. Thus, a new finding is that the hazards of all-
cause mortality associated with AMI in the general population are most likely less
severe than previously estimated.
This research found that coronary revascularisation was mainly beneficial in re-
ducing early mortality, up to five years of follow-up. This finding is in accordance with
a previous study by Chang et al. (2003). There was lower uptake of coronary revascu-
larisation by women and by patients from the most deprived areas, even though the
survival benefits of the procedure did not differ by sex or deprivation. The lower up-
take of coronary revascularisation by women could not be explained by age, diabetes,
or deprivation as suggested by a previous study (Chang et al., 2003). The European
Society for Cardiology recognises the difference in treatment after ischaemic heart
disease (IHD) and advocates equality in treatment (Chieffo et al., 2012).
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This research found mixed survival prospects associated with prescription of
statins, beta blockers, calcium-channel blockers, aspirin, and ACE inhibitors, which
could differ by subgroups of patients. The findings only partly agree with the clinical
evidence of drug therapy in AMI patients reviewed by the UK National Institute of
Health and Care Excellence (NICE) (NICE, 2013a). In accordance with the exist-
ing clinical evidence, this research found that survival prospects were improved in
patients prescribed statins. This research also found that beta blockers improved
survival prospects in patients with a history of AMI but did not change survival
prospects in patients without this history. NICE’s guideline, however, reported un-
certain survival benefits associated with beta blockers in AMI patients due to the wide
confidence intervals. This research found that survival prospects were not improved
by calcium-channel blockers in patients with a history of AMI and were worsened in
patients without this history. This is in accordance with the existing clinical evidence
and that is why the calcium-channel blockers changed from a first line to a second
line prescription in 2007 (Joint Formulary Committee, 2016b; NICE, 2013b). This
research found that patients prescribed aspirin had worse survival prospects. NICE’s
guideline included limited evidence on the effectiveness of aspirin compared to placebo
on long-term survival; it included only one study, which reported inconclusive sur-
vival benefits (CDP, 1976). Finally, this research found that survival prospects were
worsened in patients prescribed ACE inhibitors. NICE’s guideline included relatively
old studies on ACE inhibitors, which reported a survival benefit in AMI patients
with left ventricular systolic dysfunction (LVSD) and an inconclusive effect in AMI
patients with unselected LVSD (AIRE Study, 1993; Borghi et al., 1998; Køber et al.,
1995; Pfeffer et al., 1992; SOLVD Investigators, 1992). More recent studies that were
not included in NICE’s guideline estimated, like this research, significantly increased
hazard of mortality associated with ACE inhibitors (Briffa et al., 2009; Nigam et al.,
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2006).
7.1.2 Survival models for statin prescription
This research found that the survival benefit associated with statin prescription in-
creased by age and by risk of a first cardiovascular event in the next ten years.
Patients aged younger than 60 or with <10% cardiac risk had no survival benefit
from statin prescription. Patients aged over 60 with 10-19% cardiac risk had un-
certain survival benefit from statin prescription. Patients aged over 60 with ≥20%
cardiac risk had significant survival benefit from statin prescription. These findings
are in contrast with the findings of the Cholesterol Treatment Trialists’ Collaboration
(CTTC) meta-analysis and the lipid modification guideline by NICE (CTTC, 2012;
NICE, 2015). The CTTC recommended the prescription of statins to people with
more than 10% risk of a first major vascular event in the next five years, even though
it estimated uncertain survival benefits by statins for the individual risk groups due to
the small number of deaths observed during the study period (CTTC, 2012). Based
on the CTTC findings, NICE lowered the risk threshold at which statins should be
prescribed from 20% to 10% cardiac risk NICE (2015). With the change in guideline,
NICE recommended further research into the effectiveness of statins in older patients
because the CTTC did not differentiate by age and included only a small number of
older patients. Thus, a contribution by this research to the existing clinical evidence
is that the effectiveness of statins most likely differs by age in which older patients
benefit the most. In addition, statins might not be effective in the newly eligible
patients with 10-19% cardiac risk.
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7.2 Strengths
The age cohorts studied in this research were drawn from general practices that were
representative of the UK population given adjustment for sex, age, and deprivation
(Blak et al., 2011; Hippisley-Cox and Coupland, 2010b; MacDonald and Morant, 2008;
Masso´ Gonza´lez et al., 2009). The medical histories of the age cohorts provided in-
sights in the clinical practice of diagnosing medical conditions and offering treatments
in the general population. Primary care data has a higher coverage of AMI patients
compared to hospital data and disease registers (Herrett et al., 2013b), therefore the
matched age cohorts for AMI were more representative of AMI patients in the UK
than previous studies that selected patients through hospitals admissions. Moreover,
AMI cases and controls were selected from the same source population therefore valid
comparisons could be made as there was no selection bias (Hennekens et al., 1987).
The recruitment period of the age cohorts was up to 21 years and the study
period was up to 24 years. The long recruitment period meant that changes in the
prevalences of medical conditions, treatments, and lifestyle choices could be observed.
This provided insights in the past and current well-being of the study population and
clinical practice. By testing whether the effects of these risk factors on the outcome
changed over time, potential longevity risks could be identified. The long study
period meant that more deaths could be observed and that life expectancy could be
more accurately estimated. With increasing life expectancy, accurate life expectancy
becomes even more relevant for medical resource allocation and retirement planning.
Survival was estimated at four key ages, namely 60, 65, 70, and 75. These are key
ages in primary and secondary prevention of CVD and when people would typically
retire from work. CVD is mainly prevalent from the age of 60 and the effect of CVD
on mortality rate differs by age (Townsend et al., 2014). In addition, existing CVD
research and NICE recommended further research to examine the effectiveness of
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age alone to identify people at high risk of developing CVD and the effectiveness of
treatments at older ages, 70 or older, as they are often excluded from clinical trials
(Godlee, 2014; NICE, 2015; Zoungas et al., 2014).
The survival models for AMI included both cases and controls. This allowed an
estimate of the effect of a history of AMI on mortality compared to no history of AMI.
The estimates were adjusted for a wide range of risk factors that are known to explain
survival variations, resulting in more precise estimates of the hazard of mortality
associated with AMI. All interactions between risk factors were tested, instead of
restricting the interactions to the main exposure, sex, and age as most epidemiology
studies would do (Hennekens et al., 1987). This meant that survival variations could
be explored in greater detail, resulting in recommendations for more fine-tuned patient
tailored care and retirement planning. In addition, the interdependence between
patients from the same general practice was taken into account by introducing a
random effect to the survival model. This meant that the inferences of the findings
were not restricted to the practices included in the research but could be generalised
to the whole of the UK (Brown and Prescott, 2006).
The way the survival models were developed, as explained above, meant that the
findings could be used in medical management, and retirement planning. The sur-
vival models included risk factors that are routinely recorded by general practitioners
and the records are accessible to patients, therefore survival prospects could simply
be calculated for any interested individual. With respect to medical management,
the findings of this research are informative for administration of preventative health
measures, ongoing therapy, and strategic resources allocation. With respect to re-
tirement planning, the findings of this research are informative for financial planning
of retirement for individuals, pricing of annuities for actuaries, and shaping of the
pension system for the government.
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7.3 Limitations
The survival models assumed uninformative censoring, i.e. that patients who trans-
ferred from general practice had the same mortality rate as patients who stayed at
their practice. This assumption can only be proven when national death records
are linked to THIN database. However, by examining the profile of patients who
transferred compared to who stayed, the assumption may be supported or opposed.
National trends indicate that there are two groups of people who move at an older
age, where the younger group aged 60 to 69 comes from more aﬄuent areas and move
in good health and the older group aged 70 or older comes from more deprived ar-
eas and move in worse health (Pennington, 2013; Uren and Goldring, 2007). These
trends were not observed in the studied cohorts, thereby supporting the assumption
of uninformative censoring.
This research made use of data from 1987 to 2011. Over time, the incentives and
methods for data recording by general practitioners have changed (Marston et al.,
2010). For example, in 1990 clinical audits became a contractual requirement, in 1999
national standards for treatment for coronary heart disease were introduced, and in
2004 financial incentives by means of the Quality and Outcomes Framework (QOF)
were introduced (Campbell et al., 2007). Especially as a result of QOF, the record-
ing and managing of common chronic diseases, preventative measures, and lifestyle
choices improved (Campbell et al., 2007; Langley et al., 2011; NICE, 2014a; Sza-
tkowski et al., 2012). After the introduction of QOF, patients might have been more
likely to receive preventative measures, be followed-up more consistently, thereby ob-
tain better control of risk factors and in turn have better survival prospects after
diagnosis. This research found no interactions of the risk factors with year of birth
category, suggesting that the hazards of mortality associated with the risk factors do
not vary by year of treatment category.
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The medical records were incomplete with respect to lifestyle factors. In the co-
horts without a history of CVD, 46% of the youngest and 29% of the oldest cohort
had incomplete records, while in the matched cohorts for AMI this was 45% and
23%, respectively. The presence of missing data led to additional analysis and model
assumptions, and loss of precision in the estimates. Missing data were dealt with by
multiple imputation, which is a widely accepted method to deal with bias and impreci-
sion when missing data are present (van Buuren, 2012). The distributions of recorded
and imputed values were similar. Furthermore, the survival models estimated on only
complete medical records provided similar hazard ratios and performance statistics
as the models estimated on both complete and incomplete records.
The survival models were as complete as possible. There were, however, some risk
factors that could not be included due to the unsystematic or lack of recording in the
medical records during the study period. This meant that there could potentially be
some residual confounding by indication such as by family history of CVD, family
history of AMI, ratio of total cholesterol to high density lipids, psychosocial factors,
and ethnicity. The recording of these risk factors are part of QOF and has improved
over time (Mathur et al., 2014; Tucker, 2014). Thus, with future updates of the
survival models using more recent data, these factors could potentially be included.
The analysis was performed on an intention to treat basis to more accurately assess
the effect of routine current practice in the general population. With intention to
treat, both sick-user bias and healthy-user bias could not be excluded. Sick-user bias
would arise where at a given health status, general practitioners recognised people who
were at greater risk and consequently provided treatment. This bias would have led
to an underestimation of the survival benefit associated with the treatment. Healthy-
user bias would arise where at a given health status, patients who were more proactive
about their health, were more likely to be treated (Dormuth et al., 2009; Ray, 2003;
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Vonesh et al., 2000). This bias would have led to an overestimation of the survival
benefit associated with the treatment. Sick- and healthy-user biases were minimised
by inclusion of comorbidities, lifestyle choices, and socio-demographic factors in the
survival models.
7.4 Implications
The implications of the current research for the medical management and retirement
planning are discussed by addressing the aims of the research.
The first aim was to investigate how the presence and duration of comorbidities
and treatments affect the hazard of mortality at each age and whether they can be
related to age-specific medical management. The hazards of mortality associated with
the comorbidities were constant during follow-up; it did not matter how many years
patients had already lived with the comorbidity, they were still at a higher risk of
dying than patients without the comorbidity. This shows the importance of follow-up
of care. Interestingly, the hazard associated with hypertension at ages 70 and 75 was
protective in the first five years and hazardous after five years of follow-up. People at
those ages were likely to have high blood pressure but not necessarily diagnosed with
hypertension or treated with blood pressure regulating drugs. The results suggest
that diagnosing improves survival prospects even though the condition is hazardous
for survival. General practitioners might want to screen for hypertension in people
aged 70 and above as part of their medical management by measuring their blood
pressure on a regular basis.
The relative hazards of mortality associated with treatments were approximately
the same at each age, implying that the effectiveness of treatments did not differ
by age. Therefore, cardiovascular treatments should not be age-specific. The rela-
tive hazards of mortality associated with drugs prescriptions were constant during
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follow-up. This supports follow-up of AMI patients with regards to their cardiac
rehabilitation and adherence to drugs.
The second aim was to investigate the survival benefits of statins prescribed as
primary prevention of CVD for various cardiovascular risk groups at each age and
whether this can inform risk thresholds for action. The survival benefits of statins
therapy increased with the 10-year risk of a first cardiac event and with age. Only in
people with ≥20% cardiac risk and aged 65 and older did statins therapy significantly
prolong life. The current recommended thresholds for statins therapy for primary
prevention of CVD in routine practice may be too low and lead to overtreatment,
particularly in people with <10% cardiac risk or younger than 60 years old. Revision
of the guidelines on lipid modification by statins therapy should consider not only
having a risk threshold for action but also an age barrier.
The third aim was to investigate how modifiable risk factors such as cholesterol
level, blood pressure, body mass index, alcohol consumption, and smoking affect the
hazard of mortality at each age and whether they can inform public health measures.
The research’ findings are in line with NICE’s current guidelines on cardiac reha-
bilitation and prevention of further AMI, with the exception of weight management
(NICE, 2013b). As part of the cardiac rehabilitation, overweight and obese patients
are recommended to maintain a healthy weight. This research, however, found that in
non-smokers, the survival prospects of overweight patients were not significantly dif-
ferent from healthy weight patients. Also, survival prospects of smokers were less poor
when they were overweight or obese than when they were healthy weight. This is in
line with well-known obesity paradoxes in CVD patients as well as in the general pop-
ulation, of which one demonstrates that when physical activity is taken into account,
the survival prospects of obese and normal weight are no longer significantly different
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(McAuley and Blair, 2011). Based on these findings, the recommended weight man-
agement as part of cardiac rehabilitation might be too strict, and a revision of the
guideline might be considered by focussing on obese patients and emphasising cardio
fitness.
The fourth aim was to investigate the effect of general practice on the hazard of
mortality at each age and whether this is a factor additional to the socio-demographic
factors of a district to consider in resource allocation. With both survival models
developed for this research, general practice was one of the factors that contributed
the most in explaining survival variations. The adjusted survival prospects differed by
maximum ten years in effective age between general practices. This suggests that the
average period expectation of life at the cohort’s ages of 60, 65, 70, and 75 between
general practices for males differed up to 3.3, 7.9, 7.2, and 6.5 years, respectively, and
for females differed up to 3.5, 8.4, 7.9, and 7.3 years, respectively.
With the post-hoc analyses, the survival variations by general practice were not
found to be associated with health status, ethnic background, deprivation, urbani-
sation, or air pollution. A study by Gerber et al. (2010), who developed a survival
model for AMI with individual socioeconomic status as covariate and neighbourhood
socioeconomic status as random effect, suggested that neighbourhood socioeconomic
status might capture residual confounding of unequal hospital resources and social
characteristics of an area such as social cohesion and attitudes towards health. This
explanation for unexplained survival variations might also be the case for general
practices. It could be that general practices differ in their availability, quality, and
follow-up of care, such as providing support in cardiac rehabilitation. Survival vari-
ations by general practices might reduce when their performance is considered in
medical resource allocation.
The fifth aim was to estimate the years lost or gained in effective age for each of
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the medical conditions, treatments, lifestyle choices, and socio-demographic factors at
each age, and investigate how this could inform individuals about financial planning
for retirement. With the reforms of the UK pension system in 2015, individuals have
now greater freedom in what they can do with their pension pots during retirement.
This freedom, however, comes with greater responsibility and more complex decision
making in planning their finances for retirement. A key factor in retirement planning
is knowing the average period expectation of life for a certain medical history at a
certain age. This research provided estimates of years lost or gained in effective age
for different scenarios compared to the average period expectation of life at four key
ages of retirement. These estimates are informative when setting up and reviewing
financial plans for retirement.
This research found that the highest increase in effective age were associated with
a single or multiple AMIs (range across age cohorts 4-5 or 5-6 years, respectively),
cardiovascular system conditions (6-10 years), diabetes (4-6 years), and smoking (7-
10 years). In contrast, the highest decrease in effective age were associated with
prescription of beta blockers (1 year) or statins (2-3 years), and with coronary revas-
cularisation (2 years). The prevalence of multimorbidity increases with age, where
the most common morbidities in descending order are hypertension, lipid metabolism
disorder, chronic low back pain, diabetes, joint arthritis, and ischaemic heart disease
(Scha¨fer et al., 2010). Based on the presence of these morbidities in the survival mod-
els for AMI and the most prevalent drugs prescribed in these age cohorts, the three
most likely scenarios are (1) a single AMI with prescription of statins and aspirin,
(2) additionally with hypertension, and (3) additionally with diabetes, see Table 7.1.
Having a medical history of scenario 1 by age 60, 65, 70, or 75 would be associated
with a decrease in the average longevity of 3.9, 2.5, 1.2, and 1.2 years, respectively,
for men, and of 4.2, 2.6, 1.3, and 1.4 years, respectively, for women. Having a medical
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Table 7.1: Average period expectation of life for various scenarios based on the
survival models for acute myocardial infarction (AMI)
Using the UK life tables of 2010-2012 (ONS, 2016), the number of years lost or gained
in effective age associated with a single AMI, statins prescription, aspirin prescription,
hypertension, and diabetes were translated into the average period expectation of life at
different ages.
60 65 70 75
Average Men 22.2 18.2 14.5 11.1
Women 25.0 20.7 16.7 12.9
Single AMI + statins + aspirin (1) Men 18.3 15.7 13.3 9.9
Women 20.8 18.1 15.4 11.5
Scenario 1 + hypertension (2) Men 17.1 15.7 13.1 9.5
Women 19.5 18.1 15.1 11.1
Scenario 2 + diabetes (3) Men 15.9 12.0 10.3 7.4
Women 18.3 13.9 12.0 8.7
history of scenario 2 by age 60, 65, 70, or 75 would be associated with a decrease in
the average longevity of 5.1, 2.5, 1.4, and 1.6 years, respectively, for men, and of 5.5,
2.6, 1.6, and 1.8 years, respectively, for women. Having a medical history of scenario
2 by age 60, 65, 70, or 75 would be associated with a decrease in the average longevity
of 6.3, 6.2, 4.2, and 3.7 years, respectively, for men, and of 6.7, 6.8, 4.7, and 4.2 years,
respectively, for women.
The sixth aim was to investigate which medical conditions, treatments, lifestyle
factors, socio-demographic factors, and interactions of risk factors at each age do
and do not contribute in explaining survival variations and therefore to minimise the
basis risk of estimating life expectancy for the pricing of annuities. This research
found that the risk factors contributing the most in explaining survival variations
were history of different types of CVD, the interaction between body mass index
and smoking status, and general practice. Actuaries might want to focus on these
risk factors to improve longevity estimation. The following risk factors might not be
of importance for longevity estimation as these contributed the least in explaining
survival variations: hypertension, alcohol consumption status, and prescription of
172
aspirin or calcium-channel blockers.
The last aim was to investigate whether the effects of treatments, lifestyle choices,
or other risk factors on longevity change over time and might form longevity risks
that should be taken into account with pricing of annuities. Over the last five years
of the study period, from 2006 to 2011, 10% more AMI patients were prescribed beta
blockers or had coronary revascularisation. Both treatments could prolong life by 1
to 2 years. Actuaries should be aware that the effect of coronary revascularisation on
the hazard of mortality changes over time, where it is mainly effective in the reducing
early mortality. Over the last five years of the study period, 15% more people without
a history of CVD were prescribed statins. Depending on the age and cardiac risk at
prescription, statins therapy could prolong life up to 2 years. These upward trends
in treatments might form a longevity risk as a considerable group of patients could
life longer than expected.
7.5 Conclusions
The primary objectives of this research were to investigate how a history of CVD
affects longevity and which treatments improve longevity in the general population
based on a secondary data analysis derived from UK general practice patient records
of 1987 to 2011.
This research reported on the survival prospects associated with a history of a
single or multiple AMIs and how the survival prospects could be modified by coro-
nary revascularisation and drug therapy for secondary prevention. Based on previous
studies and evidence, it was unclear by how much AMI survivors in routine clinical
practice are worse off and to what the extent of survival benefits by various treatments
are. This is because previous studies excluded controls or limited adjustment for con-
founders, and made use of hospital and register data. This research fills in some of
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the gaps in evidence, and provides an important new source of information on the
survival prospects of AMI survivors in routine clinical practice. The findings suggest
that AMI survivors are to a lesser extent worse off than previously estimated and
that the current recommended guidelines of drug therapy for secondary prevention of
AMI may not necessarily be associated with improved longevity.
This research also reported on the survival benefits of statins prescribed as primary
prevention of CVD. The main evidence base to date came from clinical trials and this
is the first large observational population-based cohort study on the matter. Clinical
trials have a high internal reliability but may be poorly generalizable due to excluding
many patients who will be treated in routine practice. This research fills in some of the
gaps in evidence, and provides an important new source of information on the possible
effects of statins in routine clinical practice. The findings suggest that the current
internationally recommended thresholds for statins therapy for primary prevention of
CVD in routine practice may be too low and lead to overtreatment.
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Appendix A
Appendix statistical methods
Table A.1: Prevalence missing observations in 60-year old cohort
Prevalence of missing observations in blood pressure, body mass index, alcohol status, and
smoking status by medical history is listed in percentages. Associations of missingness with
the medical history were significant (χ2(df), p<.001).
Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
Sex Female 71,615 22.9 32.0 35.4 27.0
Male 70,626 32.0 40.6 40.2 32.5
Year of birth 1930-35 51,082 31.9 51.9 56.6 44.5
1936-40 91,159 24.9 27.5 27.2 21.4
Socioeconomic 1 16,872 27.7 35.8 38.5 29.5
status 2 9,181 26.7 33.1 34.7 28.3
3 32,659 27.3 36.1 37.8 29.9
4 20,551 27.9 37.6 38.1 30.1
5 8,072 28.3 37.7 38.4 29.8
6 16,443 28.2 37.4 39.4 30.0
7 6,527 27.0 39.3 40.4 30.9
8 13,853 23.8 33.0 34.6 27.0
9 8,484 27.2 33.9 34.9 29.7
10 9,599 30.1 39.9 40.6 32.4
Acute myocardial No 138,055 27.8 36.5 38.0 29.9
infarction Yes 4,186 14.2 29.0 31.3 22.5
Angina No 136,281 28.0 36.7 38.1 30.1
Yes 5,960 13.2 27.2 30.1 20.0
Heart failure No 141,497 26.1 36.2 37.8 29.8
Yes 744 12.0 29.4 31.3 21.0
Cardiovascular No 135,353 28.0 36.7 38.2 30.2
system conditions Yes 6,888 15.3 29.0 30.0 19.5
Diabetes No 136,956 28.1 37.0 38.1 30.2
Continued on next page
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Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
Yes 5,285 8.9 17.2 28.5 17.6
Blood pressure Normal 26,178 0.0 18.8 20.8 12.5
Pre 49,948 0.0 20.3 22.4 13.9
Hyper 27,150 0.0 23.5 26.0 17.3
Hypercholestero- No 118,126 31.4 40.7 41.9 33.4
laemia Yes 24,115 7.5 14.7 17.3 11.5
Coronary No 140,540 27.6 36.4 37.9 29.8
revascularisation Yes 1,701 14.2 26.0 26.5 19.2
Blood pressure No 105,040 33.2 40.7 41.8 33.8
lowering drugs Yes 37,201 11.0 24.0 26.3 18.2
Lipid-lowering No 135,945 28.2 37.2 38.6 30.4
therapy Yes 6,296 11.0 17.9 20.3 14.5
Body mass index Normal 36,321 11.2 0.0 10.5 5.0
Overweight 37,364 9.4 0.0 10.5 5.8
Obese 16,918 6.9 0.0 13.0 7.2
Alcohol status No 17,033 10.2 9.4 0.0 1.7
Yes 71,495 10.1 8.7 0.0 2.8
Smoking status No 59,157 10.7 13.2 12.9 0.0
Ex 14,217 8.9 12.8 12.2 0.0
Yes 26,594 15.0 18.7 16.4 0.0
Total 142,241 27.4 36.3 37.8 29.7
Table A.2: Prevalence missing observations in 65-year old cohort
Prevalence of missing observations in blood pressure, body mass index, alcohol status, and
smoking status by medical history is listed in percentages. Associations of missingness with
the medical history were significant (χ2(df), p<.001).
Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
Sex Female 133,130 18.8 25.5 27.4 20.0
Male 127,647 24.1 31.2 30.2 23.2
Year of birth 1925-30 48,160 31.4 52.8 56.9 44.6
1931-35 82,920 22.7 26.9 26.5 20.7
1936-40 129,697 16.9 20.0 19.7 13.5
Socioeconomic 1 29,725 21.3 27.8 28.8 21.2
status 2 17,101 19.6 25.3 25.8 20.0
3 55,987 21.2 27.8 28.3 21.4
4 35,731 21.9 29.0 28.6 21.6
Continued on next page
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Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
5 14,512 22.2 30.2 30.2 21.7
6 30,032 22.5 29.5 30.6 22.1
7 13,554 21.7 30.6 30.9 23.0
8 28,332 18.7 25.2 26.3 19.8
9 15,573 22.0 27.7 27.8 22.5
10 20,230 23.7 31.6 31.3 23.5
Acute myocardial No 249,894 21.9 28.7 29.1 21.9
infarction Yes 10,883 9.8 19.2 20.4 12.8
Angina No 243,786 22.3 28.9 29.3 22.2
Yes 16,991 9.1 18.9 20.4 12.9
Heart failure No 257,932 20.1 28.4 28.8 21.7
Yes 2,845 6.3 18.7 19.3 10.4
Cardiovascular No 239,188 22.4 28.9 29.4 22.3
system conditions Yes 21,589 10.6 21.0 21.2 12.8
Diabetes No 244,904 22.5 29.5 29.5 22.4
Yes 15,873 4.8 9.7 17.5 8.7
Blood pressure Normal 60,606 0.0 15.0 15.8 8.9
Pre 99,642 0.0 17.1 17.8 10.6
Hyper 44,694 0.0 21.3 22.3 14.4
Hypercholestero- No 183,692 28.4 35.2 35.3 27.4
laemia Yes 77,085 4.8 11.9 13.0 7.6
Coronary No 255,190 21.7 28.6 29.0 21.8
revascularisation Yes 5,587 7.5 15.2 16.2 9.8
Blood pressure No 161,179 30.0 34.8 34.8 27.2
lowering drugs Yes 99,598 7.5 17.7 19.0 12.4
Lipid-lowering No 227,414 23.8 30.8 31.1 23.6
therapy Yes 33,363 5.1 11.2 12.7 7.3
Body mass index Normal 69,853 11.6 0.0 8.0 4.0
Overweight 78,135 9.1 0.0 8.0 4.4
Obese 39,020 6.5 0.0 9.3 5.0
Alcohol status No 37,858 10.5 8.3 0.0 1.5
Yes 147,982 9.6 7.5 0.0 2.2
Smoking status No 116,320 10.6 11.9 10.4 0.0
Ex 41,773 7.0 10.4 9.6 0.0
Yes 46,474 14.5 16.4 14.0 0.0
Total 260,777 21.4 28.3 28.7 21.6
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Table A.3: Prevalence missing observations in 70-year old cohort
Prevalence of missing observations in blood pressure, body mass index, alcohol status,
and smoking status by medical history is listed in percentages. Associations of missing-
ness with the medical history were significant (χ2(df), p<.001), except for prevalence of
missing smoking status across sexes (χ2(1)<.01, p=.97) and body mass index categories
(χ2(2)=1.55, p=.46).
Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
Sex Female 182,873 16.3 22.5 23.9 16.0
Male 163,537 16.9 23.5 23.2 16.0
Year of birth 1920-30 120,730 27.2 39.4 40.2 31.6
1931-35 113,904 15.3 19.3 19.4 13.0
1936-40 111,776 6.4 8.9 9.9 2.1
Socioeconomic 1 38,143 15.6 21.8 22.7 14.5
status 2 21,612 14.1 19.0 19.5 13.1
3 71,863 15.7 21.6 22.4 15.2
4 46,142 17.3 23.9 24.0 16.4
5 19,082 18.5 25.7 26.4 17.7
6 39,966 17.6 24.5 25.4 16.8
7 20,291 18.1 26.4 27.1 18.7
8 41,917 15.9 22.2 22.7 16.0
9 19,899 16.1 22.0 22.9 15.6
10 27,495 18.4 25.2 25.2 17.4
Acute myocardial No 327,973 17.1 23.5 24.1 16.4
infarction Yes 18,437 8.2 13.9 14.6 8.8
Angina No 315,850 17.4 23.9 24.4 16.6
Yes 30,560 7.7 13.7 15.0 9.0
Heart failure No 339,411 15.0 23.2 23.8 16.1
Yes 6,999 4.6 15.0 15.7 8.2
Cardiovascular No 301,149 17.8 24.0 24.7 17.0
system conditions Yes 45,261 8.5 16.1 16.5 9.1
Chronic kidney No 337,002 16.9 23.5 24.1 16.4
disease Yes 9,408 3.7 2.8 4.2 0.2
Diabetes No 316,017 17.7 24.6 24.8 17.0
Yes 30,393 4.8 5.8 11.4 4.8
Blood pressure Normal 109,043 0.0 10.8 11.8 5.0
Pre 131,434 0.0 14.9 15.8 7.8
Hyper 48,487 0.0 21.6 22.6 13.7
Hypercholestero- No 200,545 26.1 33.8 34.0 24.9
laemia Yes 145,865 3.5 8.1 9.3 3.7
Coronary No 335,522 16.9 23.5 24.0 16.3
revascularisation Yes 10,888 6.0 8.4 9.4 5.0
Blood pressure No 174,281 27.1 32.3 32.3 23.5
Continued on next page
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Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
lowering drugs Yes 172,129 6.0 13.6 14.8 8.3
Lipid-lowering No 261,389 20.7 28.3 28.6 20.2
therapy Yes 85,021 3.8 6.7 8.1 3.0
Body mass index Normal 95,681 9.5 0.0 7.3 2.8
Overweight 112,167 6.8 0.0 6.7 2.9
Obese 58,936 5.0 0.0 7.4 2.9
Alcohol status No 59,774 8.4 7.2 0.0 1.0
Yes 204,919 7.4 6.1 0.0 1.4
Smoking status No 163,771 8.5 10.9 10.1 0.0
Ex 76,459 5.4 8.2 8.5 0.0
Yes 50,881 12.6 15.2 13.4 0.0
Total 346,410 16.6 23.0 23.6 16.0
Table A.4: Prevalence missing observations in 75-year old cohort
Prevalence of missing observations in blood pressure, body mass index, alcohol status, and
smoking status by medical history is listed in percentages. Associations of missingness with
the medical history were significant (χ2(df), p<.001), except for prevalence of missing blood
pressure across sexes (χ2(1)=1.76, p=.18).
Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
Sex Female 161,907 13.9 20.8 21.1 13.1
Male 131,802 14.0 19.8 18.9 12.1
Year of birth 1920-25 79,616 24.1 36.6 34.8 26.6
1926-30 99,425 14.8 21.7 21.4 14.2
1931-36 114,668 6.2 8.1 8.9 1.6
Socioeconomic 1 31,068 13.1 19.7 19.7 11.5
status 2 16,677 11.7 17.3 17.0 10.0
3 58,079 13.0 18.6 18.6 11.6
4 37,518 14.7 21.3 20.8 13.2
5 15,757 15.9 22.8 22.4 14.2
6 33,450 14.6 21.3 21.6 13.2
7 20,037 14.4 22.4 21.7 14.2
8 40,845 12.9 19.7 19.1 12.2
9 15,572 14.1 19.9 19.8 12.6
10 24,706 16.6 23.3 22.8 15.5
Acute myocardial No 274,583 14.4 21.0 20.7 13.1
infarction Yes 19,126 8.1 11.4 11.5 6.4
Continued on next page
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Covariate Category Size Blood Body mass Alcohol Smoking
pressure index status status
Angina No 260,026 14.8 21.5 21.2 13.4
Yes 33,683 7.3 11.5 11.8 6.5
Heart failure No 283,830 11.8 20.6 20.4 12.8
Yes 9,879 3.6 14.5 14.0 7.0
Cardiovascular No 237,061 15.3 21.8 21.6 13.9
system conditions Yes 56,648 8.1 14.7 14.1 7.2
Chronic kidney No 277,120 14.5 21.4 21.2 13.4
disease Yes 16,589 4.9 3.0 3.8 0.1
Diabetes No 263,224 15.0 22.2 21.4 13.7
Yes 30,485 5.1 4.4 9.3 3.2
Blood pressure Normal 109,265 0.0 10.3 10.7 4.2
Pre 107,002 0.0 15.1 14.9 7.1
Hyper 36,485 0.0 21.7 20.8 12.0
Hypercholestero- No 156,153 22.8 31.6 30.4 21.1
laemia Yes 137,556 3.9 7.7 8.5 3.0
Coronary No 282,452 14.2 20.9 20.7 13.0
revascularisation Yes 11,257 6.8 6.8 7.4 3.6
Blood pressure No 120,274 25.4 31.2 30.1 20.9
lowering drugs Yes 173,435 6.0 12.9 13.2 6.9
Lipid-lowering No 204,433 18.1 26.6 25.8 17.1
therapy Yes 89,276 4.3 6.2 7.2 2.4
Body mass index Normal 87,919 8.9 0.0 6.4 2.3
Overweight 97,187 6.3 0.0 6.0 2.2
Obese 48,711 4.9 0.0 6.6 2.1
Alcohol status No 59,629 8.0 7.3 0.0 0.8
Yes 174,901 7.0 6.3 0.0 1.1
Smoking status No 147,447 8.0 11.1 9.6 0.0
Ex 72,806 5.4 7.9 7.7 0.0
Yes 36,301 12.6 15.9 13.1 0.0
Total 293,709 13.9 20.4 20.1 12.7
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Table B.1: Description and coding of variables in matched age cohorts
Values were the latest reading before entering the study, which was at the 1st of January of
the year the patient turned the cohort’s age. The first category functioned as the baseline.
For information on the raw data, see Table 3.2.
Category Coding
Medical
condition
Acute myocardial infarction (AMI) diagnosis,
multiple AMIs had ≥30 days between events
No/single/multiple
Angina pectoris diagnosis No/yes
Cardiovascular system conditions, which include
diagnosis of: valvular heart disease, peripheral
vascular disease, cerebrovascular disease, and
other cardiovascular system disorders
No/yes
Chronic kidney disease at end stage (GFR<15) No/yes
Diabetes mellitus diagnosis No/yes
Heart failure diagnosis No/yes
Hypercholesterolaemia diagnosis or a total
cholesterol reading >5mmol/L
No/yes
Hypertension diagnosis No/yes
Ischaemic heart disease, which include diagnosis
of: angina pectoris, acute myocardial infarction,
and subsequent events or complications of these
conditions
No/angina/single
AMI and possible
angina/multiple
AMIs and possible
angina
Treatment ACE inhibitor prescription, which include:
angiotensin-converting enzyme inhibitors and
angiotensin-II receptor antagonists
No/yes
Aspirin prescription No/yes
Continued on next page
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Table B.1 – Continued from previous page
Category Coding
Beta-adrenoceptor blocking drugs prescription No/yes
Calcium-channel blocker prescription No/yes
Coronary revascularisation, which include
coronary artery bypass graft (CABG) and
percutaneous coronary intervention (PCI)
No/yes
Statin prescription, which include: atorvastatin,
cerivastatin, fluvastatin, pravastatin, rosuvastatin,
and simvastatin
No/yes
Lifestyle Alcohol consumption status No/yes
Body mass index
(weight in kg)/(height in m)2
Normal weight
(<25)/overweight
(25-30)/obese (≥30)
Smoking status No/ex/yes
Demography Sex Female/male
Socioeconomic status measured by Mosaic 10 categories,
see Table 3.3
Year of birth category 1920-25, 1926-29,
1930-35, 1936-40
District Air pollution, which includes separate variables for
2001 estimated level of nitrogen dioxide, nitrogen
oxide, sulphur dioxide, and particulate matter
Quintiles
Ethnicity, which includes separate variables for
proportion of district population defining
themselves as white, mixed, Asian or Asian
British, black or black British, and other
Quintiles
Index of multiple deprivation (IMD) Quintiles
Limiting long-term illness Quintiles
Urbanisation Urban/town and
fringe/village,
hamlet and isolated
dwelling
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Table B.2: Prevalence antiplatelet therapy in matched age cohorts
The age cohorts included cases with history of acute myocardial infarction (AMI) who were
matched to three controls on sex, year of birth, and general practice. The prevalence of the
treatment by the cohort’s age was affected by calendar year, see Figure 5.2.
Cohort Dual Aspirin only Other
antiplatelet antiplatelet
therapy agent only
Age 60 122 (1%) 2,213 (13%) 119 (1%)
Age 65 1,079 (3%) 10,152 (23%) 387 (1%)
Age 70 4,097 (6%) 22,639 (31%) 802 (1%)
Age 75 5,565 (7%) 28,451 (37%) 1,009 (1%)
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Table B.3: Characteristics of patients with complete and incomplete medical records
in matched age cohorts
The age cohorts included cases with history of acute myocardial infarction (AMI) who
were matched to three controls on sex, year of birth, and general practice. Patients with
incomplete medical records had a missing observation for alcohol consumption status, body
mass index, or smoking status.
Records Year of Size Annual death AMI (%)
birth rate (/1,000)
Age 60 Complete 1936-40 6,901 14.9 1,869 (27.1%)
1930-35 2,374 19.1 674 (28.4%)
Incomplete 1936-40 3,691 14.3 779 (21.1%)
1930-35 3,778 18.1 864 (22.9%)
Total 16,744 16.4 4,186 (25.0%)
Age 65 Complete 1936-40 16,357 17.9 4,607 (28.2%)
1931-35 9,568 23.0 2,595 (27.1%)
1925-30 2,946 29.7 810 (27.5%)
Incomplete 1936-40 5,339 15.8 817 (15.3%)
1931-35 4,608 22.8 949 (20.6%)
1925-30 4,710 30.2 1,104 (23.4%)
Total 43,528 22.5 10,882 (25.0%)
Age 70 Complete 1936-40 20,790 21.6 5,631 (27.1%)
1931-35 19,645 27.1 5,486 (27.9%)
1920-30 13,718 38.7 3,760 (27.4%)
Incomplete 1936-40 2,774 19.4 260 (9.4%)
1931-35 6,143 27.1 961 (15.6%)
1920-30 10,658 41.2 2,334 (21.9%)
Total 73,728 32.5 18,432 (25.0%)
Age 75 Complete 1931-36 27,648 32.7 7,393 (26.7%)
1926-30 20,266 44.8 5,624 (27.8%)
1920-25 11,035 59.0 3,016 (27.3%)
Incomplete 1931-36 3,240 32.1 329 (10.2%)
1926-30 6,854 46.5 1,156 (16.9%)
1920-25 7,349 58.0 1,580 (21.5%)
Total 76,392 47.6 19,098 (25.0%)
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Table B.4: Distribution of recorded and imputed values of variables with missing
data in matched age cohorts
The age cohorts included cases with history of acute myocardial infarction (AMI) who
were matched to three controls on sex, year of birth, and general practice. Patients with
incomplete medical records had a missing observation for alcohol consumption status, body
mass index, or smoking status. The distribution of imputed values is the mean across ten
imputed datasets.
Values Alcohol BMI (sd) Ex-smoker Smoker
Age 60 Recorded 83.8% 26.8 (4.2) 19.7% 29.8%
Imputed 84.0% 26.3 (4.3) 19.4% 30.0%
Age 65 Recorded 81.8% 27.0 (4.3) 26.9% 24.6%
Imputed 79.8% 26.4 (4.3) 24.8% 24.2%
Age 70 Recorded 79.9% 27.1 (4.2) 33.0% 18.8%
Imputed 78.7% 26.2 (4.3) 32.3% 17.4%
Age 75 Recorded 76.7% 26.8 (4.4) 35.1% 14.7%
Imputed 75.0% 25.9 (4.3) 34.1% 13.2%
Table B.5: Characteristics of patients lost to follow-up in matched age cohorts
The age cohorts included cases with history of acute myocardial infarction (AMI) who
were matched to three controls on sex, year of birth, and general practice. Patients who
transferred out of their practice during the study were lost to follow-up. The prevalence of
smoker is the mean across ten imputed datasets. Aﬄuent area was measured as the first
quintile of the Index of Multiple Deprivation (IMD), where the prevalence excluded missing
observations.
Transferred, Size AMI Diabetes Smoker Aﬄuent
observed age area
Age 60 No, <70 1,882 40.0% 13.4% 43.7% 13.5%
No, ≥70 10,927 23.2% 5.2% 27.1% 21.7%
Yes, <70 2,967 23.0% 6.5% 31.6% 20.8%
Yes, ≥70 968 22.6% 5.8% 28.7% 19.0%
Age 65 No, <70 3,077 37.6% 17.0% 38.9% 14.4%
No, ≥70 31,868 24.3% 8.4% 22.6% 22.1%
Yes, <70 4,511 23.1% 9.5% 27.0% 20.7%
Yes, ≥70 4,072 23.2% 7.4% 25.7% 21.5%
Age 70 No 62,254 25.3% 12.4% 18.0% 22.3%
Yes 11,474 23.5% 10.8% 22.2% 20.3%
Age 75 No 64,688 25.3% 14.3% 14.1% 22.7%
Yes 11,704 23.4% 11.7% 18.0% 20.8%
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Figure B.1: Prevalence of comorbidites by cohort’s age in patients with acute myocardial infarction
The age cohorts differed in recruitment period. The prevalence prior to 1995 is not presented due to the small numbers of medical
records available.
206Figure B.2: Prevalence of lifestyle factors by cohort’s age in patients with acute myocardial infarction
The age cohorts differed in recruitment period. The prevalence prior to 1995 is not presented due to the small numbers of medical
records available.
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Table B.6: Prevalence coronary revascularisation given ischaemic heart disease
(IHD)
The age cohorts included cases with history of acute myocardial infarction (AMI) who
were matched to three controls on sex, year of birth, and general practice. History of
IHD consisted of AMI and angina. Patients of both subtypes of IHD could be eligible for
coronary revascularisation, which consisted of coronary artery bypass graft (CABG) and
percutaneous coronary intervention (PCI). Some IHD patients had both CABG and PCI.
The prevalence of the treatment by the cohort’s age was affected by calendar year, see
Figure 5.2.
Cohort Coronary Number of
revascularisation patients (%)
Age 60 CABG 751 (16%)
PCI 167 (3%)
Total 881 (18%)
Age 65 CABG 2,479 (19%)
PCI 750 (6%)
Total 3,069 (23%)
Age 70 CABG 4,606 (19%)
PCI 1,869 (8%)
Total 6,113 (26%)
Age 75 CABG 5,036 (19%)
PCI 1,958 (7%)
Total 6,601 (25%)
Table B.7: Prevalence of diabetes in men and women with ischaemic heart disease
(IHD)
The age cohorts included cases with history of acute myocardial infarction (AMI) who
were matched to three controls on sex, year of birth, and general practice. History of
IHD consisted of AMI and angina. Patients of both subtypes of IHD could be eligible for
coronary revascularisation.
Coronary Sex Age 60 Age 65 Age 70 Age 75
revascularisation
No Men 315 (10%) 1,093 (14%) 2,209 (17%) 2,518 (19%)
Women 98 (12%) 375 (15%) 864 (18%) 1,171 (18%)
Yes Men 86 (11%) 430 (16%) 1,081 (21%) 1,219 (23%)
Women 24 (23%) 80 (19%) 217 (21%) 306 (24%)
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Figure B.3: Survival model for 60-year old matched cohort
The hazard of all-cause mortality were adjusted for the listed risk factors and general
practice. The hazard associated with single/multiple acute myocardial infarction (AMI)
was the same in patients with and without angina, and the hazard associated with statin
prescription was the same in patients with and without hypercholesterolaemia (HCL). Time-
varying hazards were split at five or ten years of follow-up (FU) after the cohort’s age.
Abbreviations: NormalW=normal weight, Overw=overweight, NS=non-smoker, ES=ex-
smoker, and CS=current-smoker.
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Figure B.4: Survival model for 65-year old matched cohort
The hazard of all-cause mortality were adjusted for the listed risk factors and general prac-
tice. The hazard associated with single/multiple acute myocardial infarction (AMI) was
the same in patients with and without angina, and the hazard associated with statin pre-
scription was the same in patients with and without hypercholesterolaemia (HCL). Time-
varying hazards were split at five years of follow-up (FU) after the cohort’s age. Abbre-
viations: NormalW=normal weight, Overw=overweight, NS=non-smoker, ES=ex-smoker,
and CS=current-smoker.
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Figure B.5: Survival model for 70-year old matched cohort
The hazard of all-cause mortality were adjusted for the listed risk factors and general prac-
tice. The hazard associated with single/multiple acute myocardial infarction (AMI) was
the same in patients with and without angina, and the hazard associated with statin pre-
scription was the same in patients with and without hypercholesterolaemia (HCL). Time-
varying hazards were split at five years of follow-up (FU) after the cohort’s age. Abbre-
viations: NormalW=normal weight, Overw=overweight, NS=non-smoker, ES=ex-smoker,
and CS=current-smoker.
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Figure B.6: Survival model for 75-year old matched cohort
The hazard of all-cause mortality were adjusted for the listed risk factors and general prac-
tice. The hazard associated with single/multiple acute myocardial infarction (AMI) was
the same in patients with and without angina, and the hazard associated with statin pre-
scription was the same in patients with and without hypercholesterolaemia (HCL). Time-
varying hazards were split at five years of follow-up (FU) after the cohort’s age. Abbre-
viations: NormalW=normal weight, Overw=overweight, NS=non-smoker, ES=ex-smoker,
and CS=current-smoker.
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Figure B.7: Adjusted survival curves associated with ischaemic heart disease (IHD)
The age cohorts included cases with history of acute myocardial infarction (AMI) who were
matched to three controls on sex, year of birth, and general practice. Due to the way AMI
and angina interacted, a factor representing IHD was generated that had the following levels:
no history, angina only, single AMI with possibly angina, or multiple AMIs with possibly
angina. The survival curves were adjusted for sex, year of birth, socioeconomic status, heart
failure, cardiovascular system conditions, chronic kidney disease (only at ages 70 and 75),
diabetes, hypertension, hypercholesterolaemia, coronary revascularisation, ACE inhibitors,
aspirin, beta blockers, calcium-channel blockers, statins, alcohol consumption status, body
mass index, smoking status, and general practice.
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Table B.8: Correlations of district’s characteristics and the adjusted hazards of
all-cause mortality associated with general practices
The age cohorts included cases with history of acute myocardial infarction (AMI) who were
matched to three controls on sex, year of birth, and general practice. The hazards were
adjusted for sex, year of birth, socioeconomic status, ischaemic heart disease, heart failure,
cardiovascular system conditions, chronic kidney disease (only at ages 70 and 75), diabetes,
hypertension, hypercholesterolaemia, coronary revascularisation, ACE inhibitors, aspirin,
beta blockers, calcium-channel blockers, statins, alcohol consumption status, body mass
index, and smoking status. The table reports the Spearman’s rank correlations r, where
r=0 stands for no correlation and |r|=1 for perfect correspondence between two variables
(Harrell et al., 1996).
Characteristic Category Age 60 Age 65 Age 70 Age 75
Deprivation (IMD) 0.03 0.02 0.10 -0.05
Urbanisation -0.08 0.03 0.04 0.05
Limiting long- 0.03 0.03 0.10 -0.08
term illness
Ethnicity White -0.03 0.01 0.01 0.05
Mixed 0.00 0.00 0.01 -0.03
Asian 0.01 -0.01 0.00 -0.05
Black 0.03 0.01 0.01 -0.07
Other 0.02 0.02 0.00 -0.04
Air pollution Nitrogen dioxide 0.00 0.06 -0.01 -0.05
Nitrogen oxide 0.03 0.07 0.00 -0.08
Sulphur dioxide 0.08 0.08 -0.01 -0.03
Particulate matter 0.00 0.06 0.00 -0.05
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Table B.9: Performance statistics of survival models based on complete medical
records and irrespective of completeness in matched age cohorts
The age cohorts included cases with history of acute myocardial infarction (AMI) who were
matched to three controls on sex, year of birth, and general practice. Matching was carried
out once on complete medical records and once irrespective of completeness of records.
Patients with incomplete medical records had a missing observation for alcohol consumption
status, body mass index, or smoking status.
Model based on Statistic Age 60 Age 65 Age 70 Age 75
Complete records R2 0.300 0.290 0.254 0.231
C 0.703 0.702 0.694 0.685
Shrinkage 0.958 0.986 0.989 0.987
All records R2 0.288 0.264 0.222 0.199
C 0.702 0.698 0.683 0.675
Shrinkage 0.974 0.988 0.992 0.993
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Table C.1: Characteristics of patients with and without Townsend deprivation score
in age cohorts without cardiovascular disease
Townsend scores were based on 2001 Census Data of England and Wales (UKDS, 2006).
Consequently, patients living in Scotland or Northern Ireland had a missing record for this
deprivation measure. Less than 0.2% of patients living in England or Wales had a missing
score.
Townsend Year of Size Death/1,000 Men (%) Lipid-lowering
score birth person-years therapy (%)
Age 60 Recorded 1936-40 75,379 9.2 36,217 (48.0%) 2,229 (3.0%)
1930-35 43,321 12.5 20,768 (47.9%) 520 (1.2%)
Missing 1936-40 7,727 10.2 3,566 (46.1%) 306 (4.0%)
1930-35 3,409 14.8 1,607 (47.1%) 26 (0.8%)
Total 129,836 10.8 62,158 (47.9%) 3,081 (2.4%)
Age 65 Recorded 1936-40 95,322 11.0 44,846 (47.0%) 11,229 (11.8%)
1931-35 64,932 14.8 30,154 (46.4%) 2,569 (4.0%)
1925-30 39,320 21.0 17,941 (45.6%) 500 (1.3%)
Missing 1936-40 16,603 12.2 7,543 (45.4%) 1,959 (11.8%)
1931-35 6,660 16.4 2,950 (44.3%) 326 (4.9%)
1925-30 2,847 23.8 1,230 (43.2%) 30 (1.1%)
Total 225,684 15.2 104,664 (46.4%) 16,613 (7.4%)
Age 70 Recorded 1936-40 77,025 12.8 34,514 (44.8%) 25,326 (32.9%)
1931-35 78,278 17.7 34,782 (44.4%) 11,373 (14.5%)
1920-30 91,846 28.1 39,498 (43.0%) 2,525 (2.7%)
Missing 1936-40 13,513 13.5 5,801 (42.9%) 4,615 (34.2%)
1931-35 13,361 19.7 5,669 (42.4%) 1,879 (14.1%)
1920-30 7,850 29.2 3,221 (41.0%) 251 (3.2%)
Total 281,873 22.7 123,485 (43.8%) 45,969 (16.3%)
Age 75 Recorded 1931-36 73,154 20.7 30,787 (42.1%) 27,689 (37.9%)
1926-30 63,971 30.1 25,997 (40.6%) 8,910 (13.9%)
1920-25 56,960 41.0 22,867 (40.1%) 1,280 (2.2%)
Missing 1931-36 12,333 21.1 4,920 (39.9%) 4,883 (39.6%)
1926-30 10,342 32.8 4,052 (39.2%) 1,391 (13.5%)
1920-25 4,885 42.7 1,816 (37.2%) 114 (2.3%)
Total 221,645 33.3 90,439 (40.8%) 44,267 (20.0%)
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Table C.2: Original and modified QRISK2 algorithm
The QRISK2 estimates the risk of developing a first cardiovascular event in the next ten
years based on a person’s information on multiple demographic, medical, and lifestyle factors
(Hippisley-Cox et al., 2008)
Variables in original QRISK2 Variables in modified QRISK2
Self-assigned ethnicity (white/not
recorded, Indian, Pakistani, Bangladeshi,
other Asian, black African, black
Caribbean, Chinese, other including
mixed)
No: excluded
Age (years) Yes
Sex (males versus females) Yes
Smoking status
(no/ex/light/moderate/heavy)
No: classified smokers as moderate
smoker
Systolic blood pressure (continuous) Yes
Ratio of total serum cholesterol/high
density lipoprotein cholesterol
(continuous)
No: substituted based on
hypercholesterolaemia (HCL) diagnosis.
Patients with no HCL diagnosis, were
ascribed a value of 4. Patients with a
HCL diagnosis, were ascribed a value of
5.
Body mass index (continuous) Yes
Family history of ischaemic heart disease
in first degree relative under 60 years
(no/yes)
No: substituted by family history of
cardiovascular disease
Townsend deprivation score (continuous) No: used corresponding median value for
quintiles: -3.15, -2.17, -1.05, 0.84, and
4.51
Treated hypertension (diagnosis of
hypertension and at least one current
prescription of at least one
antihypertensive agent)
Yes
Rheumatoid arthritis (no/yes) No: excluded
Chronic renal disease (no/yes) Yes
Diabetes (no/type1/type2) No: classified diabetes as type two
Atrial fibrillation (no/yes) No: excluded
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Table C.3: Description and coding of variables in age cohorts without cardiovascular
disease
Values were the latest reading before entering the study, which was at the 1st of January of
the year the patient turned the cohort’s age. The first category functioned as the baseline.
For information on the raw data, see Table 3.2.
Category Coding
Body mass index
(weight in kg)/(height in m)2
Normal weight (<25)/
overweight (25-30)/
obese (≥30)
Blood pressure regulating drugs prescription includes:
beta-adrenoceptor blocking drugs, thiazides and related
diuretics, adrenergic neurone blocking drugs,
alpha-adrenoceptor blocking drugs, angiotensin-converting
enzyme inhibitors, angiotensin-II receptor antagonists,
centrally acting antihypertensive drugs, drugs affecting the
renin-angiotensin system, drugs related to hypertension
and heart failure, renin inhibitors, vasodilator
antihypertensive drugs, and calcium-channel blockers
No/yes
Chronic kidney disease (CKD) at end stage (GFR<15) No/yes
Diabetes mellitus diagnosis No/yes
Hypercholesterolaemia (HCL) diagnosis or a total
cholesterol reading >5mmol/L
No/yes
Hypertension diagnosis No/yes
Lipid-lowering therapy prescription includes a type of
statin or one of the following: colesevelam, colestipol,
colestyramine, ezetimibe, bezafibrate, ciprofibrate,
clofibrate, fenofibrate, gemfibrozil, acipimox, nicotinic acid,
and omega-3-triglycerides including other esters and acids
No/yes
Sex Female/male
Smoking status No/ex/yes
Socioeconomic status measured by Mosaic 10 categories,
see Table 3.3
Statin prescription, which include: atorvastatin,
cerivastatin, fluvastatin, pravastatin, rosuvastatin, and
simvastatin
No/yes
Year of birth category 1920-25/1926-29/
1930-35/1936-40
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Table C.4: Characteristics of patients with complete and incomplete medical records
in age cohorts without cardiovascular disease
Patients with incomplete medical records had a missing observation for systolic blood pres-
sure, body mass index, or smoking status, and consequently a missing QRISK2 score. The
reported QRISK2 score is the mean (standard deviation) 10-year risk of a first cardiovas-
cular event across ten imputed datasets.
Records Year of Size Death/1,000 Lipid lowering QRISK2
birth person-years therapy (sd)
Age 60 Complete 1936-40 45,807 8.9 1,734 (3.8%) 10.6 (5.3)
1930-35 18,104 11.7 324 (1.8%) 10.4 (5.0)
Incomplete 1936-40 29,572 9.8 495 (1.7%) 10.4 (3.7)
1930-35 25,217 13 196 (0.8%) 10.2 (3.8)
Total 118,700 10.6 2,749 (2.3%) 10.4 (4.6)
Age 65 Complete 1936-40 66,764 10.7 9,884 (14.8%) 15.9 (6.7)
1931-35 40,060 14.1 1,986 (5.0%) 15.2 (6.3)
1925-30 15,998 20 299 (1.9%) 15.1 (6.1)
Incomplete 1936-40 28,558 11.6 1,345 (4.7%) 14.9 (4.7)
1931-35 24,872 16 583 (2.3%) 14.6 (4.7)
1925-30 23,322 21.6 201 (0.9%) 14.5 (4.7)
Total 199,574 15.2 14,298 (7.2%) 15.2 (5.9)
Age 70 Complete 1936-40 66,733 12.7 24,235 (36.3%) 22.5 (7.7)
1931-35 55,423 17 9,970 (18.0%) 22.0 (7.4)
1920-30 46,111 26.3 1,849 (4.0%) 21.2 (7.1)
Incomplete 1936-40 10,292 13.6 1,091 (10.6%) 19.9 (5.4)
1931-35 22,855 19.3 1,403 (6.1%) 20.1 (5.5)
1920-30 45,735 29.8 676 (1.5%) 19.7 (5.3)
Total 247,149 22.8 39,224 (15.9%) 21.3 (7.0)
Age 75 Complete 1931-36 64,358 20.4 26,585 (41.3%) 30.4 (8.2)
1926-30 43,947 29.1 7,761 (17.7%) 29.7 (7.9)
1920-25 29,948 40.3 921 (3.1%) 28.6 (7.6)
Incomplete 1931-36 8,796 22.7 1,104 (12.6%) 26.5 (5.8)
1926-30 20,024 32.5 1,149 (5.7%) 26.8 (5.7)
1920-25 27,012 41.8 359 (1.3%) 26.6 (5.5)
Total 194,085 33.4 37,879 (19.5%) 28.9 (7.5)
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Table C.5: Distribution of recorded and imputed values of variables with missing
data in age cohorts without cardiovascular disease
Patients with incomplete medical records had a missing observation for systolic blood pres-
sure, body mass index, or smoking status, and consequently a missing QRISK2 score. The
reported distributions of imputed values are the mean across ten imputed datasets.
Ex-smoker Smoker BMI (sd) SBP (sd) QRISK2 (sd)
Age 60 Recorded 12.9% 25.5% 26.4 (4.4) 139.1 (18.4) 10.5 (5.2)
Imputed 13.0% 28.1% 26.2 (4.4) 136.4 (17.7) 10.3 (4.9)
Age 65 Recorded 18.3% 21.5% 26.6 (4.5) 141.6 (17.9) 15.6 (6.5)
Imputed 19.9% 23.3% 26.2 (4.4) 138.8 (17.6) 14.7 (6.3)
Age 70 Recorded 23.4% 16.5% 26.7 (4.6) 142.4 (17.5) 22.0 (7.5)
Imputed 24.4% 18.0% 26.0 (4.5) 142.0 (17.5) 19.8 (7.2)
Age 75 Recorded 24.8% 13.4% 26.5 (4.6) 143.7 (17.7) 29.8 (8.0)
Imputed 26.5% 15.0% 25.9 (4.5) 143.1 (17.7) 26.7 (7.9)
Table C.6: Characteristics of patients lost to follow-up in age cohorts without
cardiovascular disease
Patients who transferred out of their practice during the study were lost to follow-up. The
reported mean (standard deviation) of QRISK2 and the prevalence of smokers are the mean
across ten imputed datasets. Aﬄuent area was measured as the first quintile of the Index
of Multiple Deprivation (IMD), where the prevalence excluded missing observations.
Transferred, Size QRISK2 Lipid Diabetes Smoker Aﬄuent
observed (sd) lowering area
age therapy
Age 60 No, <70 8,108 12.8 (5.4) 2.8% 6.8% 45.5% 21.0%
No, ≥70 80,756 10.2 (4.5) 2.3% 3.2% 24.1% 29.0%
Yes, <70 22,732 10.5 (4.6) 2.3% 3.6% 27.6% 27.6%
Yes, ≥70 7,104 10.3 (4.3) 1.5% 3.0% 24.6% 26.4%
Age 65 No, <70 8,437 18.0 (6.7) 8.2% 9.9% 39.4% 22.4%
No, ≥70 149,102 15.1 (5.8) 7.5% 5.4% 20.7% 30.6%
Yes, <70 21,886 15.6 (6.0) 7.3% 6.0% 24.4% 27.7%
Yes, ≥70 20,149 14.9 (5.5) 4.1% 4.6% 22.3% 26.5%
Age 70 No 204,861 21.4 (7.0) 17.4% 7.9% 16.1% 30.9%
Yes 42,288 20.9 (6.7) 8.3% 6.6% 19.6% 26.0%
Age 75 No 160,015 29.0 (7.6) 21.8% 9.4% 13.0% 30.6%
Yes 34,070 28.2 (7.2) 9.0% 7.5% 16.7% 26.4%
225Figure C.1: Prevalence of comorbidites and lifestyle factors by cohort’s age in patients without cardiovascular disease
The age cohorts differed in recruitment period. The prevalence prior to 1995 is not presented due to the small numbers of medical
records available.
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Figure C.2: Prevalence start of statin therapy given prescription prior to cohort’s age by QRISK2 group
The number of patients in each cardiovascular risk group is the mean across ten imputed datasets.
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Table C.7: Cases and controls staying in initial treatment arm of statin prescription
during follow-up
The age cohorts included patients with no history of cardiovascular disease. Adherence
of treatment arm of statin prescription was ascertained in patients who were observed in
multiple cohorts. Patients were not observed in an older age cohort when one of the following
events happened: cardiovascular event, death, transfer out from general practice, or end of
study. It was assumed that patients lost to follow-up stayed in the initial treatment arm.
Cases Controls
Age 60 1,469/1,664 (88%) 91,691/117,036 (78%)
Age 65 3,935/4,278 (92%) 82,399/98,097 (84%)
Age 70 4,560/4,673 (98%) 78,565/85,961 (92%)
Table C.8: Performance statistics of survival models based on complete medical
records and irrespective of completeness in age cohorts without cardiovascular
disease
Patients with incomplete medical records had a missing observation for systolic blood pres-
sure, body mass index, or smoking status, and consequently a missing QRISK2 score.
QRISK2 Complete records All records
R2 C Shrinkage R2 C Shrinkage
Age 60 <10% 0.110 0.615 0.952 0.122 0.624 0.976
10-19% 0.111 0.629 0.956 0.123 0.634 0.987
≥20% 0.055 0.597 0.733 0.047 0.592 0.775
Age 65 <10% 0.050 0.578 0.872 0.127 0.633 0.992
10-19% 0.118 0.629 0.950 0.127 0.633 0.975
≥20% 0.090 0.614 0.956 0.091 0.619 0.975
Age 70 10-19% 0.104 0.625 0.978 0.106 0.626 0.990
≥20% 0.120 0.635 0.992 0.107 0.629 0.993
Age 75 10-19% 0.132 0.636 0.969 0.103 0.634 0.984
≥20% 0.138 0.647 0.995 0.134 0.644 0.997
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Figure C.3: Unadjusted and adjusted hazards of all-cause mortality associated with lipid-lowering therapy prescription
The age cohorts included patients with no history of cardiovascular disease. The hazard ratios (95% confidence interval) were
adjusted for sex, year of birth, socioeconomic status, diabetes, hypercholesterolaemia, blood pressure regulating drugs, body mass
index, smoking status, and general practice. QRISK2=10-year risk of first cardiovascular event. LLT=lipid-lowering therapy.
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Figure C.4: Unadjusted and adjusted hazards of all-cause mortality associated with statin prescription in complete case
analysis
The age cohorts included patients with no history of cardiovascular disease. Patients with a missing observation for systolic blood
pressure, body mass index, or smoking status, and consequently a missing QRISK2 score, were excluded from this analysis. The
hazard ratios (95% confidence interval) were adjusted for sex, year of birth, socioeconomic status, diabetes, hypercholesterolaemia,
blood pressure regulating drugs, body mass index, smoking status, and general practice. QRISK2=10-year risk of first cardiovascular
event. LLT=lipid-lowering therapy.
